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ABSTRACT 
 
Following surgical correction of cleft lip and palate a number of patients develop post-operative 
complications including oronasal-fistulae (ONF) and hypertrophic scarring (HTS). As these 
conditions can form due to pathological wound healing, this study aimed to characterise 
fibroblast behaviour, derived from patients with differing cleft phenotypes, to identify potential 
contributing factors. Fibroblasts were isolated from oral mucosal tissues derived from 29 cleft 
patients and were subsequently characterised and compared in terms proliferation, migration, 
ECM deposition and gene expression. Cleft fibroblasts were clustered into two statistically 
distinct migratory groups: fast and slow, with fast migrating fibroblasts secreting greater 
amounts of collagen. Although these groups did not correlate with cleft phenotype, CL 
fibroblasts all presented increased motility coupled with increased collagen deposition and 
upregulation of COL1A1. As both elevated motility and collagen secretion are hallmarks of 
HTS, it is possible that patients with faster migrating fibroblasts, including those derived from 
CL, may be at greater risk of pathological wound healing. Further, as fast migrating fibroblasts 
contained greater quantities of F-actin and upregulated ARP2, a major component of the 
ARP2/3 complex which acts as an actin filament nucleator, the observed increase in motility 
may be a result of altered cytoskeletal dynamics.   
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1.1 General introduction 
Cleft lip, with or without cleft palate, is the most common craniofacial abnormality in humans 
(Dixon et al, 2011). Clefts not only affect facial aesthetics but also disrupt speech development, 
nutrition and development of the normal dentition. The defects encompass wide phenotypic 
variation with occurrence varying according to both ethnicity and gender (Dixon et al, 2011) 
although the precise aetiology remains controversial. However, there is significant evidence 
which suggests that the occurrence of clefts is due to both genetic and environmental cues 
(Mossey and Modell, 2012). Cleft repair is accomplished surgically and there are a number of 
treatment protocols available, each with associated merits and drawbacks. Following surgical 
repair there are a number of post-operative complications that can occur, most commonly, 
hypertrophic scarring and oronasal fistulae (Soltani et al, 2012; Hardwicke et al, 2014).  
1.2  Cleft anatomy 
Orofacial clefts (OFC) are a group of craniofacial abnormalities with differing degrees of 
severity and associated patient morbidity. Common manifestations of OFC include: cleft lip 
and palate (CLP), cleft palate only (CP), cleft lip only (CL), these conditions can occur both 
unilaterally and bilaterally.  
1.2.1 Cleft lip 
Cleft lip, in isolation, accounts for approximately 20% of all cases of orofacial clefts (Hoffman, 
2011). Cleft lip ranges from incomplete unilateral cleft lip to complete bilateral cleft lip 
involving the majority of the upper lip. The mildest form of cleft lip, termed microform cleft 
lip, is characterised as a small notch on the vermillion border combined with the presence of 
fibrous tissue at the peripheral regions of the defect (Kim et al, 2010). A more extensive 
incomplete cleft lip extends beyond the vermillion border, the marked border of the upper lip, 
into the cutaneous regions of the upper lip combined with varying degrees of separation of the 
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orbicularis oris muscle and overlying skin, this separated muscle partially reattaches close to 
the alar base of the nose. Conversely, in cases of complete cleft lip the orbicularis oris muscle 
fails to fuse and remains separated, extending to, and inserting into the columella, the tissue 
between the nostrils that links the tip of the nose with nasal base, medially and the alar base, 
the tissue at the side of the nose, laterally (Laberge et al, 2007). This leads to the characteristic 
nasal deformity associated with cleft lip. It is important to note that each of the aforementioned 
conditions can be unilateral or bilateral in nature.  
1.2.2  Cleft palate 
Clefting of the primary and secondary palate, as with cleft lip, manifests with varying degrees 
of severity. Combined CLP accounts for approximately 50% of all cases of OFC, with cleft 
palate in isolation comprising the remaining 30% (Hoffman, 2011). Primary palatal clefts occur 
anterior to the incisive foramen of the hard palate and extend into the alveolus and maxilla 
(Goodacre et al, 2008). Failure of the palatal shelves to fuse leads to the incidence of secondary 
palatal clefts that occur posterior to the incisive foramen, extending to this point from the soft 
palate. Submucosal cleft palate (SMCP) is a comparatively rare form of cleft palate where there 
is muscular separation of the soft palate whilst mucosal surface integrity is maintained. It is 
commonly associated with a bifid uvula, a notch to the posterior hard palate, a zona pellucida 
(Calnan’s triad) and malorientation of the palatal rugae (Ojia et al, 2013; Richard et al, 2000). 
Though cleft lip and cleft palate often occur simultaneously, the high frequency of each 
condition occurring in isolation, coupled with the development of the lip and palate being due 
to distinct embryological events, has led to speculation that cleft lip and cleft palate may be 
disparate clinical entities, of differing causation. However, some have concluded that further 
investigation of cleft lip and cleft palate is required to identify the contributory factors that lead 
to clinical appearance of one phenotype over the other (Harville et al, 2005). 
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1.3 Embryological development of the lip and palate 
Human facial development begins approximately 4 weeks after conception and continues into 
the 12th week of development, at which point many of the key facial structures including can 
be observed. Embryological development of the facial structures involves a complex interplay 
between various cell populations coupled with multiple signalling pathways to coordinate 
tightly controlled cellular behaviours including: growth, proliferation, differentiation, migration 
and apoptosis (Hu et al, 2013); the general process of facial development is outlined below.  
1.3.1 Neuralation and the origins of the neural crest 
During neuralation bilateral regions of the ectoderm become elevated to form the neural folds 
which form around a central neural groove; this developing structure termed the neural plate.  
Central reorientation of the neural plate leads to proximity and convergence of the opposing 
neural folds to form the neural tube; this will eventually differentiate into the central nervous 
system (CNS) (Bronner-Fraser, 1994). The principal pluripotent cell type in facial development 
are the neural crest cells which are able to differentiate into diverse cell lineages, including 
fibroblasts (Bronner-Fraser, 1994; Huang and Saint-Jeannet, 2004). These cells are derived 
from the boundaries of the neural folds during neuralation. This is achieved when the neural 
crest cells undergo a process of epithelial to mesenchymal transition (EMT) which permits 
delamination from the ectoderm (Strobl-Mazulla and Bronner, 2013), thereby enabling 
widespread migration across the developing embryo; the neural crest population that contribute 
to development of the facial mesenchyme are called the craniofacial neural crest cells (CNCC). 
1.3.2    Formation of the nose and lip 
Following delamination from the neural folds CNCCs undergo extensive migration along 
highly preserved migratory pathways; this includes migration to the site ventral to the forebrain, 
which will become the frontonasal prominence, and into the pharyngeal arches. The first 
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pharyngeal arch is pertinent to facial development as it separates to form the paired maxillary 
processes, which will develop into the maxilla, and the paired mandibular processes, which will 
form the mandible. The development of the external facial structures is principally a result of 
the expansion, migration, differentiation and fusion of these facial processes (Schoenwolf et al, 
2015). During the process of continued growth of the frontonasal prominence, two ectodermal 
thickenings emerge on its surface; these are the nasal placodes. Lateral and medial swellings 
develop and surround each nasal placode and grow outwards, whereas the nasal placodes 
remain stationary to form the nasal pits and develop to form components of the olfactory system 
(Senders et al, 2003). Whilst this process is taking place there is concurrent medial growth of 
the paired maxillary and mandibular prominences, the two mandibular prominences meet and 
fuse at the midline thereby forming the structures of the lower jaw. Following this, the maxillary 
prominences grow towards the midline and fuse with the lateral nasal prominences to form the 
nasal alae and lateral regions of the nose, the maxillary processes then fuse with medial nasal 
process to form the intermaxillary segment. The intermaxillary segment, also called the globular 
process, is comprised externally of the philtrum of the upper lip but also leads to formation of 
internal structures including the primary palate (Senders et al, 2003; Lan et al, 2015). Further, 
the fusion of the maxillary and mandibular prominences leads to the formation of the cheeks 
whilst the maxillary process leads to the formation of the peripheral regions of the upper lip. 
1.3.3 Formation of the hard and soft palate 
Once the formation of the primary palate is complete by the end of the seventh week, the 
secondary palate, which will comprise the posterior two thirds of the hard palate and the soft 
palate, begins to develop in a process that takes up until week 12th of development to fully 
mature. Vertical bilateral outgrowths from the maxillary processes, termed the palatal shelves, 
emerge in the same plane as the tongue. The palatal shelves undergo a period of rapid growth 
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and expansion with eventual elevation above the tongue. Continued medial growth and 
orientation into the correct plane leads to shelf proximity at the midline. Opposing palatal 
shelves, which are covered in epithelium, commence fusion with the primary palate and each 
other by interaction with filopodia on opposing borders and merge thereby forming the 
temporary midline epithelial seam (Diewert et al, 1992); this is subsequently replaced with 
mesenchyme to produce a continuous palate (figure 1). The palatal mesenchyme then 
differentiates forming both regions of bone, by replacing existing cartilaginous support and 
muscle corresponding with the hard and soft palate respectively. Disruption at any 
embryological stage, for example, by delays in cell migration, malposition, fusion deficiencies 
or obstruction has the potential to result in pathological development. Subsequently this may 
lead to clefts of the lip or palate, or a combination of cleft lip and palate (Yu et al, 2009).   
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic of embryological origins of the face and palate. A) The frontonasal 
prominence, paired maxillary processes and paired mandibular processes merge at precise 
loci to form normal facial morphology. B) The frontonasal derived lateral nasal processes 
form the outer regions of the nose whereas the medial nasal process merges with maxillary 
process to form the intermaxillary segment comprising the philtrum and the primary palate. 
Images recreated based on: (A) Dixon et al, 2011; (B) Cobourne, 2004. 
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1.4 Classification of clefts 
Currently, there are a number of accepted cleft classification systems, though there is no single 
globally recognised standard (Smith et al, 1998). In 1989, Otto Kriens introduced the 
LAHSHAL diagrammatical classification system (Kriens, 1989) whereby letters were used to 
indicate the location in which clefting was present; thus when a patients’ cleft was diagnosed 
they would be assigned letters based on the area affected. In brief: L = Lip (right) A = Alveolus 
(right) H = Hard Palate (right) S = Soft Palate H = Hard Palate (left) A = Alveolus (left) L = Lip 
(left). Upper case letters denoted a complete cleft whilst lower case letters denoted an 
incomplete cleft.  This system was subsequently modified, by omitting an ‘H’, forming the 
LAHSAL system (Figure 2) and was adopted by the Royal College of Surgeons of England to 
standardise record keeping in the Craniofacial Anomalies Register (Hodgkinson et al, 2005). 
 
 
 
 
 
 
 
Right Left 
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Figure 2: Schematic of the LAHSAL classification system for OFCs. LAHSAL is used 
in the United Kingdom. The system split the defect into right and left portions as if looking 
directly at the patient. Each region is denoted a letter and clefts are classified based on the 
region affected. Upper case letters denote complete clefts whilst lower case represents 
incomplete clefts, ‘.’ are also incorporated into the system which represents an unaffected 
region. For example: complete bilateral cleft lip and palate would be ‘LAHSAL’, left 
unilateral cleft lip and palate would be ‘..HSAL’ and left unilateral incomplete cleft lip 
would be ‘…..l’.  L/l = lip; A/a = alveolus; H/h = hard palate; S/s = soft palate. 
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1.5 Genetic aetiology of cleft lip and palate 
The precise aetiology of OFC in humans remains inconclusive at present but there is significant 
evidence to support a genetic basis to cleft development (Dixon et al, 2011). For example, 
genetic proximity between individuals with CLP, who have an approximate occurrence rate of 
0.15% in the general population, and their relatives has been shown to be a major determinant 
in occurrence rates, as siblings of patients with CLP have an increased 3.5% chance of cleft 
development, whilst this decreases to 0.6% for first cousins (Grosen et al, 2010). Further, 
concordance rates between monozygotic twins has been estimated to be 36% and a significantly 
lower 4.7% between dizygotic twin pairs (Wyszynski et al, 1996). However, the absence 
complete concordance between monozygotes suggests that whilst genetic proximity may be a 
significant contributory factor, there are likely a number of underlying environmental factors 
that also play a causal role in terms of OFC development.  
1.5.1 Syndromic and non-syndromic cleft lip and palate 
Cleft lip and cleft palate may manifest in conjunction with a number of other physical 
anomalies, in such cases the condition is referred to as syndromic CLP (sCLP) as opposed to 
non-syndromic CLP (nsCLP) in which the congenital defect occurs in isolation. Syndromic 
forms of clefting are usually associated with Mendelian modes of inheritance and tend to be a 
result of single gene mutations that can be either autosomal dominant or recessive in nature 
(Rimoin et al, 2006). In syndromic cases, clefting can either be the primary malady, that occurs 
in conjunction with other minor defects, or clefts can be a secondary condition that occur in 
conjunction with one, or multiple, detrimental congenital malformations.  
Van der Woude syndrome (VWS) is an autosomal dominant condition that is phenotypically 
very similar to nsCLP, with only lower lip pits and hypodontia manifesting as additional 
features. The syndrome is caused due to a nonsense mutation on the IRF6 gene; this was 
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identified when studying the genome of monozygotic twins that were discordant for VWS 
(Kondo et al, 2002). Popliteal pterygium syndrome (PPS) is closely related VWS as its shares 
all of its clinical features with the addition of popliteal webbing, syndactyly and genital 
malformations; although other clinical features may also be represented (Lees et al, 1999). 
VWS and PPS are clinically related due to both syndromes developing as result of differing 
mutations of IRF6, this suggests the importance of the IRF6 transcription factor to normal 
embryological development. Genetic clues provided from sCLP forms provide indications as 
to possible causal candidate loci in non-syndromic forms of clefting. As such, genetic markers 
involved in VWS/PPS may also be related in nsCLP predisposition; this suggestion has led to 
identification of IRF6 variants that may also be associated with nsCLP (Zucchero et al, 2004). 
To date, several other candidate loci have been identified to have potential causal links to cleft 
palate development. However, as nsCLP susceptibility arises through a myriad of genetic and 
environmental factors, coupled with largely sporadic rather than Mendelian inheritance 
(Jugessur et al, 2009), identification of contributory genetic factors has proven difficult.  
There are a number of methodologies employed to aid in gene discovery of markers associated 
with development of nsCLP.  Candidate gene approaches are the most widely used technique, 
they make use of prior knowledge with regards to gene function and its potential influence on 
the development of disease. In terms of nsCLP, many candidate genes have been selected based 
on their expression within the developing facial mesenchyme in animal models. For example, 
the elevated expression of transforming growth factors (TGFs), in particular the TGF beta 3 
(TGFB3) isoform, within the developing palatal epithelium during palate morphogenesis 
(Fitzpatrick et al, 1990) coupled with the finding that murine models lacking TGFB3 display 
clefts of the secondary palate with complete penetrance (Proetzel et al, 1995) due to a failure 
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of palatal shelf fusion (Kaartinen et al, 1997), established TGF isoforms as potential candidate 
genes in the development of nsCLP (Lidral et al, 1997).  
Linkage analysis is a statistical methodology that makes use of the linkage phenomenon 
whereby alleles in close chromosomal proximity tend to be inherited together more frequently 
than expected by chance. This analysis is generally conducted on large multiplex families, or 
smaller consanguineous families, which have multiple members with CLP; this enables the 
identification chromosomal loci that have greater statistical likelihood to contain genetic 
markers that are associated with clefting. This technique has implicated sequence variations in 
the proximity of SOX9 as being associated with the sCLP Pierre Robin Sequence (PRS) (Benko 
et al, 2009). PRS can be associated with cleft palate and is characterised by micrognathia, 
underdevelopment of the lower jaw, glossoptosis, downward displacement of the tongue 
coupled with the resultant airway obstruction and a wide U-shaped cleft palate (Figueroa et al, 
1991). The condition is termed a sequence, as opposed to a syndrome, due to having multiple 
conditions that manifest due to a single anomaly (Shprintzen et al, 1992). In the case of PRS 
the primary anomaly is micrognathia, which leads to a group of clinical manifestations that 
arise from the abnormal posterior displacement of the tongue. Abnormal mandibular growth 
leads to malpositioning of the tongue which physically obstructs the palatal shelves from fusing, 
giving rise to the characteristic wide U-shaped palatal cleft (Breugem et al, 2009).  
A major advancement in identification of genes contributing to nsCLP was established due to 
the use of genome wide association studies (GWAS). This technique involves large scale 
examination and comparisons between the entire genome of cleft patients and unaffected 
controls to determine whether genetic variants, and previously identified candidate genes, are 
associated with OFC. For example, GWAS was used in order to investigate the potential role 
of IRF6 variants, which have consistently been associated with both syndromic and non-
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syndromic forms of cleft, across 460 nsCLP patients relative to 952 control patients; it was 
concluded that the IRF6 variant, rs642961, was involved in the development of nsCLP within 
the selected sample population (Birnbaum et al, 2009). Further, utilisation of GWAS data to 
study genetic susceptibility to nsCLP has resulted in the identification of many other genetic 
markers that have potential causal roles (Setó-Salvia et al, 2014). However, the development of 
nsCLP is unlikely to be the result of a single genetic anomaly, rather it is likely that the cause 
is multifactorial with several converging genetic and environmental factors that each play a 
contributory role (Dixon et al, 2011).  
1.6 Influence of the environment 
Normal foetal development is not just a product of the genetic blueprint as it is also significantly 
influenced by external environmental factors. A prerequisite of healthy foetal development is 
adequate maternal nutrition; thus maternal dietary deficiencies may have significant adverse 
effects. The dietary deficiencies coupled with other environmental factors that can increase the 
risk of OFC development are discussed below.  
1.6.1 Folic acid  
Folate is an essential vitamin that is present in leafy green vegetables, legumes and some fruits. 
Folic acid (FA) is a stable synthetic form of folate that has a 70% higher bioavailability than 
naturally occurring folates, as a result it is often used to fortify foods and in vitamin 
supplementation products (McNulty et al, 2004). Folic acid has a number of essential biological 
roles including acting as a carrier for one-carbon methylation reactions and in production of 
thymine and purine bases during nucleic acid synthesis; thus it is required for optimal DNA 
synthesis and cell division (Figueiredo et al, 2009). The developing embryo is completely 
reliant on maternal dietary intake (Pisano et al, 2010); therefore, adequate maternal folate levels 
are essential. 
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1.6.2 Folic acid deficiency associated congenital abnormalities 
Development of the lip and palate occurs as a result of the growth, migration and convergence 
of several facial prominences in response to the precise interplay between intracellular and 
external stimuli, such as folic acid (Wahl et al, 2015); therefore, maternal deficiency of folic 
acid can have significant adverse effects during development. FA deficiency has been identified 
to play a causal role in a number of craniofacial developmental disorders including neural tube 
defects (NTD) such as anencephaly and encephalocele (Wald et al, 1991). Folate deficiency has 
also been demonstrated to increase the risk of CLP (Wilcox et al, 2007). A number of studies 
have found significant reductions in OFC incidence in offspring with mothers who take folic 
acid supplements or multivitamins containing folic acid (Shaw et al, 1995).  In addition, a 
reduction in the prevalence of OFCs in children born between 1990 and 1996 was observed 
immediately following introduction of folic acid fortification of US national grain supplies 
thereby suggesting its protective role against OFC (Yazdy et al, 2007). The offspring of animal 
models that have been subjected to low folate and folate deficient diets were shown to be at 
significantly greater risk of cleft development when compared with the offspring of mothers 
with normal folate intake (Domoslawska et al, 2013; Elwood et al, 1997). Furthermore, drugs 
that have been shown to block normal FA activity induced cleft palate in 39% of murine 
offspring and this was coupled with other craniofacial deformities (Azarbayjani et al, 2001).  
1.6.3 Other environmental factors associated with cleft formation 
 Maternal zinc deficiency has been highlighted as having a possible causal link to orofacial 
clefts (Munger et al, 2009) and as zinc has been shown to be involved in a wide variety of 
metabolic processes (Vallee et al, 1993) it may be involved in craniofacial development. 
However, the precise role of zinc in palatal development remains unclear. Cholesterol 
deficiency may also be a contributing factor to OFC (Murray et al, 2004). This may be due to 
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the involvement of cholesterol in the maturation and post-translational modifications of the 
protein sonic hedgehog (shh) (Porter, 2006; Lewis et al, 2001). Hence it is suggested that 
cholesterol deficiency may perturb the shh signalling pathway which may lead to cleft 
development (Porter, 2006). Both deficiency and excess vitamin A, specifically its derivative 
retinoic acid (RA), have roles in OFC development (Lammar et al, 1985; Nugent et al, 1999). 
It has been shown that RA is involved in palatogenesis through interaction with its receptors 
RAR (retinoic acid receptor) and RXR (retinoid X receptor). When activated, these receptors 
stimulate the retinoic acid response element (RARE), initiating transcription of targets that play 
roles in palatal shelf outgrowth, elevation and fusion (Nugent et al, 1995; Ackermans et al, 
2011). Thus dietary excess of Vitamin A can lead to overexpression of these targets by RARE 
whilst deficiency may lead to under-expression of these targets. Conversely however, levels 
marginally above the recommended daily allowance (RDA) have been shown to protect against 
CLP (Mitchell et al, 2003).  
Maternal tobacco smoking during pregnancy has been linked to CLP development, this increase 
in risk has been quoted as being greater than 20% in susceptible individuals (Little et al, 2004). 
Similarly, excess alcohol consumption has been reported to increase susceptibility to OFC 
(Lorente et al, 2000), though data is somewhat inconsistent (Meyer et al, 2003). Adverse effects 
from prescription medicine have also been associated with cleft development. Statins are 
commonly used to lower levels of cholesterol, however their inhibitory effect may be passed 
on to the developing foetus, through placental transmission and subsequently they may exert an 
inhibitory effect on shh and other associated morphogens (Edison et al, 2004). Other 
medications that may be implicated in CLP development include corticosteroids (Pradat et al, 
2003) and anticonvulsants (Abrishamchian et al, 1994). Maternal use of recreational drugs, such 
as cocaine, have also been implicated in development of CLP. A study of infants with mothers 
that used cocaine during pregnancy found that 14% developed cleft lip whilst 21% developed 
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cleft palate (Fries et al, 1993). It was proposed that cocaine exposure could cause 
vasoconstriction of uterine blood vessels which increased intrauterine hypoxia leading to 
perturbed development (Webster et al, 2007). This hypoxic effect may also occur during heavy 
maternal smoking (Webster et al, 2007) and high altitude living as increased risk of craniofacial 
defects has been observed at higher altitudes (Castilla et al, 1999). Planned pregnancy has 
recently been shown to reduce the risk of CL/P (Mossey et al, 2007) likely due to lifestyle 
changes that occur prior to the critical period of facial development in the first trimester. 
1.7 Epidemiology of cleft lip and palate 
A relatively large number of studies have aimed to identify the international incidence of CLP 
although the precise indication of incidence rates has been hindered by the different 
experimental techniques and data collection mechanisms utilised between research groups. This 
issue has been exacerbated by institutional differences in classification systems, variance in 
sample sizes, low population generalisation and the lack of randomized sampling (Mossey et 
al, 2002). Furthermore, data collected from many developing countries lack national registries 
of congenital malformations. Due to this, cleft prevalence is largely taken from treatment 
centres in more developed areas thus outcomes are potentially inaccurate as data from more 
rural regions that lack adequate surveillance systems is limited (Mossey et al, 2009; Acuña-
González et al, 2011). 
Despite the aforementioned difficulties epidemiological studies of OFC have been conducted 
and the commonly quoted global incidence rate is reported to be 1 in 700 live births (WHO, 
2002). According to data derived from the cleft registry and audit network (CRANE), an annual 
report is published with regards to the number of children born with clefts in the United 
Kingdom. The total number of children born with OFC between 1st January 2017 and 31st 
December 2017 was 1068, this equated to a national incidence rate of 1 in 657 live births 
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(CRANE, 2018). Further, the majority of children born with clefts displayed cleft palate in 
isolation (45%) whilst significantly fewer displayed cleft lip in isolation (22%). When clefts of 
the lip and palate occurred in conjunction (CLP), it was found that 22% patients had unilateral 
CLP whilst the remaining 11% displayed bilateral CLP (CRANE, 2018). In terms of global 
incidence rates, a large-scale study was undertaken that comprised data collection over a five-
year period which included 34 US states and 30 countries (Tanaka et al, 2013). The data was 
normalised such that the incidence rate was estimated per 10,000 live births. The study found 
that the majority of US states had prevalence rates between 7 and 13 per 10,000 live births, with 
outliers in West Virginia (2.59) and Maryland at (21.46) but an overall national average of 7.75 
(per 10,000 live births respectively). The US national average was comparable with that of 
another large-scale study which concluded the US incidence rate as 10.2 per 10,000 live births 
(International Perinatal Database of Typical Oral Clefts working group, 2011).  Internationally, 
there are large variations between reported incidences thus suggesting ethnicity as a potential 
contributory factor for OFC. Countries with the highest reported rates are Japan (19.05), Mexico 
(13.69), and Norway (12.73) whilst the countries with the lowest rates were Cuba (3.81), Spain 
(3.79) and South Africa (3.13), although the causal factor which results in individuals to be at 
greater or lower risk based on country of origin has not yet been identified (Tanaka et al, 2012). 
Notably however, these rates were extracted from birth defect surveillance systems, some of 
which were solely hospital based and therefore only represented a portion of the population that 
accessed these facilities. Despite this, the general trend mirrored those of other studies which 
found Asian populations had the highest prevalence rates (Habib, 1978) whilst African 
populations had the lowest (Vanderas, 1987). 
A retrospective European multicentre study of the incidence of cleft palate found that out of 
3852 cases 54.8% were isolated CP, 18% were associated with other malformations such as 
cleft lip and 27.2% were related to recognised syndromes (Calzolari et al, 2004). Cleft lip is 
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approximately twice as common in males whereas cleft palate is twice as common in females 
(Martelli et al, 2012). This gender bias extends to cleft laterality, with an approximate 2:1 ratio 
of left unilateral clefts in males compared with females (Dixon et al, 2011). The occurrence of 
OFC among 54,000 relatives of cleft sufferers was documented in a landmark Danish study 
which found an occurrence rate of 3.5% amongst first degree relatives (parents; siblings), 0.8% 
amongst second degree relatives (half siblings, nieces/nephews, aunts/uncles and grandparents) 
and 0.6% between third degree relatives (first cousins) (Grosen et al, 2010). It is important to 
note that whilst comprehensive, this study only recorded occurrence rates amongst a large 
Danish experimental group and as ethnicity was likely to have an influence on incidence of 
OFC these values may not be globally representative. 
1.8  Clinical management 
Treatment of CLP occurs immediately after birth as mothers are referred to specialist nurses in 
order to receive advice on caring for cleft patient and in some cases pre-surgical intervention 
may be required prior to definitive repair (Pool, 1995). Repair of the cleft lip typically occurs 
at approximately 3 months of age whereas repair of the cleft palate occurs at 6 months of age. 
When cleft lip and palate occur in combination patients are subject to two operations, the first 
to repair the cleft lip and the second to repair the cleft palate (Sitzman et al, 2017).  
1.8.1  Pre-surgical intervention 
Large cleft defects or those with a severe protruding pre-maxilla often merit early intervention 
in order to improve prognosis (Figure 3). Markedly wide clefts of the lip may require initial 
treatment via lip taping; this procedure follows similar principles to the orthodontic brace in 
that there is gradual tissue remodelling under tension via regular tightening. The procedure 
involves placing surgical tape on either cheek attached to a skin adhesive; the length of the tape 
is then progressively decreased as either end of the alveolar defect increases in proximity. There 
are varying reports of success using this technique and one study reported that routine use of 
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this technique, yielded an average decrease in the alveolar gap from 12.4mm to 5.8mm (Pool, 
1995). The use of infant orthopaedics, such as Latham palatal devices which are screwed onto 
the palate and gradually tightened to reduce cleft width, remain highly controversial. The 
procedure involves surgically pinning the device onto the palate coupled with a screw that is 
tightened daily which gradually moves to draw each palatal segment closer. In the case of 
patients with severe protrusive pre-maxilla this device may also be connected to the nasal 
septum in order to align it correctly for future definitive surgery (Nahai et al, 2005). However, 
a Dutch cleft study group concluded such orthopaedic devices have no effect on facial 
appearance (Prahl et al, 2006), thus the technique is not used in the UK (though popular 
elsewhere worldwide). A surgical technique that may be utilised in cases of bilateral CLP, or 
very wide unilateral CLP, is the lip adhesion technique. The basic principle of this technique 
involves changing the class of the defect from complete to incomplete to aid in definitive repair 
and reduce deformity (Nagy et al, 2009). 
 
 
Figure 3: Photographs of orofacial clefts from two patients. A) Frontal view, B) 
lateral view. Both patients may benefit from pre-surgical intervention such as lip taping 
or lip adhesion in order to reduce the severity of the deformity prior to surgery. 
A) B) 
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1.8.2  Definitive surgery and post-operative complications 
Both globally and regionally there is considerable difference in the surgical protocols used to 
treat CLP. This was recently highlighted by the Eurocleft study which found that for treatment 
of just one cleft phenotype (unilateral complete cleft lip affecting the hard and soft palate) there 
were 194 variations in cleft closure protocols between 201 cleft teams throughout Europe (Shaw 
et al, 2001). The time points for cleft lip and cleft palate repair are also subject to wide variation, 
some surgical protocols include neonatal repair (Desai et al, 1990). However, neonatal repair is 
controversial due to the possibility of the patient suffering from undiagnosed syndromic OFC, 
including congenital heart disease (Shafi et al, 2003) or respiratory issues, which may lead to 
anaesthetic complication (Kulkarni et al, 2013). In the UK, lip closure routinely occurs 
approximately three months after birth (Somerville et al, 2005), thus providing adequate time 
to detect other genetic anomalies. Further, surgical repair is not generally conducted until the 
criteria for the rule of 10’s has been fulfilled in order to mitigate the risk of post-operative 
complications. This criterion suggests that surgical repair is not conducted until the patient is at 
least 10 weeks of age, weighs more than 10 lb (4.5kg) and has a haemoglobin count greater 
than 10g/dl (Chow et al, 2016). Palatal closure occurs around six months of age as up until this 
time infants are obligate nasal breathers thus closure may lead to respiratory distress (Smith et 
al, 2013). This early palatal closure aids in speech development but may impede facial growth, 
whilst late (adult) palatal closure increases the likelihood of normal facial aesthetics but also 
irreversible damage to speech (Richard et al, 2006). Though the surgical procedures may vary 
the fundamental goals of cleft surgery remain the same.  
The functional aim of cleft lip surgery is to re-establish the muscular competence of the 
orbicularis oris muscle that encircles the mouth although improvement in aesthetic quality is 
important. Aesthetic improvements include restoration of Cupid’s bow, the double curve of the 
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upper lip, with clear demarcation of the vermillion border as well as restoration of the vertically 
grooved philtrum to establish typical facial features. In the case of complete cleft lip, 
rhinoplasty may also be necessary to correct the cleft nose deformity at the end point of facial 
growth (Singh et al, 2009). The main complication of cleft lip surgery is the failure to re-
establish the muscular integrity of the orbicularis oris muscle, possibly leading to a secondary 
deformity due to the manifestation of a visible muscular lateral bulge (Matic et al, 2011). 
Hypertrophic scarring is a further post-operative complication resulting from pathogenic wound 
healing and is characterised by visible lip regression, leading to asymmetry and potential nasal 
stenosis (Soltani et al, 2012), possibly necessitating revision surgery.  
The main surgical outcome of palatoplasty is to reshape the palatal defect such that it mimics 
typical anatomical form and function. Further, surgical repair should aim to reinstate the ability 
to completely close the velopharyngeal sphincter thus permitting velopharyngeal competence. 
Various complications can arise post-operatively, the most important of which is palatal 
dehiscence, which gives rise to varying degrees of oronasal fistula (ONF). Development of an 
ONF reinstates the link between the oral and nasal cavities following primary palatal surgery, 
thus necessitating secondary surgery (Anani et al, 2012). This defect is often recurrent (Diah et 
al, 2007) and leads to nasal regurgitation of food, hyper-nasal speech and increased nasal air 
flow (Sadhu et al, 2009). This abnormal association linking the oral and nasal cavities tends to 
develop on the secondary palate. The regions of the secondary palate mostly affected are hard 
palate (54%) and the hard-soft palatal junction (36%) (Diah et al, 2007). The diameter of fistulae 
can also vary with larger fistulae presenting more serious symptoms. According to Diah et al, 
(2007), ~10% of fistulae were relatively small (1-2mm), 36% were medium size (2-5mm) and 
54% were greater than 5mm. Post-operative ONF formation may be due to a number of factors 
including surgical technique (Amaratunga, 1988), type of cleft (Murthy et al, 2011), width of 
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cleft (Parwaz et al, 2009) and age of palatal closure (Emory et al, 1997). However, a recent 
comprehensive systematic review, pertaining to the incidence of ONF following primary palatal 
repair, concluded the global incidence of ONF to be 8.6% with surgical technique and continent 
of origin having no significant effect on ONF development. It was however found that ONF 
had a greater statistical likelihood in cases of CLP compared with clefts in isolation (Hardwicke 
et al, 2014). The Pittsburgh fistula classification system was developed in order to standardise 
types of fistula and replace ambiguous descriptive classifications. The system addresses 7 types 
of fistula with each type relating to the region of the palate affected (Smith et al, 2007).  
Velopharyngeal insufficiency can result from inadequate extension of the soft palate either due 
to limited soft tissue availability or surgical technique, leading to hypernasality. Speech therapy 
may be sufficient to correct minor cases of hypernasality; however, patients with an anatomical 
defect may require prostheses (pharyngeal obturators) or, most often, surgery (posterior 
pharyngeal wall augmentation or pharyngoplasty) to restore normal speech (Fisher et al, 2009).  
Hypertrophic scarring (HTS) is a post-operative complication that generally occurs 3-6 months 
following cleft repair. The reported incidence of HTS following cleft repair varies widely 
however a recent comprehensive retrospective study found that the incidence of HTS following 
cleft repair was 25% (Soltani et al, 2012). The condition is characterised by deposition of large 
amounts of collagen during the wound healing process often leading to potentially painful thick 
red scarring at the site of repair. Following formation of a hypertrophic scar its size may remain 
stable or begin to regress (Muir et al, 1990). Regression of the scar can lead to shortening of 
one side of the repair leading to lack of healing uniformity across the wound area (Rabello et 
al, 2014); this may necessitate revision surgery in order to restore aesthetics and symmetry.  
Another major complication of palate repair, albeit delayed, is the possibility of maxillary 
hypoplasia (Moreira, 2014; Shetye, 2004). The manifestation of this mid-facial deficiency leads 
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to a concave facial profile, often accompanied by a crossbite, which, in severe cases, may 
require orthognathic surgery to restore facial aesthetics (Sakaguchi et al, 2008). The 
development of this condition cannot solely be attributed to the width of cleft, the surgical 
protocol applied or individual differences in wound healing (Farranto et al, 2014; Weinzweig 
et al, 2006). Rather, excessive hypertrophic scarring following primary palatoplasty has been 
cited as the cause (Fudalej et al, 2012), this may be due to excessive palatal wound contracture 
by myofibroblasts during the proliferative phase of wound healing leading to the generation of 
rigid collagen-rich tissues (Beyeler et al, 2014). Whilst there is little research into the potential 
physiological deficiencies of cleft fibroblasts, it is possible that due to a number of genetic 
factors that contribute to cleft formation, fibroblasts in affected individuals may be behave 
abnormally thereby giving rise to pathological wound healing due to abnormalities in migration 
or proliferation which are fundamental processes to normal wound healing. 
1.9 Histological structure of clefts 
The oral mucosa, which is the tissue type present in the lip and palate, comprises three distinct 
layers: the oral epithelium, lamina propria and underlying submucosa. The oral epithelium is 
characterised by five epithelial layers, the most superficial layer is the stratum corneum, which 
is a layer of approximately 15-20 flattened dead cells, with both nuclei and organelles absent 
which plays a protective role. The stratum granulosum is a transitional layer that comprises 
migrating keratinocytes from the significantly thicker stratum spinosum that lies beneath. The 
deepest layer of the stratified squamous epithelium is the stratum basale, a single layer of highly 
proliferative cuboidal epithelial cells that migrate more superficially to form and maintain the 
other epithelial layers (Squier et al, 2001). The lamina propria is the connective tissue layer of 
the oral mucosa and is composed largely of fibrous collagen type I and III as well as elastin 
which is secreted by the population of fibroblasts that are present throughout the lamina propria. 
These fibroblast populations are critical to normal wound healing following cleft repair as they 
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secrete essential growth factors that attract other fibroblasts and rapidly proliferate following 
the creation of wounds such as those caused by surgical incisions. Due to the fundamental roles 
that these cleft fibroblasts play, this cell type was selected to characterise in the present study.  
1.10 Fibroblast use in biological research  
Fibroblasts are stromal cells of mesenchymal origin with many functions that are pivotal to both 
human development and maintenance. Fibroblasts are generally abundant but are often found 
in vivo as single cells embedded within the fibrillar extracellular matrix (Eckes et al, 1993). 
Dormant fibroblasts in vivo are often described as being in a quiescent state prior to activation 
from an external stimulus, such as due to exposure to cytokines and growth factors, which 
initiate their functional response (Chen et al, 2012). Fibroblasts are one of the most widely used 
cell types in biological research due to their abundance and amenability to culture in vitro, 
despite this, molecular characterisation of fibroblasts remains poorly defined. Fibroblasts have 
been shown to express a number of molecular markers, including vimentin, although other cells 
of mesenchymal origin also express this molecule (Camelliti et al, 2005). However, fibroblastic 
lineage is often assessed by the absence of other distinct genetic markers characteristic of other 
cell types (Chang et al, 2002). Fibroblast morphology is often described as spindle shaped, 
however in vitro, specific morphology may be influenced based on the level of confluence, cell 
cycle, supplementation conditions and differentiation state. Fibroblasts often display 
cytoplasmic extensions with lamellipodia and filopodia branched towards the direction of 
migration demonstrating cellular polarity (Bliokh et al, 1980).  
1.10.1 Physiological function of fibroblasts  
Fibroblasts are primarily secretory cells that provide mechanical integrity to tissues through 
continuous production of ECM molecules such as collagens and glycosaminoglycans. 
Fibroblasts deposit crucial components of the ECM, including ground substance and a number 
of fibres, into the local milieu to provide tissue integrity by increasing its mechanical strength. 
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Fibroblasts also play a key role in tissue homeostasis, this is achieved through continued ECM 
remodelling via secretion of both ECM precursors and enzymes involved in the breakdown of 
matrix macromolecules; this balance of ECM production and degradation is conducted in 
regulated manner to ensure tissue homeostasis. Further, fibroblasts also secrete a large cohort 
growth factors and cytokines that act in both an autocrine and paracrine manner leading to 
recruitment and activation of other local cell types thereby playing a critical role in both the 
early inflammatory phases and the later tissue remodelling stages of wound healing.  
1.10.1.1 The role of the ECM 
The extracellular matrix is a complex biological, physical and physiological support network 
that has many functions. Its primary function is as a natural scaffold that provides mechanical 
integrity to tissues, this is achieved primarily through fibrillar collagen proteins which are 
embedded into heterogeneous support network which contain an abundance of cell types and 
macromolecules. Many cell types use ECM components, including glycoproteins such as 
fibronectin, to permit integrin regulated cell-ECM adhesion to enable the cell to undertake their 
specific function. This adhesion can occur through cellular focal adhesions, which connect 
cellular actin to the ECM, or through hemi-desmosomes, which connect the ECM to 
intermediate filaments such as vimentin (Alberts et al, 2015). The ECM also behaves as a 
physical barrier between tissues and acts as an intermediary for intercellular communication. 
In addition, the ECM acts as physical storage unit for a host of growth factors which can be 
mobilised following physiological change thus permitting swift local growth factor induced 
responses without the immediate need for cellular secretions (Taipale et al, 1997).  
During craniofacial development, the facial prominences expand as a result of cell proliferation 
and ECM deposition by new and existing cells in the surrounding tissues (Schoenwolf et al, 
2015). The increase in volume of craniofacial tissues prior to fusion is understood to be 
contributed to equally by both proliferation and ECM accumulation thus precise production of 
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ECM is pivotal to normal facial development as perturbations may lead to disrupted facial 
development and potentially the formation of clefts (Meng et al, 2009). Due to this, cleft 
fibroblast production of ECM components may be a contributing factor for different clinical 
manifestations of clefts. In addition, controlled secretion of ECM by fibroblasts is key to normal 
wound healing following cleft repair with overproduction leading to increased risk of HTS and 
ONF. Differences in ECM production may also contribute to patients, with phenotypically 
comparable clefts, displaying distinct clinical outcomes following cleft repair. 
1.10.1.1.1 Collagen synthesis and function 
Collagen fibre production is achieved due to the synthesis of intracellular precursors which are 
secreted into the extracellular space in order to undergo maturation into collagen fibres. 
Initially, fibroblasts transcribe and translate alpha chain peptide precursors with the amino acid 
glycine comprising approximately one third of the peptide sequence; this is referred to as pre-
pro-polypeptide. The elevated glycine content is important in the eventual formation and 
stabilisation of collagens. As glycine is the smallest amino acid, its high content permits close 
peptide association thereby facilitating the formation of hydrogen bonds and intermolecular 
crosslinking (Shoulders and Raines, 2009). Following this, the pre-pro-polypeptide chain 
undergoes a series of post translational modifications. First the signal peptide sequence at the 
beginning of the chain, which was involved in the initiation of protein synthesis, is removed 
thereby converting pre-pro-polypeptide into pro-polypeptide. This then undergoes 
hydroxylation and glycosylation of amino acids along the peptide chain, these modifications 
enable three modified pro-polypeptide chains to fold into a triple helix structure to form pro-
collagen (Kielty and Grant, 2002). Pro-collagen is then processed into secretory vesicles and 
exocytosed into the extracellular space. When in the ECM, collagen peptidases cleave the ends 
of the pro-collagen chains to form tropocollagen, tropo-collagens then undergo assembly into 
collagen fibrils via the action of lysyl oxidases which covalently bond lysine residues between 
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opposing tropocollagen molecules to form collagen fibrils (Kielty and Grant, 2002). Collagen 
is a key structural protein in the ECM which owes its ubiquity and efficacy to both the tensile 
strength and compressibility of its fibres. Currently there are 28 types of collagen identified 
(Richard-Blum, 2011), each with differing tissue abundances relating to their local function. 
Collagen type I and type III are understood to make up approximately 80% and 20% of the total 
dermal and mucosal collagen, respectively (Tracy et al, 2016), with other collagen types, such 
as collagen type V, being produced in smaller amounts (2-4%) (Smith et al, 1986). Collagens 
can be broadly categorised into two distinct types: fibrillar and non-fibrillar collagens. Fibrillar 
collagens include types I, II, III and V which due to their interconnected fibrils allow the ECM 
to act as a biological scaffold.  
1.10.1.1.2 The function of Glycosaminoglycans 
Glycosaminoglycans (GAG) are linear polysaccharide components of the ECM that exist both 
independently and bound to larger proteoglycan sugars. GAGs are hydrophilic in nature 
therefore have an important function in the maintenance of osmotic balance between the ECM 
and neighbouring tissues in order to provide adequate local hydration (Couchman et al, 2012). 
This is achieved by means of the negative charges along their chains attracting positive sodium 
ions (Na+) which, via osmosis, attract water molecules. Chondroitin sulphate (CS) and dermatan 
sulphate (DS) are the most abundantly produced GAGs in dermal and mucosal ECM (Tracy et 
al, 2016). CS and DS are very similar in structure however the presence of iduronic acid along 
the chain of DS makes it a distinct GAG. CS and DS can exist both bound to proteoglycans or 
as unbound GAGs, the latter has been shown to act as a preliminary substrate for fibroblast 
migration in the ECM. It has also been suggested that CS and DS may be associated with 
improved wound healing as scarless foetal wounds contain much greater amounts of CS and 
DS when compared with adult skin (Carrino et al, 2000).  Heparin sulphate (HS) is another type 
of GAG that is secreted and binds to cell surfaces in the ECM, this protein has an array of 
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functions but one of its major roles is acting as regulator to aid in cell response to particular 
growth factors such as fibroblast growth factor (FGF) and epithelial growth factor (EGF) as a 
result modulating proliferation and other cell behaviours (Rabenstein, 2001).  
1.10.1.1.3 Overview of related ECM molecules 
Fibronectin is secreted by fibroblasts into the ECM milieu as soluble glycoprotein dimers, these 
bind to integrin receptors on surrounding cell surfaces leading to clustering of integrins and 
increased local fibronectin concentrations. Integrin bound fibronectin molecules interact with 
each other to form associations with the local ECM neighbouring cell populations, thus are 
involved in key cell behaviours (Wierzbicka-Patynowski et al, 2003).  Fibronectin molecules 
also offer additional structural support to surrounding tissues and also play a role in cell-ECM 
adhesion and cell proliferation. Furthermore, these molecules aid in cellular migration they 
increase tension within the ECM. This tension plays a role in fibroblast to myofibroblast 
transition which is essential for both normal ECM regulation and ECM deposition in acute 
wounds (Pankov et al, 2002). Fibronectin is also essential during embryogenesis as it has been 
shown to act as scaffold for cell attachment and as a guidance system for migrating embryonic 
cells and structures (Sakai et al, 2003). Elastin is secreted from fibroblasts as its precursor 
tropoelastin; following formation of elastic fibres it functions to provide a degree of elasticity 
to the ECM and surrounding tissues and offers some resistance against mechanical stresses and 
strain (Kristensen et al, 2016).  
1.10.2  Fibroblasts in disease  
As previously outlined, fibroblasts exhibit an array of functions that are critical to health and 
normal homeostatic conditions and perturbations to normal fibroblast behaviours can lead to a 
number of adverse physiological effects. The major function of fibroblasts continued ECM 
remodelling, excessive or diminished production of ECM, due to abnormal fibroblast 
behaviour, can have significant adverse effects. Following surgical repair of clefts there are a 
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number of post-operative complications that can occur, including hypertrophic scarring and 
formation of oronasal fistulae. Whilst these complications are likely the result of many 
contributory factors, pathological cleft fibroblast ECM deposition may potentially play a 
significant role in their formation.  
Hypertrophic scarring is a cutaneous condition that can occur following traumatic injury or 
surgery. The condition is characterised by excessive unaesthetic scarring and is believed to be 
a result of disproportionate collagen deposition by fibroblasts following injury (Soltani et al, 
2012). In the maturation phase of normal wound healing collagen production and collagen 
breakdown by matrix metalloproteinases are in equilibrium; however, in hypertrophic scars this 
does not occur. Increased quantities of collagen fibres at the wound site leads to increased 
mechanical tension across the wound that causes greater fibroblast-to-myofibroblast 
differentiation which in turn secrete greater amounts of collagen thereby exacerbating the 
condition (Schmieder et al, 2017).  Keloid scarring is similar to hypertrophic scarring however 
the former is characterised by excessive scar tissue formation beyond the boundaries of the 
original wound. Keloid scarring is also caused by excessive fibroblast deposition of ECM and 
despite the clear clinical distinction, may be caused by the same pathophysiological process 
(Schmieder et al, 2017). Chronic wounds are injured tissues that have a significantly delayed 
wound healing process often with prolonged inflammatory phases leading to greater incidence 
of bacterial invasion thus patient morbidity (Levinson, 2013). Fibroblasts at the site of chronic 
wounds have been shown to have an abnormal morphology and significantly decreased 
proliferation thus hindering the phase of healing in which expansion of local fibroblast 
populations leads to greater total ECM deposition at the site (Agren et al, 1999). Fibroblasts in 
chronic wounds have been shown to have a perturbed response to TGFβ1, which would 
normally induce myofibroblast differentiation and lead to wound contraction, due to down 
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regulation of TGβR2 (Kim et al, 2003; Cha et al, 2008). Due to these fibroblast abnormalities, 
chronic wounds might result in delayed healing and significant patient distress.  
1.10.3 Fibroblast motility 
Cell motility is central to normal fibroblast activity in a range of biological processes including 
embryonic development, wound healing and maintenance of regular homeostasis (Alberts et al, 
2015). For example, during normal dermal wound healing a cascade of events are initiated 
following coagulation, this includes an inflammatory response as a result of chemical stimuli 
released via platelet degradation and locally recruited leukocytes. The resulting increase in 
cytokine concentration at the wound site leads to a chemotactic response whereby fibroblast 
migrate to the site of injury from adjacent tissues in response to chemical signals leading to the 
secretion of essential biomolecules, including collagens and glycosaminoglycans, to construct 
a provisional extracellular matrix (McDougall et al, 2006; Acharya et al, 2008); adequate 
fibroblast motility into the wound site is therefore critical to wound site matrix remodelling. 
The speed of fibroblast migration is critical in normal wound healing and can be a significant 
contributory factor in fibrosis, which is characterised by the accumulation of fibrous connective 
tissues resulting in the formation of excessive scarring across the wound site (Darby et al, 2007). 
This is due to the exertion of a tractional force onto the underlying matrix by fibroblasts when 
migrating, this increased mechanical stress across the matrix stimulates myofibroblast 
differentiation via mechanotransduction (Huang et al, 2012). Myofibroblasts synthesise 
abundant ECM and cause wound contracture resulting in further increases in wound site tension 
thereby promoting additional fibroblast differentiation via positive feedback (Tomasek et al, 
2002). As the initial rate of fibroblast migration is related to the amount of ECM deposition and 
wound contracture, fibroblast migration rates into the wound following cleft repair are related 
to fibrosis (Beyeler et al, 2014). Thus it is possible that cleft patients with disrupted fibroblast 
migration rates may be at increased risk of pathological wound healing and development of 
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post-operative complications. Due to this, it is important to understand the mechanisms and 
underlying the regulatory processes of fibroblast migration which would aid in understanding 
the pathological wound healing observed in some patients following cleft repair.  
1.10.3.1 Model of cellular locomotion 
The coordinated activity of many intercellular proteins regulates the processes that drive cell 
migration. External stimuli such as growth factors, cytokines and physical stresses are detected 
by membrane bound receptor molecules inducing a signalling cascade that promote cell 
migration toward or away from the stimuli (Alberts et al, 2015). In response to external stimuli 
the initial locomotory response is the protrusion of cytoskeletal projections called lamellipodia 
and filopodia. These cellular projections are thought to form due to polymerisation forces. 
Cytoskeletal actin filaments at the periphery of the cell membrane undergo repeated small scale 
polymerization with actin monomers, due to the elasticity of actin fibres each additional 
monomer exerts a force on the dynamic cell membrane, this elastic force propels the membrane 
forward leading to the formation of cellular protrusions (Mogilner et al, 1996; Caballero et al, 
2015). These protrusions are thought to act as the cell’s mechanoreceptors which assess the 
feasibility of migration in a particular direction (Riveline et al, 2001) and form the cells leading 
edge. This leading edge forms in the region closest to the stimuli in the case of a chemo-
attractive response or will form in the opposite direction due to a chemo-repellent response. 
Following establishment of migration directionality, nascent adhesion complexes form between 
the base of the leading edge and the underlying substrate. This adhesion stabilises the site of 
membrane protrusion and firmly attach the cell extensions to the ECM. The cell-ECM adhesion 
sites produced can vary widely, nascent adhesions usually form first as they are small simple 
complexes that can be produced rapidly in the immediate region behind the leading edge. As 
migration continues nascent adhesions mature into focal complexes and are normally situated 
further back from the leading edge at the lamellipodium-lamellum border; these complexes can 
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mature into complete focal adhesions and are situated at sites of parallel to large actin bundles 
or stress points at the centre of the cell body (Zimerman et al, 2004). These anchorage points 
are central to normal cell migration and limit retrograde flow which are inward pulling forces, 
usually responsible for cell spreading, produced by excess tension from actin polymerization at 
the cell border (Mayor et al, 2016; Anderson et al, 2008). Adhesion sites limit inward pulling 
forces by acting as traction points that are able to resist these regressive forces by allowing 
effective transfer of kinetic energy onto the migrating surface. The next step in cell locomotion 
is the translocation of the cell body. The mechanical forces required to translocate the cell are 
produced by interactions of non-muscle myosin II with bundles of actin through formation of 
actomyosin complexes. Myosin II contraction leads to rearrangement of the network of actin 
filaments eventually forming parallel bundles of actin fibres, which have lower resistance to 
the contractile force produced by myosin II, leading to greater mechanical force generation.  
Contractile myosin II is primarily located at the rear of the cell leading to inward cytoskeletal 
pressure creating forward dynamic flow of cellular components (De Pascalis et al, 2017).   
Following myosin II and actin contraction large amounts of energy is generated which enables 
the cell to propel itself forward through use of the tractional force produced between the cell 
body and the ECM via adhesion sites (Ananthakrishnan et al, 2007). The cycle of cell migration 
is completed by retraction of the cells trailing edge. Detachment of the trailing edge can only 
be achieved by disassembly of the adhesive anchorage sites that form in the early stages of cell 
motility. The detachment of adhesive complexes occurs by the interaction of microtubules with 
focal adhesions. Microtubules bind to adhesion complexes and induce release of cytoskeletal 
stress fibres that were responsible for the mechanotransduction of cellular contraction force 
leading to detachment of cell-ECM adhesive contacts (Broussard et al, 2008; Kaverina et al, 
1999; Raab et al, 2017). It is important to note that migration is a highly dynamic process and 
many of the aforementioned functions often occur concurrently in different regions of the cell.  
 31 
 
1.10.3.2 Molecular regulation of cell motility 
The individual processes in cell migration are regulated by interaction of intercellular regulatory 
molecules which influence cell mechanics. The Rho family of GTPases are small guanine 
nucleotide-binding proteins that, coupled with downstream effectors, act as molecular switches 
within the cell and can stimulate cytoskeletal conformational change and the formation of 
adhesive complexes. Though there are over 20 members of the Rho family, Rac1, RhoA and 
CDC42 are thought to be the most significant in relation to cell motility (Lawson et al, 2017). 
Intercellular Rac1 and CDC42 proteins are activated in response to external stimuli. Through 
interaction with the downstream effectors Wiskott–Aldrich syndrome protein (WASP) and 
WASP-family verprolin homologue (WAVE), which in turn activate the Arp2/3 complex, RAC1 
and CDC42 regulate lamellipodial actin dynamics through repeated actin polymerisation. This 
leads to cellular polarity due to the initial formation of cellular protrusions and the leading edge 
(Tapon et al, 1997); however, in general the formation of broad lamellipodial pods are thought 
to be due to the action of RAC1 whereas formation of filopodia is due to the action of CDC42 
with actin at the peripheral regions of the leading edge (Hernández-Vásquez et al, 2017). RhoA 
proteins are primarily located towards the rear and the trailing edge of the migrating cell 
(Kurokawa et al, 2005). Following activation, RhoA stimulates its downstream serine/threonine 
kinase effector rho-associated coiled-coil-containing protein kinase (ROCK1 and ROCK2). 
Myosin phosphatases bind to myosin II and prevent its phosphorylation hence interaction with 
actin filaments due to relaxed state of myosin.  ROCK proteins inactivate myosin phosphatase 
subunits thus allowing continued myosin II phosphorylation (Foxall et al, 2016).  Activated 
myosin II promotes the maturation of nascent adhesion molecules in focal adhesion complexes 
thus permitting mechanotransduction of force from actomyosin contraction and the generation 
of tractional forces which propel the cell forward (Machacek et al, 2009; Parsons et al, 2010).  
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1.10.4 Myofibroblasts  
Myofibroblasts are terminally differentiated fibroblasts that are distinguished by responses to 
specific stimuli (Schmitt-Gräff et al, 1994). Myofibroblasts are characterised by incorporation 
of smooth muscle actin into their cytoskeletons, this actin isoform is not found in 
undifferentiated fibroblasts and is generally only present in smooth muscle cells (Gabbiani, 
2003; Tomasek et al, 2002). Fibroblast to myofibroblast differentiation occurs in response to a 
number of interlinked factors and only following a normal wound healing response. During the 
proliferative phase of wound healing local fibroblast proliferation increases significantly. Each 
new fibroblast recruited to the site generates new cell-ECM contacts through secretion of 
collagens and fibronectin; this secretion generally occurs along lines of tension increasing 
mechanical stress at the site (Hinz et al, 2001). Migrating fibroblasts, within the dynamic ECM 
complex, exert tractional forces between their cell body and the ECM molecules to which they 
are attached, this leads to increased rigidity between fibroblast-ECM contacts and increased 
intercellular stress resulting in a myofibroblast differentiation response (Hinz et al, 2003).  
Coupled with mechanical stress the presence of elevated levels of transforming growth factor 
1 (TGFβ1) at the wound site is also understood to play a causal role in fibroblast to 
myofibroblast differentiation (Marinković et al, 2012). TGFβ1 is present in the ECM milieu in 
its latent form and is activated in response to environmental changes such as imbalances in pH, 
oxidative stress or due to proteolytic cleavage that would likely occur during a wound healing 
response. Activated TGβ1 has been shown to stimulate fibroblast to myofibroblast 
differentiation as treated cells subsequently express smooth muscle actin (Vaughan et al, 2000); 
furthermore, this has been shown to occur both in vitro and in vivo (Desmoulière et al, 1992). 
In addition, inhibition of TGFβ1 during the wound healing process has been shown to 
significantly decrease smooth muscle actin levels in local fibroblast populations indicating 
decreased overall differentiation (Hinz et al, 2001). Although the precise involvement of 
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TGFβ1 in myofibroblast differentiation remains unclear it has been speculated that due to the 
physiological effects of TGFβ1 on cell migration, proliferation and adhesion, TGFβ1 may 
induce mechanosensitivity in the local fibroblast populations leading to an exaggerated 
response to mechanical stresses and thus myofibroblast differentiation (Hinz et al, 2003). An 
important distinction to make is that in healthy tissues this fibroblast to myofibroblast 
differentiation does not occur. This is due to latency of TGFβ1 and the relative elasticity of the 
ECM as a result of a mature network collagen fibres, elastin fibres and glycosaminoglycans. 
Due to the ability of these ECM fibres to deform, less mechanical stresses are transferred to the 
largely quiescent ECM embedded fibroblasts. These fibroblasts also have fewer cell-ECM 
contacts which further decreases cell stress and prevents differentiation (Hinz et al, 2003.  
Myofibroblasts are highly responsive to the effect of secreted cytokines at the site of injury, as 
a result these cells are involved in the secretion of large amounts of ECM related molecules, 
particularly during the proliferative phase of healing when collagen production is significantly 
greater than collagen degradation by MMPs (Bagalad et al, 2017). In addition to producing 
significant amounts of ECM myofibroblasts are also pivotal to wound contracture. 
Myofibroblast contraction is associated with its characteristic smooth muscle actins interaction 
with non-muscle myosin; this generates the contractile forces responsible for wound contraction 
(Powell et al, 1999). Mechanotransduction of contractile forces generated by myofibroblasts 
during this process are transferred from intercellular actin stress fibres to the ECM through use 
of specialised transmembrane molecules which connect cytoskeletal components to integrin 
associated fibronectin (Powell et al, 1999; Tomasek et al, 2002); this contractile force reduces 
the space between ECM components leading to gradual wound contraction. Following wound 
contraction, local myofibroblasts undergo apoptosis in order to prevent an exaggerated wound 
healing response (Desmoulière et al, 1995); however, in some cases myofibroblasts may persist 
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in the wound site, in such cases pathological healing can occur leading to incidence of 
hypertrophic scarring and fibrosis (Tomasek et al, 2002; Van De Water et al, 2013). 
1.11  Wound healing  
A wound is characterised by damage or disruption to the normal anatomical form and function 
of biological tissues. This damage can range from superficial injury due to breakdown of 
epithelial integrity to damage of multiple tissue types extending into subcutaneous matter 
causing perturbations to nerves, blood vessels and organs as well other tissue types (Robson et 
al, 2001). In the case of primary cleft repair, surgical incisions are required to re-orientate 
tissues into the correct plane restoring the aesthetic and functional roles of the lip and palate. 
This process results in formation of wounds along lines of incision which are sutured together 
to enable primary intention wound healing. However, if the normal wound healing process is 
disturbed by overproduction of ECM by local fibroblasts, HTS can occur and the precise tissue 
orientation can become disrupted leading to tissue regression and failed repairs.  
1.11.1  Normal wound healing  
The role of wound healing is to restore normal tissue integrity and function. This process is 
governed by complex interplay between an array of immunological, cellular and biochemical 
components in an organised cascade which work in unison to deliver adequate repair over a 
predictable period of time. Wound healing occurs in three major overlapping phases: the 
inflammatory phase, the proliferative phase and the maturational phase. Wound healing can 
occur by primary intention, where wound boundaries are held adjacent to each other to promote 
faster healing, or by secondary intention when wound boundaries cannot be placed in proximity.  
1.11.1.1 Inflammatory phase 
Immediately following the generation of a wound, extravasation of blood into the injured tissue 
triggers vasoconstriction of local blood vessels with the functional aim of preventing 
exsanguination. Combined with this vasoconstrictive reflex, both the extrinsic and intrinsic 
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coagulation cascade are activated (Sinno et al, 2013).  This leads to aggregation of platelets at 
the site which in turn interact with exposed collagen and other extracellular matrix molecules 
leading to release of clotting factors and the eventual formation of a blood clot comprising 
principally fibrin and fibronectin (Hawiger, 1987). This fibrin clot acts as a provisional matrix 
onto which cell migration can occur during the later stages of wound healing. Degranulation of 
platelets at the site leads to release of stored growth factors and cytokines via the exocytotic 
function of platelets; this increases local concentration of chemoattractants such as epidermal 
growth factor (EGF), platelet derived growth factor (PDGF) and transforming growth factor 
beta (TGFβ) which leads to the initial migration of neutrophils to the site (Lawrence, 1998). 
Neutrophils remove foreign particulate matter and scavenge for debris and also phagocytose 
any bacteria at the site.  Monocytes are then attracted to the wound site and alongside removing 
foreign bodies, secrete increased quantities of EGF, PDGF and TGFβ in an autocrine fashion 
leading to the recruitment of fibroblasts, which deposit provisional ECM, and promotion of 
angiogenesis (Broughton et al, 2006). This marks the end of the inflammatory phase and the 
start of the proliferative phase.  
1.11.1.2 Proliferative phase 
Following attainment of haemostasis and a successful immune response the wound begins to 
undergo intensive tissue repair through the proliferative phase of wound healing (Young et al, 
2011). The proliferative phase is initiated approximately 48 hours post injury and generally 
overlaps with the inflammatory phase. The proliferative phase is characterised by increased 
cellular growth and activity due to the functional aim of replacing the fibrin clot, which offers 
limited protection against further traumatic injury, coupled with revascularisation, wound 
contraction and epithelisation of the wound site (Gonzalez et al, 2016). The proliferative phase 
can take up to 3 week following wounding based on the type of tissue effected, severity, age 
and general health of the patient (Guo et al, 2010) 
 36 
 
1.11.1.2.1 The role of fibroblasts in the proliferative phase of wound healing  
Fibroblasts from tissues adjacent to the site of injury migrate into the wound in response to 
chemotactic proteins secreted during the inflammatory response, the secreted chemokines at 
the wound site are diverse general include members of the epidermal growth factors (EGF), 
fibroblast growth factor (FGF) and Transforming growth factor (TGF) families (Barrientos et 
al, 2008) are diverse. Fibroblasts are able to migrate into the fibrin clot and subsequently break 
down, the fibrin and fibronectin in the provisional matrix by the action of secreted matrix 
metalloproteases (MMPs). Once at the site of injury fibroblasts are stimulated by local 
cytokines, including TGFs which have been shown be potent fibroblast mitogens and also act 
to increase fibroblast collagen deposition and differentiation (Liu et al, 2016), this stimulates 
fibroblasts to undergo extensive proliferation to generate an increased concentration in the 
injured area (Stadelmann et al, 1998). Fibroblasts secrete extracellular matrix proteins, namely: 
hyaluronic acid, fibronectin, and proteoglycans such as heparan sulphate, chondroitin sulphate 
and dermatan sulphate which are all deposited into the surrounding tissues aiding in the 
formation of granulation tissue (Bainbridge, 2013). Fibroblasts also synthesise collagens which 
are essential ECM components that provide mechanical integrity and support to the repair site 
and replace the fibrin clot foundation which provided little resistance to further traumatic injury. 
This collagen matrix also provides a surface upon which other cell types can adhere and migrate 
thereby aiding in eventual angiogenesis and connective tissue formation (Robson et al, 2001).  
During the proliferative phase, collagen production by fibroblasts is significantly higher than 
collagen breakdown leading to a net gain of total collagen at the wound site. This collagen 
contains a higher proportion of unorganised collagen type III (40%) when compared with 
normal uninjured tissues (20%) (Velnar et al, 2009). During the proliferative phase of wound 
healing fibroblasts differentiate into myofibroblasts in response to elevated TGFB1 
concentrations (Evans et al, 2003) and increased tractional forces across the ECM produced by 
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migrating fibroblasts (Li and Wang, 2011). Myofibroblast differentiation at the site leads to 
wound contracture due the interaction of smooth muscle actin with myosin based complexes 
which generate contractile force which pull the wound edges into proximity (Shin et al, 2004). 
1.11.1.2.2 Revascularisation  
Increased cellular activity at the wound site increases local oxygen and nutrient requirements 
which is provided through angiogenesis initiated in response to secreted growth factors such as 
vascular endothelial growth factor (VEGF) and a decreased local pH. These conditions promote 
migration of endothelial cells to the wound site which migrate out from damaged or pre-existing 
capillaries forming capillary sprouts (Greenhalgh, 1998). This vascular sprouting is the 
foundation of new blood vessels as the sprouts grow due to proliferation and eventually 
reattaching to neighbouring blood vessels thereby increasing local blood flow and giving 
granulation tissue its distinctive red colour (Tonnesen et al, 2000).   
1.11.1.2.3 Epithelialisation  
Epithelialisation begins to occur a few hours following injury when the basal layer around the 
periphery of the wound begins to increase in size due to increased epithelial proliferation. 
Epithelial cells then detach from the periphery of the wound and migrate along the deposited 
collagen fibres across the surface of the wound as epithelial sheets (Baum et al, 2005), 
continued proliferation leads to multilayers and the eventual epithelisation (Pastar et al, 2014).  
1.11.1.3 Maturational phase 
The final phase of the healing process commences approximately 8 days after injury and is 
related to the maturation of the repair in a process that can take many months to reach 
completion (Broughton et al, 2006) as it is focussed primarily on the development of new 
epithelium and the formation of scar tissue. The remodelling phase begins when the collagen 
production and collagen degradation reach equilibrium, following this the disorganised 
collagen type III fibres, which were produced abundantly by fibroblasts during the proliferative 
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phase, are gradually replaced by the more organised collagen type I.  Due to this, the tensile 
strength of the scar tissue is increased reaching 50% of the strength of surrounding uninjured 
tissues after 3 months and eventually 80% strength following completion of the healing process 
(Morton et al, 2016); despite completion of wound healing scar tissue does not reach the same 
level of tissue integrity as uninjured tissue. 
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1.12 Aims of the study 
Background: Following cleft repair approximately 10% of patients develop ONF (Hardwicke 
et al, 2014) and 25% develop HTS (Soltani et al, 2012). To date a number of risk factors have 
been suggested including width of cleft and surgical protocol, although these are likely 
contributory factors, it is possible that pathological wound healing, due to fundamental 
differences in fibroblast behaviour at the wound site, can also contribute to the development of 
these post-operative complications.  
Aim: To investigate the differences in extracellular matrix production and expression between 
cleft fibroblast to identify markers that may be associated with the pathological wound healing. 
Background: Due to the formation of the lip and palate being distinct embryological events 
coupled with the high incidence of cleft lip and cleft palate occurring in isolation, it has been 
speculated that CL, CP and CLP may be disparate clinical entities with differing causation. As 
expansion of the facial growth centres occurs in part due to extracellular matrix accumulation, 
it is possible that differences in the behaviour of fibroblasts, which are the principle secretors 
of ECM, may be associated with cleft phenotype.  
Aim: To characterise the behaviour of cleft fibroblasts isolated from patients with differing 
cleft phenotypes to determine whether they are physiologically distinct.  
Background: Folate deficiency has been repeatedly associated cleft development (Jahanbin et 
al, 2019). Despite this, the precise physiological mechanisms and cell behaviours that are 
contributed to by folic acid in order for it to induce its protective function remains undefined.  
Aim: To investigate the behavioural changes induced by the presence of folic acid to cleft 
fibroblasts in vitro.  
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CHAPTER TWO:  
MATERIALS AND METHODS  
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2.1 Ethical approval for collection of human tissue following cleft repair 
All work including sample collection and subsequent tissue processing was fully compliant 
with the University of Birmingham’s ethical code of conduct. Ethical approval for the project 
entitled “Cellular characterisation of the human cleft palate with clinical correlation” (IRAS 
project ID: 171283) was obtained prior to sample collection (REC reference: 15/NW/0079).  
Samples were stored and anonymised by the Human Tissue Authority (HTA) licenced Human 
Biomaterials Resource Centre (HBRC reference: 13-163) based at the University of 
Birmingham. In addition, prior to commencement of the project, training for Good Clinical 
Practice (GCP) was successfully completed and certification was awarded by the National 
Institute of Health Research Clinical Research Network (NIHR CRN).  
2.1.1 Sample collection 
Samples were collected from patient’s undergoing primary surgery to repair cleft lip only (CL), 
cleft palate only (CP) or cleft lip and palate (CLP) at the Birmingham Children’s Hospital 
(BCH) irrespective of gender or ethnic background in order to obtain a broad sample cohort. 
Patients previously diagnosed by BCH clinicians as presenting physical characteristics 
indicative of syndromic forms of CLP as well as patients undergoing revision surgery were 
excluded from the study. Consent was obtained from the child’s legal guardian by completion 
of HBRC documentation after the aims of the project were clearly explained and any queries 
addressed. The samples that were collected are summarised in table 1. 
2.1.2 Transportation of samples 
During surgical cleft repair, tissue excess to requirement was removed and wrapped in sterile 
gauze and placed into a sterile universal container, which contained 10ml of Dulbecco's 
modified eagle medium (DMEM), in theatre. Samples were then immediately transported to 
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the BCH laboratories where they were logged and the containers packaged ready for transport. 
Samples were then sent to the HBRC by licensed carriers where the samples were anonymised 
and any patient related information recorded and stored for the duration of the project. Samples 
were then transported to the Birmingham Dental Hospital laboratories (BDH) for tissue 
processing. Transportation of samples was conducted as quickly and efficiently as possible with 
less than 2 hours from operating theatre to BDH laboratories (Figure 4). 
 
 
 
Epidermis removal via overnight 
incubation in trypsin-EDTA 
Cell based assays
Cell staining
Real time PCR
Explant culture followed by 
fibroblast isolation
Cleft patients identified 
from surgical schedule 
Patients assessed in 
order to confirm they 
meet the slection 
criteria
Consent obtained from 
legal guardian prior to 
surgery
Tissue samples 
collected from theatre
Samples logged at BCH 
laboratories and 
transported to the 
HBRC
Anonymised samples 
recived at BDH 
laboratories from the 
HBRC
Figure 4: (A) Summary of sample collection protocol. (B) general fibroblast characterisation 
protocol following arrival of cleft tissue samples  
(A) 
(B) 
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Patient ID ID number Study group Tissue type CLP (LIP) CLP (PALATE) CL CP Lip tissue Palate tissue LUCLP RUCLP BLCLP Age (days) Weight (kg) Sex
S101590 15 CLP (LIP) LIP 1 0 0 0 1 0 1 0 0 113 5.8 M
S101593 16 CLP (PALATE) PALATE 0 1 0 0 0 1 0 0 1 252 13.5 M
S101594 17 CLP (LIP) LIP 1 0 0 0 1 0 1 0 0 129 7 M
S101637 6 CLP (LIP) LIP 1 0 0 0 1 0 0 0 1 111 5.7 F
S101633 2 CL LIP 0 0 1 0 1 0 0 0 0 128 6.2 M
S101636 12 CL LIP 0 0 1 0 1 0 0 0 0 186 7.5 M
S101597 8 CLP (PALATE) PALATE 0 1 0 0 0 1 1 0 0 186 8 F
S101596 4 CL LIP 0 0 1 0 1 0 0 0 0 104 7.2 F
S101600 3 CLP (PALATE) PALATE 0 1 0 0 0 1 0 1 0 176 6.3 M
S101635 5 CLP (PALATE) PALATE 0 1 0 0 0 1 0 1 0 227 5.6 F
S101601 9 CLP (LIP) LIP 1 0 0 0 1 0 0 1 0 227 5.6 F
S101603 10 CLP (LIP) LIP 1 0 0 0 1 0 1 0 0 132 7.5 M
S101632 1 CLP (LIP) LIP 1 0 0 0 1 0 0 0 1 130 6.9 M
S101604 14 CLP (LIP) LIP 1 0 0 0 1 0 1 0 0 109 6.8 M
S101631 11 CLP (PALATE) PALATE 0 1 0 0 0 1 0 1 0 179 6.9 F
S101634 13 CLP (LIP) LIP 1 0 0 0 1 0 0 1 0 179 6.9 F
S101605 7 CLP (PALATE) PALATE 0 1 0 0 0 1 1 0 0 241 8.8 M
S230110 25 CLP (PALATE) PALATE 0 1 0 0 0 1 0 1 0 254 8.1 F
S245930 27 CLP (PALATE) PALATE 0 1 0 0 0 1 0 0 1 255 8.9 M
S248308 20 CL LIP 0 0 1 0 1 0 0 0 0 89 4.3 F
S250290 23 CLP (LIP) LIP 1 0 0 0 1 0 0 0 1 141 6.28 F
S245348 22 CLP (PALATE) PALATE 0 1 0 0 0 1 0 1 0 218 9.2 M
S277778 19 CL LIP 0 0 1 0 1 0 0 0 0 168 - M
S278580 26 CL LIP 0 0 1 0 1 0 0 0 0 193 - F
S281630 24 CP PALATE 0 0 0 1 0 1 0 0 0 463 - M
S281750 18 CP PALATE 0 0 0 1 0 1 0 0 0 220 - M
S285028 28 CP PALATE 0 0 0 1 0 1 0 0 0 372 - M
S286370 21 CP PALATE 0 0 0 1 0 1 0 0 0 544 - F
S287316 29 CP PALATE 0 0 0 1 0 1 0 0 0 285 8.2 M
Total = 29 Total = 29 Total = 4 Total = 2 Total = 9 Total = 9 Total = 6 Total = 5 Total = 15 Total = 14 Total = 6 Total = 7 Total = 5 Total = 29 Total = 23 Total = 29
CLEFT SAMPLES FOR CELL CULTURE
Table 1: Summary of details pertaining to cleft tissue samples collected from the BCH where: 1 = positive and 0 = negative. Patient ID = 
anonymised patient reference number; ID number = shorthand notation used for laboratory purposes; CLP (LIP) = lip tissues isolated from patients 
with CLP; CLP (PALATE) = palatal tissues isolated from patient with CLP; CL = cleft lip; CP = cleft palate; LUCLP = left unilateral CLP; 
RUCLP = right unilateral CLP; BLCLP = bilateral CLP. 
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2.2 Cell culture 
All cell culture and tissue processing was conducted aseptically and, unless otherwise stated, 
were conducted within a Guardian MSC TI200 class II laminar flow cabinet (Monmouth 
Scientific, UK). All cultures were maintained at 37°C in an atmosphere of 5% CO2 in a 
humidified Heracell™ 150i CO2 incubator (Thermo Fisher Scientific, UK). Cells were cultured 
in tissue culture treated T75 Nunc™ EasYFlask flasks (Thermo Fisher Scientific, UK). Unless 
otherwise stated, cells were cultures in Dulbecco’s modified eagles medium (DMEM) (Biosera, 
UK), which was supplemented with: 10% foetal bovine serum (FBS) (Biosera, UK), 2.5% 4-
(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) buffer (1M) (Sigma, UK), 1% 
Penicillin-Streptomycin (10mg/ml) (Sigma, UK), 1% amphotericin B (250 μg/ml) and 1% L-
glutamine (200 mM) (Sigma, UK). Cultures were monitored using an inverted light microscope 
(Primovert, Zeiss, Germany) was used to assess the degree of confluence, monitor for signs of 
infection and cell counting. Cell counts were conducted using an improved Neubauer 
haemocytometer (Agar Scientific, UK). 
2.2.1 Primary fibroblast isolation and culture 
Fresh excess cleft lip and palate tissue was obtained from CLP patients and stored in 5ml 
trypsin- ethylenediaminetetraacetic acid (EDTA) (0.25%) (Invitrogen, UK) overnight at 4°C in 
order to facilitate detachment of the epidermis. Following overnight incubation, sterile scalpels 
were used in order to remove the epidermis from the underlying tissue.  This submucosal 
connective tissue was fragmented into approximately 1mm2 fragments, using a sterile scalpel 
and placed into a T25 flask, with sterile tweezers, to permit adherence. CLP fibroblasts were 
cultured via explant culture in supplemented DMEM (sDMEM), as per the supplementation 
protocol described in section 2.2, and were maintained in controlled incubators. Culture 
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medium was removed and replenished 5 days after initial seeding, so explants were not 
disrupted, and every 2 days subsequently. 
2.2.2 Sub-culturing 
When 80% confluent, cell cultures were rinsed with 5ml 37°C phosphate buffered saline (PBS) 
in order to remove any residual supplemented DMEM that could potentially interfere with cell 
detachment. Cells were then treated with 4ml trypsin-EDTA (0.25%) and incubated at 37°C for 
approximately 5 minutes, light microscopy was utilised in order to visually inspect the cells to 
assess if they had detached from the surface of the flask. When all cells were detached, 4ml 
sDMEM was added to the flask in order to inactivate the trypsin-EDTA. This solution was then 
transferred to a universal tube and centrifuged (Jouan, UK) at 900rpm for 5 minutes to create a 
cell pellet in the base of the universal. The supernatant was then aspirated followed by 
resuspension of the cell pellet in 5ml sDMEM ready for cell seeding and counting.  
2.2.3 Cell counting 
Cells were pelleted and re-suspended as described in section 2.2.2. Cells were then counted 
using a haemocytometer following cleaning of the surface. Coverslips were first placed onto 
the counting platform of the haemocytometer followed by the addition of ten microliters of cell 
suspension which was pipetted into the counting chamber and viewed using a light microscope.   
The counting chamber comprised of four separate grids, each comprising of 16 distinct equally 
sized squares, the number of cells in each grid was counted and an average was calculated. For 
consistency the cells touching the upper or left boundaries of the grid were excluded whilst 
those on the lower and the right of the grid were included. Once the average cell number per 
gird was obtained, the value was multiplied by 1x104 thereby providing the number of cells/ml 
and this value was corrected with the corresponding dilution factors in order to obtain the total 
cell number in the cell suspension. 
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2.2.4 Cryopreservation and cell retrieval  
Following subculture, cells were cryopreserved in order to maintain stocks of cells at low 
passage for all future experiments. Once pelleted, cells were re-suspended to a concentration of 
1x106 cells/ml in cryopreservation media which consisted of: 60% Supplemented DMEM, 30% 
FBS and 10% dimethyl sulfoxide (DMSO) (Sigma, UK). This cell suspension was then placed 
into cryogenic vials (Thermo Fisher Scientific, UK) and stored in expanded polystyrene boxes, 
which permit gradual changes in temperature, overnight in an ultra-low temperature freezer at 
-80°C (New Brunswick, UK). The cryovials were then transferred to liquid phase nitrogen 
dewars for long term storage at -196°C. When required, cryopreserved cells were retrieved from 
storage and rapidly thawed in a water bath (Grant, UK) at 37°C, this was then diluted into 10ml 
of sDMEM. Following centrifugation (900g for 5 minutes), the supernatant was aspirated and 
cell pellets were re-suspended in sDMEM and seeded into T75 flasks. 
2.3 Supplementation with experimental reagents  
A number of dietary factors and cytokines can have a significant effect on cell behaviour. In 
order to assess the effects of folic acid, transforming growth factor alpha (TGFα) and members 
of the transforming growth factor beta (TGFβ) superfamily, these were added in a range of 
physiologically relevant concentrations into cell cultures following cell seeding. See table 2 for 
details relating to dilution protocols and concentrations used to treat cells. The normal 
formulation for DMEM contains a basal level of FA therefore for the purposes of FA 
supplementation studies FA negative sDMEM (Sigma, UK) was used. This media was utilised 
so that cell behaviour in the absence of FA could be observed whilst permitting controlled and 
consistent FA concentrations throughout all experiments.  
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Experimental 
reagent 
Reconstitution protocol Concentrations 
used for 
experiments 
Source 
Folic acid 1M NaOH for a 50mg/ml stock. 
Primary stocks were diluted in 
deionised water to make secondary 
stocks of 1mg/ml. 
20nM, 10μM, 
20μM, 30μM  
Sigma, UK 
Recombinant 
Human TGF-β1 
10mM citric acid for 0.1mg/ml stock 5nM and 20nM  PeproTech UK 
(100-21) 
Recombinant 
Human TGF-β2 
Deionised water for 0.1mg/ml stock 5nM and 20nM PeproTech UK 
(100-35B) 
Recombinant 
Human TGF-β3 
10mM citric acid for 0.1mg/ml stock 5nM and 20nM PeproTech UK 
(100-36E) 
Recombinant 
Human TGF-α 
Deionised water for 1mg/ml stock 5nM and 20nM PeproTech UK 
(100-16A) 
Table 2: Experimental reagents employed to assess how cleft fibroblasts respond following 
their addition to the supplementation protocol; all reagents were reconstituted according to the 
manufacturer’s recommendation.  
 
2.4 Cell proliferation assays 
A number of methodologies were employed in which indicate the total cell number within 
cultures which, when paired with data relating to the initial seeding densities and culture 
duration, can be used to infer cell proliferation rates. These included growth curves obtained 
via manual counts from which population doubling times (DT) were calculated and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays which require 
spectrophotometric analysis. 
2.4.1 Growth curves and doubling times 
In order to assess how CLP fibroblasts grew in culture growth curve models were employed. 
Once cells had reached approximately 80% confluence cells were trypsinised, pelleted and re-
suspended as previously described (section 2.2.2). Cells were then seeded into 35mm petri 
dishes (Corning, UK) at a concentration of 5x104 and incubated at 37°C. Cell growth was then 
assessed by counting the number of cells in each 35mm petri dish every 48 hours post-seeding, 
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until confluence was reached, using a haemocytometer as previously described in section 2.2.3. 
In order to calculate population doubling times the following equation was used:  
𝐃𝐨𝐮𝐛𝐥𝐢𝐧𝐠 𝐭𝐢𝐦𝐞 =
Duration (hours in culture) x log(2)
log(final  concentration) − log(initial concentration)
 
 
 
2.4.2 MTT assay as an indicator of cell proliferation 
Cell metabolic activity was assessed through use of the MTT reduction assay (Vybrant® MTT 
Cell Proliferation Assay Kit, Thermo Fisher scientific UK), from which data pertaining to cell 
growth was extrapolated. The MTT assay is based on a redox reaction between MTT and the 
mitochondrial respiration products NADH and NADPH, which results in the yellow MTT 
solution forming insoluble purple formazan crystals (Koyanagi et al, 2016).  This reaction takes 
place due to the presence of mitochondrial reductase which is present in live cells thus the 
amount of formazan produced can be related to the number of viable respiring cells. This 
reaction can also act as an indication of cell proliferation as generally the higher the number of 
active cells the greater the concentration of formazan crystals that form, though increased 
cellular respiration due to external factors may also have an effect. Cells were seeded into 96 
well plates (Thermo Fisher Scientific, UK) at a concentration of 2.5x103 followed by the 
addition of 200μl of supplemented DMEM in each well. This assay involved the addition of 
10μl MTT (5mg/ml in PBS) per 100μl of media in each well followed by incubation at 37°C 
for 4 hours, the media was then removed and 50μl DMSO was added to each well which acts 
as a solubilising agent to dissolve the formazan crystals. The 96 well plate was then placed onto 
a plate rocker for 5 minutes, to aid in crystal dissolution, followed by insertion into a universal 
microplate spectrophotometer (ELx 800, Bio-TEK instruments) and the absorbance of each 
Equation 1: equation used in order to calculate fibroblast doubling times 
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well was measured at 540nm and were conducted daily. Blank cell negative wells were used as 
controls and were treated as previously described, when cells were treated with experimental 
reagents, see table 2, negative controls were also implemented within which samples were 
subject to the same methodology as above but in the absence of the experimental variable.  
2.5  Cell viability assays 
2.5.1 Trypan blue dye exclusion assay  
The Trypan blue dye exclusion assay is commonly to stain non-viable cells. Trypan blue is 
negatively charged and does not interact with viable cells, however cells with damaged 
membranes readily absorb the dye causing them to be stained blue and observable under light 
microscopy. Cleft fibroblasts were pelleted and re-suspended, 100μl of this cell suspension was 
then placed in an Eppendorf tube containing an equal of Trypan blue dye (0.4%) (Sigma, UK). 
Damage to the integrity of cell membranes leads to uptake the dye, causing them to be labelled 
blue, and regarded as non-viable; cells that do not uptake the dye remain unstained and are 
considered viable. The number of viable and non-viable cells are counted as in section 2.2.2. 
Percentage cell viability is then calculated using the following equation: 
𝐕𝐢𝐚𝐛𝐥𝐞 𝐜𝐞𝐥𝐥𝐬 (%) = [1.00– (𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 ÷ 𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟𝑜𝑓 𝑐𝑒𝑙𝑙𝑠)] × 100 
 
2.5.2 Live/dead viability assay 
Live/dead assays are common dye-based cell viability assays whereby live cells are stained 
with calcein AM (Ebioscience, UK) and generally fluoresce green while non-viable cells are 
stained with propidium iodide (Sigma, UK) and fluoresce red however fluorescence can be 
varied due to differing dye illuminating wavelengths. Calcein AM is cell permeable, when it 
passes through the cell membrane of a viable cells the presence of active intracellular esterases 
Equation 2: equation used in order to calculate cell viability  
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cleave ester groups thereby converting the structure of dye so that it fluoresces green, this 
reaction does not occur in non-viable cells. Propidium iodide penetrates damaged cell 
membranes where the dye interacts with negatively charged nucleic acids producing red 
fluorescence in non-viable cells. In order to conduct live/dead staining 20μl 2mM propidium 
iodide stock solution was added to 10ml of sterile serum free DMEM containing 5μl 4mM 
calcein AM stock solution; this working reagent (2µM calcein AM and 4µM propidium iodide) 
was made fresh for each assay. Two types of live/dead staining were employed: the adherent 
cell imaging and the microplate method, which was used when cell numbers were low. 
2.5.2.1 Imaging and counting labelled adherent cells 
Cells were seeded onto 35mm petri dishes at a concentration of 1x104 and cultured for 24 hours. 
Following this, cultures were incubated with 1ml live/dead working reagent for 45 minutes at 
37°C. Cells were then washed with once with PBS followed by the addition of 1ml of DMEM 
to each culture and imaged immediately using a fluorescent microscope (Nikon TE300 Inverted 
microscope, UK). If quantification was required, cells were detached from dishes by incubation 
with 2ml trypsin for 5 minutes followed by centrifugation at 900g for 5 minutes and re-
suspended in 1ml PBS, the number of green and red fluorescing cells were then counted using 
a haemocytometer.  
2.5.2.2 Microplate method 
Cells were seeded in 96-well plates at a concentration of 1x103 and cultured for 24 hours. 
Following this, 100µl live/dead working reagent was added to each well and incubated for 45 
minutes at 37°C/5% CO2 and each well was then washed with PBS followed. The fluorescence 
intensity of each well was then measured using a fluorescent microplate reader (Twinkle 
CB970, Berthold technologies, UK) at 490nm (for Calcein AM) and 530nm (Propidium iodide).  
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2.6 Selection of a suitable cell migration assay 
There are a number of cell migration assays that are used to assess migration rates in adherent 
cells. Here, three assays were assessed in order to determine the most suitable for determination 
of migration rates of cleft fibroblasts in vitro. The parameters assessed included: uniformity of 
wound area and assay reproducibility (based on the initial width of the wound and differences 
in wound area between replicates), alterations to surface topography and cell viability. 
2.6.1 Scratch wound assay 
Scratch wound assays were conducted as previously described (Liang et al, 2007).  CLP 
fibroblasts grown in T75 flasks were re-suspended into sDMEM and subsequently seeded into 
six well plates at concentration of 5x105 and grown to confluence. Once cells reached the 
suitable level of confluence was determined via microscopy, a 200μl pipette tip was used to 
scratch the monolayer through the centre of the well in one precise movement, and this approach 
introduced a linear wound with a defined margin. Each well was then washed twice with 
phosphate buffered saline (PBS) in order to remove the cellular debris created by scratching the 
monolayer leaving a cell free region.  
Following comparative analysis, the scratch wound assay was deemed unsuitable for the 
analysis of cleft fibroblast migration due its lack of reproducibility as a result of its tendency to 
produced wounds with irregular margins and varying wound widths across the length of the 
scratch. Further, it was shown that the mechanical disruption of the monolayer led to significant 
topographical damage to the tissue culture polystyrene which manifested as linear abrasions 
across the surface; this also resulted in significant cell death along the wound margins which 
persisted despite washing with PBS.  
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2.6.2 Parafilm assay 
Parafilm (Pechiney Plastic, USA) was cut into 1mm x 20mm strips using a scalpel, and was 
subsequently disinfected by immersion in hydrogen peroxide for 30 minutes and air dried. 
Using sterile tweezers, the strips were placed across the centre of a six well plate and adhered 
to the tissue culture polystyrene by application of gentle pressure with the tweezers. Once the 
Parafilm was in place cells were seeded into the well at a concentration of 5x105 and were 
grown to confluence. Once this level of confluence was confirmed through microscopy, sterile 
tweezers were employed to gently detach the Parafilm from one side in order to permit removal 
of the strip in one precise movement. The well was then washed twice with PBS leaving a cell 
free region in place of the Parafilm strip.  
The Parafilm assay was also deemed to be unsuitable for the comparison of cleft fibroblast 
migration derived from different patients. This was due to the deposition of hydrophobic 
paraffin residues on the surface of the cell free region following removal of the Parafilm strip, 
which could potentially disrupt normal fibroblast motility. Further, there was considerable 
fibroblast migration beneath Parafilm prior to its removal which led to irregular initial cell 
boundaries at the periphery of the wound.    
2.6.3 Ibidi cell migration assays 
Ibidi culture inserts (Thistle Scientific, UK) are commercially available cell culture inserts that 
enable the production of defined linear 500μm cell free region. This is achieved due to 
separation of two small silicone wells by 500μm thick wall. The Ibidi culture insert was used 
according to the manufacturer’s recommendation and placed into a 35mm petri dish, the 
presence of an inert degradable surface coating at the bottom of the insert permits firm 
adherence to tissue culture polystyrene. Cells were then seeded into each well at a concentration 
of 5x104 and grown to confluence at which point the insert was removed using sterile tweezers 
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and the petri dish was washed twice in PBS, leaving a linear cell free region with reproducible 
dimensions (Figure 5). The Ibidi cell migration assay was deemed most suitable assay for the 
comparative assessment of cleft fibroblast migration in vitro. This was due to its generation of 
a defined cell free region with well-defined borders within a confluent monolayer. Further, there 
was no cell migration beneath the insert prior it its removal indicating the insert was tightly 
adhered to the well. There was a slight residual material following removal of the insert but this 
was shown to dissipate following washing with PBS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
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Figure 5: Ibidi in vitro migration assay. (A) Photograph of Ibidi tissue culture insert adhered 
to the base of a multiwall (B) Cell free region produced following removal of the insert.  
(A) 
(B) 
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Figure 6:  Imaging of cell wound closure using three different wound healing 
assay at 0 hours and 24 hours. (A) At 0 hours the initial cell free region formed 
via scratching the surface of the monolayer was irregular along the wound edge 
there also seemed to be a build-up of cells along the periphery of the wound despite 
washing. (B) At 24 hours cells had begun to migrate into the wound but there was 
also a cluster of dead cells visible (arrowed) which may have been cells wounded 
by scratching the monolayer. (C) The Parafilm strip assay produced the largest cell 
free region at 0 hours however there were a number of cells that migrated 
underneath the Parafilm where the strip was attached (green arrow). Additionally, 
there was a visible deposition of material onto the surface of the cell culture dish 
(red arrow). (D) At 24 hours cells had begun to migrate into the wound and the 
deposited surface residue was still present after 24 hours (arrowed). (E) The Ibidi 
insert produced a well-defined wound edge with cells growing at either side. (F) 
After 24 hours cell had begun to migrate into the wound (n=9) error bars = 200μm.  
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(A) (B) 
(C) (D) 
(E) (F) 
Figure 7: Live/dead staining for scratch, Parafilm and Ibidi wound healing 
assays. The scratch wound assay (A-B) caused clumping of cells along the wound 
edge with a number of dead cells (stained in red) being released from the base of 
the aggregation and floating into the culture. The Parafilm strip assay (C-D) did not 
lead to clearly defined borders at the wound edge as there was cell migration into 
the wound site; most cells that had migrated into the wound remained viable and of 
a regular morphology. The Ibidi wound healing assay (E-F) produced well defined 
wound edges with cells at the periphery appearing viable. Error bars = 200μm. 
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2.6.4 Proliferation inhibited cell migration assays 
 
In order to assess the potential influence of cell proliferation on the rate of cell migration, into 
a cell free area, Ibidi cell migration assays were repeated with growth inhibited cells and 
compared with their non-inhibited counterparts. Cells were treated with 4μg/ml mitomycin C 
(Sigma, UK) for 3 hours and seeded into each well of an Ibidi insert at a concentration of 5x104. 
When confluent, inserts were removed and images of cell migration into the cell free region 
were captured at multiple time points following removal.  
2.6.5 Culture substitution migration assays 
Due to the differences in cell migration rates observed between cells derived from different 
patients a culture substitution assay was developed in order to assess the effects of secreted 
cytokines and cell migratory behaviours. Two groups of cells (one fast migrating and one slow 
migrating) were seeded into separate Ibidi cell culture inserts, at a concentration of 5x104 per 
well, alongside 3ml of sDMEM, after 24 hours the culture media from both was removed and 
placed into separate vials. Ibidi inserts were them removed and cultures were washed. Next, the 
stored cell culture medium from each culture was placed into the well of the opposing cell type 
such that fast cells were supplemented with conditioned media from slow migrating cells and 
slow migrating cells were supplemented with conditioned media form fast migrating cells. 
Phase contrast images were then captured at multiple time points for later analysis wound 
closure.  
2.6.6 Image capture, processing and analysis  
Phase contrast images were obtained using a Nikon TE300 Inverted microscope (Nikon, UK) 
and captured using MicroManager (V14.1.4) at 0 hours, 12 hours, 24 hours, 48 hours after 
removal of the culture insert, or initiation of a wound. This permitted digital images of cell 
migration into the wound area to be observed at various time points and comparisons between 
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patients and experimental conditions to be made. For each replicate a total of 3 images were 
taken in order to image the whole length of the wound, surface markers were used to ensure 
that the same region was not imaged twice and all assays were conducted in triplicate providing 
a total of 9 images per patient for each time point. Images were imported into the open source 
software imageJ (version 1.51) (Schindelin et al, 2012) and a stage micrometre was used in 
order determine and set the scale. Using the free form drawing tool the boundaries of the wound 
were measured by carefully drawing around the leading edges of each opposing cell boundary 
in order to obtain the area of the wound that remained cell free. The area of any cells that had 
migrated into the wound, and were not a part of the leading edges of the wound, was measured 
and subtracted from the initial measurement in order obtain an absolute area. Cell migration 
rates were presented in terms of remaining wound area (RWA%) which was obtained using the 
following equation:  
 
𝐑𝐞𝐦𝐚𝐢𝐧𝐢𝐧𝐠 𝐰𝐨𝐮𝐧𝐝 𝐚𝐫𝐞𝐚 (%) =
Area (24 hours post wounding)
Area (0 hours post wounding)
x100 
 
 
 
2.6.7 Ibidi assays following supplementation with experimental reagents  
In order to assess the effect of FA, differing TGFβs and TGFα on wound closure, cells were 
treated with each reagent using the treatment protocol defined in table 2. Ibidi inserts were then 
utilised in order to assess cell migration as described in section 2.6.3.  
 
Equation 3: equation pertaining to the calculation of RWA(%) based on initial 
wound area and remaining wound area after 24 hours. 
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2.7 Real time polymerase chain reaction 
A quantitative real time polymerase reaction (qPCR) methodology was utilised in order to 
compare differences in the basal gene expression profiles between cleft patients. This technique 
was also employed to assess any variance in gene transcripts in response to external stimuli 
including folic acid and transforming growth factors.  
2.7.1 Cell lysis 
When cleft fibroblasts were 80% confluent, media was aspirated from T75 flasks and washed 
with PBS in order to completely remove any remnants of supplemented DMEM, as it could 
have interfered with cell lysis, and were then pelleted as in section 2.2.2. Total ribonucleic acid 
(RNA) was then extracted from cell pellets using an RNeasy mini kit (Qiagen, UK) according 
to the manufacturer’s instructions. Following centrifugation 350μl of lysis buffer (buffer RLT) 
including mercaptoethanol (Sigma, UK) was added to the cell pellet to lyse the cells, this 
solution was then transferred to an Eppendorf followed by the addition of 350μl 70% ethanol.  
2.7.2 RNA extraction 
The cell lysates were then processed further to produce the pure RNA required for cDNA 
synthesis. Following cell lysis, each 700μl sample was placed into an RNeasy spin column 
which was mounted on a collection tube which acted to collect any flow through following 
centrifugation steps. Samples were then centrifuged (Centrifuge 5415D, Eppendorf UK) at 
10,000rpm for 30 seconds to remove excess buffer whilst retaining the RNA on the spin column 
membrane. This was then washed with 350μl of buffer RW1, which was used to clean the 
sample to remove any impurities from lysed cells including remnants of carbohydrates, proteins 
and fatty acids whilst retaining the RNA. Deoxyribonuclease I (DnaseI) (Qiagen, UK) was then 
added to the RNeasy membrane and incubated at room temperature for 15 minutes to eliminate 
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any potential DNA contamination, followed by a second wash with buffer RW1. The samples 
were then washed twice with buffer RPE so that any remaining salts would be removed. The 
RNeasy spin column was then transferred to a 1.5ml collection tube followed by the addition 
of 30μl RNase free water (Sigma, UK) to the membrane. The samples were then centrifuged at 
10,000rpm for 1 minute to elute the RNA which was stored at -80°C until required. 
2.7.3 RNA quantification 
The purity and concentration of the cleft fibroblast RNA was determined by the measurement 
of the optical density (OD) of the sample using a spectrophotometer (Biophotomerter plus, 
Eppendorf UK). This analysis also assessed the absorbance ratio between 260/280nm 
(OD260/280nm), pure RNA has a ratio of 2.0 however ratios between 1.8 and 2.1 are generally 
deemed an acceptable level of purity for qPCR applications (Gallagher, 2001). To quantify and 
assess the purity of the RNA 2μl of the RNA sample was placed into a plastic cuvette containing 
68μl of diluent (RNase free water) and placed into a spectrophotometer which had already been 
normalised against the background OD of 70μl of RNase free water and the optical density was 
measured, only samples within the acceptable range were processed further.  
2.7.4 cDNA synthesis 
RNA samples were reverse transcribed to form complimentary DNA (cDNA) from each patient 
using a cDNA synthesis kit (Tetro™ Reverse Transcriptase kit, Bioline UK). Samples were 
thawed and diluted to a concentration of 2μg/ml, 12μl RNA was then placed into a 100μl tube 
containing 8μl of mastermix. The samples were incubated, using a thermal cycling block 
(Veriti, Applied Biosystems UK), at an annealing temperature of 45°C for 30 minutes to 
activate reverse transcriptase and generate DNA from an RNA template; this was followed by 
a 5-minute incubation at 85°C to deactivate enzymatic activity.  
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2.7.4.1 Concentrating cDNA  
Complimentary DNA was then diluted with RNase free water to a final volume of 500μl and 
placed into labelled micron filters (Millipore, UK). Samples were centrifuged twice at 
10,000rpm and 8,000 rpm respectively until 50μl of cDNA was achieved. The filters were then 
inverted and spun at 800rpm for 1 minute in order to elute the concentrated cDNA sample.  
2.7.5 Primer design  
Genes of interest were selected following a review of the literature and their primers were 
designed using the following online open source software. Gene ascension numbers were 
obtained by searching the Genbank nucleotide database, once the ascension number was 
identified it was input into the primer identification tool Primer-BLAST. Where possible, the 
parameters for the real time primers were set to obtain a product length between 200 base pairs 
with a guanine and cytosine content between 20-80% and melting temperatures between 57-
60°C. Details relating to primers are shown in table 3. 
2.7.5.1 Validation of real time PCR primers 
Prior to real time PCR, preliminary experiments were conducted on each primer designed to 
determine the amplification efficiency of the primers following a DNA amplification cycle. A 
primer efficiency of 2.0 denoted a 100% efficiency, meaning that the concentration of amplicon 
doubled following each PCR cycle. Although an efficiency of 2.0 is considered optimal, in 
practice primer efficiencies of 1.7–2.2 are considered acceptable for qPCR according to the 
manufacturer, as the data analysis software takes into account each primer when calculating the 
amount of amplicon (Dietrich et al, 2011). This efficiency was assessed via serial dilutions of 
test cDNA, derived from pooled cleft fibroblast RNA, in RNase free water (100%, 50%, 10%, 
1%, 0.1% and 0%) followed by efficiency analysis using a light cycler 480 (Roche, UK) (Figure 
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10).  Melt curve genotyping was conducted to confirm that only one target was being amplified 
as the presence of primer dimers could interfere with amplicon quantification (figure 11). 
2.7.6  Housekeeping genes  
Housekeeping genes (HKG) are essential for accurate qPCR analysis as HKGs offer a baseline 
point of reference, relating to the amount of amplicon, from which a ratio of gene expression 
between gene targets and HKG can be calculated and presented as fold changes. A total of 
4HKG were selected from the literature (table 3), the most suitable was determined based on 
the expression of HKG with the lowest geometric mean between all of the cleft patient cDNA. 
This was determined using the Microsoft Excel based statistical analysis program entitled 
‘Bestkeeper’ (Pfaffl et al, 2004). Based on this analysis actin beta (ACTB) was deemed the most 
suitable HKG due to the low standard deviation (SD) across the patient cohort (Figure 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8: Overview of housekeeping genes. (A) Cycle thresholds of 4 HKG assessed in 
this study. (B) Outline of data pertaining cleft patients CP’s, ACTB demonstrated the lowest 
overall standard deviation therefore was selected as the reference HKG.  
ACTB B2M GAPDH YWHAZ
geo Mean [CP] 18.47 13.37 20.83 21.12
ar Mean [CP] 18.48 13.38 20.85 21.12
min [CP] 17.62 12.47 19.06 20.54
max [CP] 18.84 14.52 22.47 21.9
std dev [± CP] 0.19 0.4 0.74 0.32
CV [% CP] 1.05 3 3.54 1.53
min [x-fold] -1.82 -1.73 -3.46 -1.49
max [x-fold] 1.3 2 3.14 1.72
std dev [± x-fold] 1.15 1.33 1.68 1.25
(A) (B) Cycle thresholds:  Housekeeping genes 
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Gene 
symbol 
Gene name Accession 
number 
Primer sequence (5’ – 3’) Amplicon 
size (bp) 
Efficiency 
Housekeeping Genes 
ACTB Actin Beta NM_001101 F-CATCGAGCACGGCATCGTCA 
R-TAGCACAGCCTGGATAGCAAC 
211 2.021 
B2M Beta-2-Microglobulin NM_004048 F-ACCCCCACTGAAAAAGATGA 
R-ATCTTCAAACCTCCATGATG 
114 1.834 
GAPDH Glyceraldehyde-3-Phosphate 
Dehydrogenase 
NM_002046 F-CTCCTGTTCGACAGTCAG 
R-GCCCAATACGACCAAATC 
111 2.017 
YWHAZ Tyrosine 3-Monooxygenase/ 
Tryptophan 5-Monooxygenase 
Activation Protein Zeta 
NM_003406 F-ACTTTTGGTACATTGTGGCTTCAA 
R-CCGCCAGGACAAACCAGTAT  
94 1.988 
Target Genes 
ACTA1 Actin, Alpha 1 NM_001100.3 F- AGCTACCCGCCCAGAAACTA 
R- GTCGCCCACGTAGGAATCTT 
200 1.739 
ACTA2 Actin, Alpha 2 NM_001613.2 F- GCCAAGCACTGTCAGGAATC 
R-GTCACCCACGTAGCTGTCTT 
213 2.126 
BMP7 Bone Morphogenetic Protein 7 NM_001719.2 F- CAGGTCATTGGCTGGGAAGT 
R- GGCTGGTAGGCGCTCATAAT 
72 1.954 
CDC42 Cell Division Cycle 42 NM_001791.3 
 
F- GGTGGAGAAGCTGAGGTCAT 
R- CATCGCCCACAACAACACAC 
99 1.937 
CK5 Keratin 5 NM_000424.2 F-CCAAGCCAATTGCAGAAC CA 
R-AAATTTGGGATTGGGGTGGG 
198 1.931 
COL1A1 Collagen Type I Alpha 1 Chain NM_000088.3 F- GGTCAAGATGGTCGCCCC 
R- GGAACACCTCGCTCTCCAG 
262 1.911 
COL2A1 Collagen Type II Alpha 1 Chain NM_001844.4 
 
F- CTTGGCCCAAAGAAAACCCG 
R- GTAGGTGACGTTCTGGTGGG 
186 1.820 
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COL3A1 Collagen Type III Alpha 1 Chain NM_000090 F- TGGAGGATGGTTGCACGAAA 
R- ACAGCCTTGCGTGTTCGATA 
73 2.150 
COL4A1 Collagen Type IV Alpha 1 Chain NM_001845 
 
F- GGCAGATTCGGACCACTAGG 
R- GCGTCTGTGGCAATACTAGC 
186 1.878 
COL5A1 Collagen Type V Alpha 1 Chain NM_000093.4 
 
F- CTTGGCCCAAAGAAAACCCG 
R- GTAGGTGACGTTCTGGTGGG 
152 1.816 
CSPG4 Chondroitin Sulfate Proteoglycan 4 NM_001897.4 F- GTCACAGCTGGCCCTCG 
R-TCCTGGGCTGCCTCCAG 
299 1.761 
DSE Dermatan Sulfate Epimerase NM_013352.3 F- GGCTGGGAGCGGATCTTTC 
R-TGGCTGTCGTAGTTGGCATT 
192 1.919 
EGF Epidermal Growth Factor NM_001963 F- CTTGGGAGCCTGAGCAGAAA 
R- GCACAAGTGTGACTGGAGGT 
89 1.839 
EGFR Epidermal Growth Factor Receptor NM_201283 F- GGTGGCATTTAGGGGTGACT 
R- 
CAAGGGAACAGGAAATATGTCGAA 
173 1.794 
ELN Elastin NM_001081754.2 F- CTTAAGCCAGTTCCCGGAGG 
R-GGGCTGCAGACACTCCTAAG 
193 1.779 
FGF12 Fibroblast Growth Factor 12 NM_004113.5 F- TGGTGAAGGCTATCTCTACAGT 
R- CTGATTCTTGCTGGCGGTAC 
119 2.143 
FN1 Fibronectin 1 NM_212478.2 F- CCGCCGAATGTAGGACAAGA 
R- GACAGAGTTGCCCACGGTAA 
261 2.047 
FOLH1 Folate Hydrolase 1 NM_004476.1 
 
F- CAGTAGAGCAGCAGCACAGG 
R- AAACCACCCGAAGAGGAAGC 
182 1.887 
HSPG2 Heparan Sulfate Proteoglycan 2 NM_005529.6 F- TACACACGCCACCTGATCTC 
R-GCAGCTGCCAGTAGAAGGAC 
184 1.791 
ICAM1 Intercellular Adhesion Molecule 1 NM_000201.2 
 
F- TCTTCCTCGGCCTTCCCATA 
R- AGGTACCATGGCCCCAAATG 
152 1.935 
IRF6 Interferon Regulatory Factor 6 NM_001206696 F- CTAAGACGTCGAGGAGCGTG 
R- CCCAGGCCTTTGCTCAATCT 
100 1.747 
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LAMA1 Laminin Subunit Alpha 1 NM_005559.3 F- GTCCAATCTGTACGTCGGGG 
R- CACTGTTCTGGAAAAGCCCG 
243 1.993 
MCM2 Minichromosome Maintenance 
Complex Component 2 
NM_004526.3 
 
F- CACCTCCGAGTGCTTTGTCT 
R- ATACGCAACTCACGCCAAGA 
137 1.922 
MK167 Marker Of Proliferation Ki-67 NM_002417.4 
 
F- CGTCCCAGTGGAAGAGTTGT 
R- CGACCCCGCTCCTTTTGATA 
143 1.862 
MMP2 Matrix Metallopeptidase 2 NM_174745.2 F- TGCTCCACCACCTACAACTT 
R- CCTGGAAGCGGAATGGAAAC 
121 1.706 
MMP9 Matrix Metallopeptidase 9 NM_031055.1 F- TCTTCCCTGGAGACCTGAGA 
R- TTTCGACTCTCCACGCATCT 
107 1.974 
MTHFR Methylenetetrahydrofolate 
Reductase 
NM_001330358.1 
 
F- GAAGGTGCCTCTGTTCCCTC 
R- GGCTGGGTTCCTACTGATGG 
173 1.854 
PCNA Proliferating Cell Nuclear Antigen NM_002592.2 
 
F- CGGTTACTGAGGGCGAGAAG 
R- GCTGAGACTTGCGTAAGGGA 
95 1.808 
PXN Paxillin NM_002859.3 
 
F- GGAAAAGTTGCGGGGCATAG 
R- CAAGAACACAGGCCGTTTGG 
239 2.029 
RAC1 Rac Family Small GTPase 1 NM_018890.3 
 
F- TACGCCCCCTATCCTATCCG 
R- AACACATCGGCAATCGGCTT 
91 1.905 
RHOA Ras Homolog Family Member A NM_001313941.1 
 
F- AGCCAAGATGAAGCAGGAGC 
R- TTCCCACGTCTAGCTTGCAG 
162 1.944 
SOX9 SRY-Box 9 NM_000346.3 F- AGGAAGTCGGTGAAGAACGG 
R- CGCCTTGAAGATGGCGTTG 
84 1.969 
TGFA Transforming Growth Factor 
Alpha 
NM_001308158.1 
 
F- CTTGGAGAACAGCACGTCCC 
R- CCAGAATGGCAGACACATGC 
162 
 
1.764 
TGFB1 Transforming Growth Factor Beta 
1 
NM_000660.6 F- ATGGAGAGAGGACTGCGGAT 
R- TAGTGTTCCCCACTGGTCCC 
167 1.747 
TGFB2 Transforming Growth Factor Beta 
2 
NM_001135599.3 F- CCCCGGAGGTGATTTCCATC 
R- CAACTGGGCAGACAGTTTCG 
171 1.979 
TGFB3 Transforming Growth Factor Beta 
3 
NM_003239.4 F- GTGCCGTGAACTGGCTTCT 
R- CTTGGCGATGGGGAGAAAGT 
207 2.006 
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TGFBR1 Transforming Growth Factor Beta 
Receptor 1 
NM_004612.3 F- GTGACAGATGGGCTCTGCTT 
R- 
AGGTGATGACTTTACAGTAGTTGGA 
213 1.918 
TGFBR2 Transforming Growth Factor Beta 
Receptor 2 
NM_001024847.2 F- GTTGGCGAGGAGTTTCCTGTT 
R- GTCCTATTACAGCTGGGGCA 
487 1.924 
TUBA1 Tubulin Alpha 1 NM_006009.3 F- AAGCAGCAACCATGCGTGA 
R-CCGTCTCACTGAAGAAGGTGT 
282 1.991 
VCAM1 Vascular Cell Adhesion Molecule 
1 
NM_001078.3 
 
F- GGACCACATCTACGCTGACA 
R- TTGACTGTGATCGGCTTCCC 
184 1.951 
VIM Vimentin NM_003380.4 F-CGGCTGCGAGAGAAATTGC 
R-CCACTTTCCGTTCAAGGTCAAG 
124 1.845 
Table 3:  Table outlining all the names of all the primers, sequences and ascension numbers used in this study. Primer efficiency relates to how 
well each primer amplifies its target each PCR cycle, an efficiency of 2.0 denotes 100% efficiency. 
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2.7.7  Analysis of gene expression levels 
In order to assess expression levels of target genes white 96 well plates (LightCycler 480 multi 
well plates, Roche UK) were prepared via the addition of 10μl of SYBR green (LightCycler® 
480 SYBR Green I Master, Roche UK), 0.1μl of forward and reverse primer, 1μl of test cDNA 
and the addition of RNase free water (to bring the mix to a total volume of 20μl) into each well 
of the multiplate. Once the plate had been prepared, it was covered with a plastic sealing foil in 
order to prevent evaporation and centrifuged at 1500rpm for 3 minutes (Hettich Universal 320R, 
DJB Labcare UK). The plate was then placed onto the 96 well block of the light cycler and the 
amplification cycles were initiated (table 4). Gene expression was quantified by measuring the 
gradually accumulating fluorescent signal in each well (Figure 9). The cycle at which the 
fluorescent signal exceeded the background fluorescence was measured and called cycle 
threshold (Ct). Ct was inversely proportional to the amount of target present in each sample so 
the quicker Ct was achieved the greater the amount of target gene present in the sample. This 
Ct value was then compared with the Ct value of HKG in order to obtain the delta cycle 
threshold (ΔCt) from which fold changes were calculated allowing comparisons to be made 
between samples. The Pfaffl methodology was utilised in order to calculate the relative 
expression of each sample as it makes use of individual primer efficiencies leading to a more 
accurate value (Pfaffl, 2001). The Pfaffl method was used by means of the following equation:  
  𝑭𝐨𝐥𝐝 𝐜𝐡𝐚𝐧𝐠𝐞 =
(𝐄 𝐭𝐚𝐫𝐠𝐞𝐭)
 ∆𝐂𝐏𝐭𝐚𝐫𝐠𝐞𝐭(𝐜𝐨𝐧𝐭𝐫𝐨𝐥−𝐬𝐚𝐦𝐩𝐥𝐞)
 
(𝐄 𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞)∆𝐂𝐏𝐫𝐞𝐟𝐞𝐫𝐞𝐧𝐜𝐞(𝐜𝐨𝐧𝐭𝐫𝐨𝐥−𝐬𝐚𝐦𝐩𝐥𝐞)
 
 
Equation 4: Calculation of fold changes based on the Pfaffl method. Etarget = efficiency of 
target gene; Ereference = efficiency of HKG; ΔCPtarget = Ct target control minus Ct of target 
sample; ΔCtreference = Ct of reference control minus Ct of reference sample. 
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 Treatment 
temperature 
Duration Number of 
cycles 
Pre incubation 95 °C 5 minutes 1 
Denaturation 95 °C 20 seconds  
60 Annealing 60 °C 20 seconds 
Extension 72 °C 30 seconds 
Melt curve 95 °C Until complete 1 
Cooling 4 °C Hold 1 
Figure 9: The cyclic temperature changes for the HKG used for gene analysis (ACTB). 
Pre-incubation followed by denaturation of DNA occurs at 95°C (A), the green spot indicates 
the point at which the target was quantified (B) and the green line indicates the point at which 
melt curve analysis took place (C).  
A B  C 
Table 4: Outline of the relative temperatures and durations used during each cycle in order 
to amplify DNA and conduct real time PCR. 
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Figure 10: Amplification curve for ACTB. The HKG was serially diluted to 100%, 50%, 
10%, 1%, 0.1% and a no template control. This was followed by qPCR in order to assess the 
amplification efficiency for each primer, a perfect amplification efficiency is 2.0 however 
ranges between 1.7 and 2.2 are acceptable (see table 3 for all efficiency values).  
Figure 11: Melting curve for ACTB. Melt curve analysis was conducted in order to confirm 
that only a single amplicon was being amplified by the primer. The presence of a single peak 
demonstrates that only one product (the target) was being amplified. This analysis was 
conducted for all HKG and target genes and if multiple peaks were present primers were 
redesigned.  
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2.7.8 PCR following supplementation with experimental reagents 
In order to assess the effect of FA, differing TGFβs and TGFα supplementation on cleft 
fibroblast gene expression, fibroblasts were grown to confluence in T75 flasks and incubated 
in DMEM for 24 hours under the experimental conditions defined in table 2. RNA was then 
isolated followed by cDNA synthesis so that qPCR could be conducted on various genes of 
interest, see section 2.7.1 to section 2.7.7.  
2.7.9 Human cell motility PCR array 
A PCR array (RT² Profiler™ PCR Array Human Cell Motility, Qiagen UK) was utilised in 
order to assess the differences in gene expression between six samples for 84 different markers; 
each related to cell motility. The protocol was similar to that in section 2.7.7 however primers 
were already lyophilised to each well and the temperatures and number of cycles varied (see 
table 5). 
 
 Treatment 
temperature 
Duration Number of cycles 
Pre incubation 95 °C 10 minutes 1 
Denaturation 95 °C 15 seconds 45 
Annealing and 
extension 
60 °C 1 minutes 45 
Cooling 4 °C Hold 1 
Table 5: Treatment protocol for PCR array. In accordance with the manufacturers 
recommendation the temperatures and durations of each PCR cycle was changed to obtain 
optimal measurement of gene targets for the Human cell motility PCR array.  
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2.8 Immunostaining 
Immunostaining is a biochemical technique whereby specific biomarkers are visually 
identified. This is achieved by selectively targeting specific antigens within a sample through 
the use of primary antibodies, that have complimentary epitopes against the target of interest, 
which can either be detected directly or indirectly, through the use of secondary antibodies 
which bind to the primary antibody and permit signal amplification (Duraiyan et al, 2001). To 
detect antigen-antibody complexes, either chromogenic detection, which involves enzymatic 
conversion of a substrate into a chromogenic product with detectable pigmentation, or 
immunofluorescence (IF) detection, which makes use of conjugated fluorophores which emit 
light when excited and permit fluorescent detection at specific wavelengths, can be utilised; IF 
of specific antigens within biological samples was employed here. Immunohistochemistry 
(IHC) refers to the use imaging antigen-antibody complexes within tissue sections whereas 
immunocytochemistry (ICC) refers to imaging cell preparations; IHC and ICC were used here. 
2.8.1 Tissue preparation 
Cleft samples were immediately washed in PBS for 5 minutes, samples were then placed into 
labelled histology cassettes and put into pots containing 20ml of 10% neutral buffered formalin 
(Sigma, UK) and incubated for 24 hours at in a fume hood (Permier laboratory system, UK) at 
room temperature. The tissue was then placed into sample pots containing a graded series of 
industrial methylated spirit (IMS) (VWR chemicals, UK) with serially increasing concentration 
starting from 35% IMS with a gradual increase to 100% IMS, this was followed by three 
incubations in xylene (Genta medical, UK) in order to thoroughly dehydrate the samples. 
Following xylene treatment sample cassettes were immersed in liquid paraffin wax (Histoplast, 
Thermo Fisher Scientific, UK) and incubated overnight at 60°C to allow the wax to penetrate 
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the sample. Following overnight wax incubation, the samples were subject to two further 1-
hour wax incubations to remove any xylene residue.  
2.8.2 Wax embedding 
Wax embedding was conducted using a tissue processing station (Tissue TEK, Sakura, UK). 
Following tissue preparation samples were placed into a heated liquid paraffin wax holding 
bath and the samples cassettes were removed using heated forceps. Tissue samples were then 
placed into a heated stainless steel base mould and orientated into the correct position, liquid 
paraffin was then poured into the mould whilst ensuring the sample stayed in the correct 
position and placed onto a cooling plate (-20°C) until the paraffin wax solidified. The wax block 
was then removed from the moulds and any excess wax was removed from the sample block. 
2.8.3 Microtomy and section mounting 
Wax embedded tissues were sectioned using a rotary microtome (Leica RM2035, Leica UK). 
Wax blocks were cooled and mounted onto the specimen holder and clamped into position. The 
paraffin block was then orientated into the correct plane in relation to the microtome blade. Any 
excess wax at the base of the block was trimmed, using the rotary action of the hand wheel, 
until the sample was at the base of the block. Samples were then cut at a uniform speed to form 
5μm thick sections. Once cut, forceps were used to carefully remove sections from the knife 
holder and were placed into a warm water bath (20°C) to remove any surface wrinkles, leaving 
uniform sections. Sections were then placed onto separate glass microscope slides (Surgipath, 
UK) and incubated at 45°C for 2 hours to permit adequate section adhesion onto the glass slide.  
2.8.4 Immunofluorescent staining protocol 
Tissue sections adhered to glass slides were first deparaffinised by two 5 minute washes in 
xylene. Samples were then rehydrated via washing for 5 minutes each in serially decreasing 
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concentrations of ethanol starting at 100% and decreasing to 35%, followed by a final wash in 
deionised water. Glass slides were then inserted into a slide holder and placed into a plastic 
container containing 500ml of antigen retrieval buffer (1mM sodium citrate; 0.05% Tween 20). 
Anti-bumping granules were then placed into the container and it was covered in Clingfilm, 
this was followed by microwaving the slides for 20 minutes or until boiling. Samples were 
allowed to cool before washing twice in distilled water. Slides were then incubated at 37°C in 
permeabilisation buffer (0.2% Triton X-100 in PBS) for 45 minutes followed by two washes in 
PBS. Glass slides were then drained of any excess liquid and a circle was drawn around each 
sample using an ImmEdge hydrophobic barrier pen (Vector laboratories, UK) followed by the 
addition of 100μl of blocking buffer (10% bovine serum albumin (BSA) onto each sample for 
60 minutes, prior to washing twice in PBS. Primary antibodies were then diluted in blocking 
buffer using a microliter syringe (Hamilton, UK) and 100μl of this solution was placed onto 
each sample and incubated overnight in a humidified chamber at 4°C (table 6 for list of 
antibodies and concentrations used). Glass slides were then washed in PBS followed by the 
addition of 100μl of secondary antibody and incubated for 60 minutes at room temperature in 
a dark room. After washing twice in PBS one drop of Vectashield antifade mounting medium 
with 4′,6-diamidino-2-phenylindole (DAPI) (Vector laboratories, UK) was added on top of each 
sample followed by mounting glass coverslips which were secured using clear nail varnish.  
2.8.5 Immunocytochemistry on fixed cell cultures 
In order to conduct immunocytochemistry (ICC) on cell cultures, cells were first grown onto 
uncoated sterile coverslips until partially confluent, culture medium was then removed followed 
by 2 washes in PBS. Cells were then fixed by immersing coverslips in 4% buffered 
paraformaldehyde (Sigma, UK) for 15 minutes, followed by 2 further washes in PBS. Due to 
most targets being internal, cells were permeablised using permeabilisation buffer (0.2% Triton 
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X-100 in PBS) for 60 minutes so that the antibodies could pass through the cell membrane and 
potentially bind to intracellular targets. Cells were then treated with blocking buffer (10% BSA) 
for 60 minutes in order to block any non-specific binding sites. After washing PBS, the cells 
were incubated overnight at 4°C with primary antibodies to allow them to bind to the targets of 
interest. After a further PBS wash, secondary antibodies were incubated with the cells for 60 
minutes in a dark room to prevent photodegradation of the secondary antibody bound 
fluorophores. Vectashield antifade mounting medium with DAPI was then added to the cells 
and coverslips were mounted onto glass slides and sealed with clear nail varnish.  
 
 
2.8.6 Imaging of fluorescent markers 
Samples were imaged using an LSM700 confocal microscope (Zeiss, Germany). Green 
channels were used to image FITC conjugated fluorophores and blue channels were used to 
image DAPI conjugated fluorophores; all images were taken using the same laser intensity. 
 
Antibody Product 
ID 
Species Reactivity Dilution 
factor 
Source 
Primary antibodies 
CK5 SC-23877 Mouse Human 1:100 Santa Cruz 
TGFβ1 SC-146 Rabbit Human 1:200 Santa Cruz 
TGFβ2 SC-90 Rabbit Human 1:200 Santa Cruz 
TGFβ3 SC-82 Rabbit Human 1:200 Santa Cruz 
TGFβR1 SC-398 Rabbit Human 1:200 Santa Cruz 
TGFβR2 SC-400 Rabbit Human 1:200 Santa Cruz 
TGFα SC-36 Mouse Human 1:100 Santa Cruz 
VIM SC-6260 Mouse Human 1:100 Santa Cruz 
Secondary antibodies 
FITC SC-2365 Bovine Anti-Rabbit 1:200 Santa Cruz 
FITC SC-2366 Bovine Anti-Mouse 1:200 Santa Cruz 
Table 6: List of antibodies and the dilution factors used for immunohistochemistry and 
immunocytochemistry.  
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2.9 Staining methods  
2.9.1 Collagen staining 
Sirius red F3B (BDH chemicals) staining is a commonly used technique to visualise and 
quantify the amount collagen that has been deposited onto a cell culture plate or within a tissue 
section. Sirius red is highly anionic due to the presence of six sulfonate groups on the dye, these 
groups strongly interact with cationic collagen fibres leaving red staining across the molecule 
(Junqueira, et al 1979; Rich, et al 2005).  Sirius red staining was conducted using an established 
protocol (Tullberg-Reinert et al, 1999; Lattouf et al, 2014) to investigate collagen production. 
Cleft fibroblasts were treated with mitomycin C for 3 hours in order to inhibit proliferation and 
then seeded into 6 well plates at a concentration of 1x106 and cultured for: 7 days. Culture 
medium was then removed and each well was washed 3 times with PBS, followed by fixation 
with 4% buffered paraformaldehyde for 15 minutes. Sirius red was dissolved into distilled water 
at a concentration of 1mg/ml, this solution was then treated with hydrochloric acid to reach a 
final pH of 3. Sirius red (1ml) was then added to each well and incubated at room temperature 
on an orbital shaker overnight. Cultures were then washed 3 times with 5% HCL in order to 
remove any unbound dye. The bound Sirius red was then dissolved by the addition of 1ml 0.2M 
sodium hydroxide (NaOH) under constant shaking for 30 minutes in order to elute the dye, this 
change in pH resulted dissociation of the dye from collagens due to alteration to its ionization 
state thereby weakening its affinity. This solution (100μl) was then pipetted into a 96 well plate 
and the absorbance was assessed at 490nm using a spectrophotometer in order to quantify the 
amount of dye in the sample.  
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2.9.2 Glycosaminoglycan staining 
Alcian blue is a cationic dye which, due to the presence of copper within the dye molecule, 
stains acidic polysaccharides, such as glycosaminoglycan, blue (Björnsson, 1993). The pH of 
the dye solution can affect the type of macromolecules that are stained, when at pH 1 only 
sulphated polysaccharides such as chondroitin sulphate, dermatan sulphate and heparin sulphate 
are stained. However, increasing the solution to pH 2.5 leads to staining molecules with 
attached carboxyl groups such as hyaluronic acid (Green et al, 1974). Alcian blue staining and 
quantitation was conducted based on an established protocol (Fraizer et al, 2010; Björnsson, 
1993). Cells were treated with 4μg/ml mitomycin C in culture medium for 3 hours, in order to 
inhibit proliferation and were then seeded into 6 well plates at a concentration of 1x106 and 
cultured for7 days. Cell culture medium was then removed and the cells were washed 3 times 
with PBS, followed by fixation in buffered 4% paraformaldehyde for 20 minutes. Alcian blue 
Figure 12: Collagen staining. (A) Calibration curve pertaining to collagen concentration 
and absorbance. (B) Example of cleft fibroblast secreted collagen staining with Sirius red. 
(A) (B) 
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8GX (Sigma, UK) solution was made up by dissolving 1g dye in 100ml OF 18mM H2SO4 
(Sigma, UK) to achieve a final pH of 1 followed by the addition of 0.25% Triton X-100, this 
solution was filtered in order to remove any undissolved particulate matter. Alcian blue (1ml) 
was added to each well and incubated at room temperature overnight on an orbital shaker. 
Cultures were washed 3 times with 5% HCL to remove any unbound dye, before dissolving the 
stain in 1ml DMSO and transferring this solution to a 96 well plate for spectrophotometric 
analysis at an absorbance of 600nm.  
2.9.3 Haematoxylin and Eosin (H&E) staining 
Paraffin embedded sections on glass slides were de-waxed by immersion in xylene for 5 
minutes followed by treatment with 100% and 95% IMS for two washes of 30 seconds each; 
followed by a further wash in distilled water. Slides were placed in Gills III Haematoxylin 
(Surgipath, UK) for 2.5 minutes and rinsed in water before differentiation with 0.3% acetic acid 
(Merck, UK) for 30 seconds followed by treatment with 0.3% HCL for a further 30 seconds. 
Slides were then immersed in Scott’s tap water substitute (Surgipath Europe Ltd), which 
enhances the stain intensity, for 1 minute followed by treatment with eosin (Surgipath, UK) for 
1 minute before rinsing in 100% xylene and 3 further washes in xylene for 1 minute each. Once 
staining was complete, sections were covered dropwise with DPX mountant (Merck, UK) 
followed by coverslip placement.  
2.9.4 Actin staining and quantitation  
Phalloidin staining is a technique used to reveal the presence of actin within a treated sample. 
Phalloidin binds specifically to F-actin by tightly binding at the sites between actin subunits 
and interacts stoichiometrically with actin molecules meaning the staining intensity can be 
correlated with the amount of actin present in the sample and quantified (Wehland et al, 1977). 
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Phalloidin staining was conducted using ActinGreen™ 488 ReadyProbes™ Reagent 
(Thermofisher, UK) according to the manufacturer’s recommendation. Cleft fibroblasts were 
grown on sterile glass coverslips until 70% confluent and then fixed with 4% buffered 
paraformaldehyde for 15 minutes then washed 3 times with PBS. The cultures were then 
permeablised by treatment with 0.2% Triton x-100 for 60 minutes, following this 1ml of PBS 
was added to each culture. Two drops of ActinGreen reagent were then added to each ml of 
PBS and incubated at 37°C for 60 minutes. When stained the coverslips were washed and then 
counterstained with DAPI and mounted onto glass slides using clear nail varnish. Fluorescently 
labelled cells were then imaged using an LSM700 confocal microscope (Zeiss, Germany), using 
the same magnification and laser intensity for all samples, and actin was quantified using 
imageJ (version 1.51). In order to quantify phalloidin staining, five randomly selected images 
were captured in red green and blue (RGB) channels so that both total intracellular actin and 
total cell nuclei, in the same frame of view, would be captured respectively. Image stacks, which 
had both actin and nuclei stains, were then converted into single images followed by conversion 
into 8-bit greyscale, thresholding was then applied so that the entirety of the captured image 
would be converted into binary form with white objects on a black background. The integrated 
density, which provides you with the sum of the all of the pixels within a frame of view (total 
pixel value), was calculated for both binary images of actin and total cell nuclei. The integrated 
density of actin was then divide by the integrated density of the cell nuclei in order to provide 
a ratio of actin to cell number, this process was repeated for each randomly selected image and 
an average was calculated (Figure 13). 
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2.10 Cell adhesion 
 
2.10.1 Cell to substrate adhesion 
Cells were seeded at a concentration of 5x104 into 35mm petri dishes, in the presence or absence 
of folic acid (see table 2 for details). After 24 hours the supernatant in each well was removed 
and centrifuged at 900g for 5 minutes, the cells were then re-suspended in 1 ml DMEM and 
counted using a haemocytometer in order to obtain the number of cells that had not adhered to 
the petri dish.  
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Figure 13: Thresholding method of quantitation based on ratio of phalloidin staining 
and nuclei staining. Phallodin and nuclei staining for cleft tissue sections (A) and cultured 
cleft fibroblasts (B), phallodin stains (green) (B and E) were isolated to calculate the 
integrated density of actin and this was adjusted with respect to total cell numbers based on 
nuclei staining (blue) (C and F).  
(A) (B) (C) 
(D) (E) (F) 
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2.10.2 Cell to cell adhesion 
CellTracker™ Green CMFDA (5-chloromethylfluorescein diacetate) Dye (Thermo Fisher 
Scientific, UK) is a fluorescent dye commonly used to stain live cells in response to stimuli. 
The uncharged dye freely diffuses into cells where intracellular esterases cleave lipophilic 
groups on the compound resulting in a charged compound that bind covalently intracellular 
components and begins to fluoresce (Lulevich, et al, 2009). The dye remains in the cell for an 
extended period of time and does not leach to neighbouring cells. CMFDA stock solution was 
reconstituted in 50μl DMSO to obtain a 10mM stock solution, this was then diluted into pre-
warmed 37°C DMEM to obtain a 10μΜ working concentration. Cells were trypsinised and 
centrifuged at 900g for 5 minutes followed by resuspension in 5ml CMFDA working solution 
and incubated at 37°C for 45 minutes. Cells were then centrifuged and resuspended in sDMEM 
(see table 2 for details) and seeded onto confluent monolayers of unstained cells in 35mm petri 
dishes under experimental conditions. After 24 hours the supernatant, containing non-adherent 
cells, was removed, centrifuged and re-suspended in 200μl PBS. This cell suspension was then 
transferred to a 96 well plate and the fluorescent intensity of the cells was read using a 
fluorescence plate reader at 490nm in order to quantify number of cells that did not adhere.  
2.11 Bicinchoninic acid protein assay 
The bicinchoninic acid (BCA) assay (Pierce™ BCA Protein Assay Kit, Thermo Fisher 
Scientific, UK), was used to determine the total protein concentration within serum free cultures 
of cleft fibroblasts. This assay is comprised of a two-step reaction, the first step made use of the 
well-established biuret reaction whereby interaction with protein in the media causes Cu2+ to 
be reduced to Cu1+, this cation then interacts with bicinchoninic acid leading to purple coloured 
by-product. This purple by-product can be quantified calorimetrically as the intensity of the 
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colour is directly correlated with the amount of protein within a given sample. Calibration 
curves using purified bovine serum albumin (BSA) were first created by serially diluting BSA 
in deionised water in concentrations between 6.25% to 100% and a negative control comprising 
of just diluent. The BCA reagent was prepared by mixing of reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) reagent 
B (4% cupric sulphate) in a 50:1 ratio for a total working volume of 25ml. 200μl of BCA 
working reagent was then placed into 96 well plates with 25μl of each standard or sample. The 
microplate was then placed on an orbital shaker for 1 minute followed by incubation at 37°C 
for 30 minutes then absorbance of each well was measured at 570nm using a spectrophotometer.  
2.12 Proteome Profiler Human XL Cytokine Array 
Cytokines, chemokines and growth factors are ECM related molecules that mediate specific 
cell responses. The Proteome Profiler Human XL Cytokine Array Kit (R&D systems, UK) is a 
membrane based sandwich immunoassay that has 105 soluble antibodies marked on the surface 
of a nitrocellulose membrane. Proteins within a sample bind directly to their specific antibody 
on the membrane surface, the quantity of bound protein can then be quantified through us of X-
ray analysis and quantification of the pixel density for each region of interest. This assay was 
used to quantify cytokine secretion by cleft fibroblasts into the culture medium (Figure 14).   
2.12.1 Sample preparation of cleft fibroblast Secretome 
Cleft fibroblasts were seeded at a concentration of 1x106 into T75 flasks and were incubated 
for 24 hours to allow cells to adhere to the surface of the flask. After incubation, cultures were 
washed with PBS followed by the addition of 5ml serum free media into each flask and the 
cells were incubated for a further 24 hours to allow cytokine release into the medium. Cell 
culture supernatants were removed and stored in 1ml aliquots at -80°C until needed. 
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Figure 14: Schematic outlining the general staining principles employed to conduct the cytokine array. (A) Capture antibodies are 
adhered onto specific locations of the nitrocellulose membrane; these antibodies are complimentary to specific cytokine targets secreted by 
cleft fibroblasts. (B) Biotinylated detection antibodies are later exposed to the membranes which in turn bind to the capture antibody-cytokine 
complex. (C) Due to its high affinity streptavidin-horse radish peroxidase (HRP) adhere to detection antibodies. (D) Luminol is oxidised by 
HRP in the presence of hydrogen peroxide thereby emitting a light signal output that is detectable by x-ray. 
Capture antibody 
Secreted cytokine target 
Biotinylated detection antibody 
Luminol oxidation 
(A) (B) (C) 
Streptavidin-HRP complexes 
(D) 
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2.12.2 Experimental procedure 
All reagents, samples and the experimental procedure was prepared and conducted as directed 
by the manufacturer. Each nitrocellulose membrane was placed into one well of a provided 4 
well multi dish using flat bottomed tweezers with the membrane facing upwards. Following 
this, 2ml blocking buffer was pipetted into each well and the 4 well multi dish was placed on a 
rocking platform shaker for 1 hour. Samples were then thawed and 300μl of each was diluted 
into 1200μl of blocking buffer to give a final volume of 1.5ml. After incubation, blocking buffer 
was removed from each well and 1.5ml of each diluted sample was placed into one of the wells 
containing the nitrocellulose membrane and incubated overnight at 4°C on a platform shaker. 
Membranes were then removed and placed into individual plastic containers and washed 3 
times for 10 minutes each in 1x wash buffer. The detection antibody cocktail was then prepared 
by pipetting 30μl of detection antibody into 1.5ml of array buffer for each sample, this was then 
placed into each well of the multi dish and the membranes were placed back into the wells and 
incubated at room temperature for 1 hour, followed by a further 3 washes with wash buffer. 
Next, 2ml of streptavidin-HRP was placed into each well and incubated with the membrane for 
30 minutes at room temperature and washed as before. Each membrane was then removed and 
the excess wash buffer was drained off, the membranes were then placed into a plastic sheet 
protector and 1ml of chemi-reagent mix (2.5ml stabilized hydrogen peroxide and 2.5ml 
luminol) was added dropwise to each membrane for 1 minute. The excess reagent was then 
removed and the samples were prepared for analysis.  
2.12.3 Data analysis 
Each nitrocellulose membrane was placed into a C-Digit® Blot Scanner (LI-COR, UK) and 
subjected to a 12-minute scan in order to obtain a digital chemiluminescence reading for each 
sample spot that was proportional to the amount of protein present in the cell supernatant.  
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Analysis of the pixel intensity of each spot was conducted using the Li-COR software. Spheres 
of a standard size were created and allocated to each spot, including reference spots, across the 
array in order to locate each cytokine (Figure 15). The pixel intensity of each spot was then 
quantified and the average background pixel intensity was subtracted, leaving a quantitative 
value for each cytokine from which comparisons between samples were made. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Scans of nitrocellulose membranes used for cytokine array. (A) Digital 
chemiluminescence readings from nitrocellulose membranes placed into a C-Digit® Blot 
Scanner.  (B) LI-COR software was used to place standard spheres above the location of 
each sample spot to provide individual cytokine pixel intensity readings.  
(A) (B) 
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2.13 Statistical analysis 
All statistical analysis was conducted using a statistical analysis package (IBM SPSS Statistics, 
USA). Data sets were first subject to F-test to assess how the data was distributed, for normally 
distributed data (parametric) comparisons between data sets were made using a student’s t-test 
or one-way analysis of variance (ANOVA). However, if the data was abnormally distributed 
(non-parametric) the Mann-Whitney test was conducted; significance was only inferred when 
p<0.05 with a two-tailed distribution.  For correlational analyses the distribution of the data was 
first assessed by conducting a Shapiro-Wilk test of normality. With data sets that were normally 
parametric, Pearson’s correlation was conducted, whereas for data that was non-parametric, 
Spearman’s rho was conducted. Unless expressly stated all data was presented as a mean value 
with error bars denoting standard deviations between replicate samples. Statistical significance 
was expressed as follows: *, ** and *** denote p<0.05, p<0.01 and p<0.001 respectively.  
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CHAPTER THREE: 
 CHARACTERISATION OF HUMAN CLEFT FIBROBLASTS 
 86 
 
3.1 Confirmation of the Fibroblast phenotype 
 
To confirm the cell populations isolated from cleft tissue samples comprised of primary cleft 
fibroblasts as opposed to a heterogeneous cell population, pooled cleft patient cells were 
assessed in terms of gene transcript expression for both vimentin (VIM), a type of intermediate 
filament is only found in cells of mesenchymal origin and is commonly used as a fibroblast 
marker (Change et al,2002) and cytokeratin-5 (CK5),  a type of intermediate filament specific 
to epithelial cells (Corr et al, 2015), by real time PCR. It was found that VIM was expressed in 
both pooled cleft fibroblasts and an immortalized H400 keratinocytes (human oral squamous 
cell carcinoma cell line) control. However, CK5 was only expressed significantly within H400 
cells and was not significantly expressed by pooled cleft fibroblasts. It is important to note that 
real time PCR cycle threshold (Ct) data with values greater than 40, as with CK5 expression in 
pooled cleft fibroblasts, were considered as null expression, as despite potentially being 
expressed within the cell population the amount was too low to accurately quantify and compare 
to control samples (McCall et al, 2014).  
Immunohistochemical staining for VIM in pooled cleft fibroblasts was strongly positive, 
indicating its presence within the cultured cell population and thereby offering further support 
towards the confirmation of the fibroblast phenotype.  
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DAPI Vimentin Merge 
Figure 17: Vimentin staining in cells isolated from cleft tissues. Positive immunocytochemical 
staining was observed for the fibroblast marker vimentin (green) in cultured cleft fibroblasts 
(passage one) thereby indicating that the cleft cells isolated from tissue samples were likely 
fibroblasts.  
Figure 16: Vimentin and cytokeratin-5 gene expression in H400s and pooled cleft 
fibroblasts. Vimentin and cytokeratin-5 were expressed in the positive control (H400) against 
which the expression levels have been normalised. Vimentin (a fibroblast marker) was 
expressed in a higher ratio in pooled cleft fibroblasts whereas cytokeratin-5 (an epithelial cell 
marker) had negative expression (where Ct values were >40 or null negative gene expression 
was inferred). This indicated that there was likely no epithelial cell contamination within cleft 
cell populations. 
*** 
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3.2 Analysis of cleft fibroblast growth with increasing passage  
As passaging is a traumatic process that can have a significant effect on normal cell behaviour, 
including proliferation and gene expression (Hughes et al, 2018), it was necessary to determine 
the influence of passaging on cleft fibroblast such that the optimal passage number for 
comparative assessment between patient samples could be selected. To conduct the analysis, 
cleft fibroblasts derived from the lip of a single cleft patient were assessed, multiple patient 
samples could not be utilised due low level passages being required to expand stocks of low 
passage number fibroblast for future analysis. Growth curves were generated from cleft 
fibroblasts varying between passage zero, which would act as the control due to these cells not 
yet being subject to passage, and passage five over a 10-day period. Two days after initial 
seeding cell numbers were comparable for all passages, at day four passages four and five had 
slight non-significant decreases in cell number when compared with passage zero cell numbers. 
This disparity increased at days 6 and 8 with cell numbers for passage four and five significantly 
lower than there passage zero counterparts (p<0.05 based on two-tailed distribution t-test). At 
day 10 all cultures were confluent and cell numbers were comparable across passage zero to 
five (Figure 18A). Fibroblast doubling times (DT), which were derived from growth curves 
data, revealed that there were no significant differences between passage zero to three; however, 
passage 4 and 5 had significantly longer DT when compared with fibroblasts of earlier passages 
(p<0.05) (Figure 18B). Despite this, MTT absorbance values following fibroblast growth for 4 
days did not shown any significant differences between passages (Figure 18C). As fibroblast 
growth was shown to be unaffected at low passages, all subsequent cell based assays were 
conducted with passage two fibroblasts thus any disruptions in cell behaviour would be 
consistent across the patient cohort. 
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3.2.1 Expression of genes associated with cell proliferation with increasing passage  
The expression of proliferation associated genes were assessed to determine any changes in 
expression with increasing passage as increased doubling times had been observed from 
passage four onwards. MCM2 expression was stable in fibroblasts that were from passage zero 
and one; however, MCM2 expression was significantly upregulated from passage 2 onwards 
relative to passage zero cells (p<0.01) (Figure 19A). MKI67 expression was similar between 
passages zero to passage two whereas fibroblasts from passage three to five displayed 
significantly lower expression than passage zero (p<0.01) (Figure 19B). PCNA expression was 
shown to be comparable between passages zero to five with no significant changes in expression 
(Figure 19C). The data shows that there were changes in the expression of genes associated 
with cell proliferation as passages increased; however, these changes occurred at an earlier 
passage than the passage at which changes in cell growth were observed.  
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(A) 
(C) 
(B) 
Figure 18:  Assessment of cleft fibroblast growth with increasing passage. (A) Growth 
curve analysis revealed that the rate of cleft lip fibroblast growth, derived from a single 
patient, was similar between passage zero (control) to three, however from day four onwards 
cell growth was decreased in passages four, at day 10 all cultures were confluent.  (B) There 
was no significant difference in cell doubling times between passage the passage zero 
control and three, however passage four and five had significantly higher doubling times 
when compared with passage zero (p<0.05; two tailed t-test) (C) There was no significant 
difference in the absorbance values of cleft fibroblasts between passage zero and five 
following four days in culture (n=3). 
* * * * 
* * 
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(A) (B) 
(C) 
Figure 19:  Changes in expression of gene transcripts associated with cell proliferation 
with increasing passage in cleft lip derived fibroblasts. (A) MCM2 expression levels 
were similar in passage zero (control) and one, however from passage two onwards there 
was an approximate two-fold increase expression when compared with the passage zero 
control (p<0.01); this increased expression remained with all subsequent passages. (B) 
MK167 expression was comparable between passage zero, one and two. However, from 
passage three onwards there was a significant decrease in expression when compared with 
passage zero control cells (p<0.01). (C) There were no significant differences in expression 
of PCNA between passage zero and five (n=3).   
** 
** 
** 
* 
*** 
** 
*** 
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3.2.2 Expression of genes associated with cleft development with increasing passage  
To determine the most suitable passage number to conduct gene expression analysis on markers 
that may be involved in the manifestation of different cleft phenotypes, the change in expression 
of three genes, each of which have been associated with CLP development, were assessed 
between passage zero (control) to passage five. This data would permit the selection of the most 
suitable passage number for real time PCR analysis which would be kept consistent for all 
future analysis. The expression of IRF6, a transcription factor that is elevated in the developing 
palatal shelves and is thought to regulate epithelial to mesenchymal during palatal fusion (Ke 
et al, 2015), was comparable in fibroblasts from passage zero to two, while from passage three 
to five there was a 2.5-fold significant increase in expression relative to the passage zero control 
(p<0.01) (Figure 20A); this indicated passaging disrupted expression of a known CLP markers 
thus fibroblasts with elevated passages should not be used for analysis. SOX9, a transcription 
factor that is elevated in early neural crest progenitor cells (Haldin and LaBonne, 2010) and are 
involved in the regulation of craniofacial cartilage formation (Lee et al, 2011), displayed 
significantly reduced expression between the passage zero control and passage one (p<0.01), 
this decreased further at passage four and five (Figure 20B). This significant decrease in SOX9 
expression suggests that the expression of a number of genetic markers may be disrupted after 
a single passage with further perturbation at elevated passage numbers, thus analysis of gene 
expression across the patient cohort must be conducted at the same passage so that any 
perturbation to gene expression caused by passage are consistent for each cleft sample. 
However, TGFA, a potent epithelial mitogen that has been correlated with the development of 
nsCLP (Lu et al, 2013), displayed stable expression between the passage zero control and each 
passage number assessed (Figure 20C), this suggests that a number of markers involved in cleft 
development may be unaffected by the passaging process. All subsequent real time PCR assays 
were conducted with passage one fibroblasts as this was the lowest possible passage number 
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that ensured sufficient cell stocks for all future assays. Further, as all samples were assessed at 
the same passage any genetic dysregulation caused by subculture would be consistent across 
all the samples assessed.  
(A) (B) 
(C) 
Figure 20: Expression of genetic markers associated with cleft development with increasing 
passage. (A) IRF6 expression levels were similar from passage zero to two, however from passage 
three onwards there is an approximate 2.5-fold increase in expression (p<0.01). (B) SOX9 
expression is significantly decreased from passage zero to one (p<0.01); this expression decreased 
further after passage four (p<0.05). (C) There were no significant differences in the expression 
levels of TGFA between passage zero and five (n=3).  
** 
** 
** 
** ** 
* 
** *** 
* 
* 
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3.3 Growth curve assays and doubling times for all cleft fibroblast samples 
Fibroblast growth is a pivotal behaviour that leads to increased fibroblast concentration thus 
ECM remodelling within wounded and developing tissues. In order to establish whether 
fibroblast proliferation was associated with the cleft phenotype manifestation, growth curves 
were generated to determine the individual growth rates of fibroblasts isolated from each cleft 
patient. Fibroblasts from patients were seeded at the same concentration and displayed similar 
cell numbers after 2 days in culture (Figure 21A). However, after 4 days there was some 
dissimilarities, with the greatest variation observed after 6 days in culture (Figure 21B). At day-
8, many of the growth curves were approaching confluence with a marked plateau after 10 days 
for all patient samples. Population doubling times were calculated from growth curves. The 
fastest growth was observed for S101603 with a doubling time of 26.11 hours whereas the 
slowest growth rate was observed in S101634 and had a doubling time of 32.41 hours, 
interestingly both the fastest and the slowest growth was observed in fibroblasts derived from 
the same cleft phenotype (CLP(L)). Neonatal human dermal foreskin fibroblasts (NHDFF) 
were used as non-cleft control cells, it was shown that NHDFF’s shared comparably similar DT 
to a number of cleft fibroblasts although the majority of the patient cohort displayed slightly 
longer DT due to a comparably reduced growth rate. When comparing cleft types, there were 
no significant differences in terms of population doubling times between CLP(L), CLP(P), CL 
and CP (Figure 22). There were no significant differences in DT in terms of cleft laterality 
between LUCLP, RUCLP and BLCLP. This suggests that fibroblast growth is not influenced 
by the underlying cleft phenotype. 
 
  
 95 
 
 
  
(A) 
(B) 
Figure 21: Comparative growth curve assays for each patients fibroblasts to 
assess changes in cell number with time. (A) Cell growth over a 10-day period after 
an initial seeding concentration of 0.02 x106 with cell counts every 48 hours. (B) The 
most variation in cell numbers was observed at day 6 with the majority of cell counts 
between 0.5x106 and 0.8x106 however there were a number of outliers with values 
above and below this range. Neonatal human dermal foreskin fibroblast (NHDFF) 
control cells displayed greater cell numbers at day 6 than the majority of cleft 
fibroblasts although there were a number of samples with comparable cell numbers 
at day 6 (n=12).  
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Figure 22: Fibroblast doubling times. (A) Population doubling times (DT) were 
calculated based on the cell numbers obtained from growth curve models. There were 
differences between patient fibroblasts with DT varying between 26.11 hours and 32.41 
hours; NHDFF DT was faster than the majority of cleft samples although a minority of 
patients displayed a comparable DT (n=3). (B) Averaged DT was similar between cleft 
phenotypes with no significant difference. (C) DT did not differ significantly based on cleft 
laterality.   
(A) 
(B) (C) 
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3.3.1 Expression of genes associated with cell proliferation 
Expression of gene transcripts associated with cell proliferation were assessed for each cleft 
patients fibroblasts and correlated with cell doubling times (DT), expression of each gene was 
also compared between cleft types and cleft laterality.  
MCM2 expression varied across samples although most patient-derived fibroblasts 
demonstrated expression higher than that of that of the non-cleft human gingival fibroblast 
(HGF) control; HGFs were used as control for real time-PCR assays as they are oral fibroblasts 
thus are likely to be more comparable to oral cleft fibroblast in terms of gene expression when 
compared to NHDFF which are dermal fibroblasts (Ebisawa et al, 2011). The highest overall 
expression was 5.74-fold whilst the lowest was 0.65-fold (Figure 23A). MCM2 expression was 
plotted against DT to assess their correlation (Figure 23B) however Spearman’s rho revealed 
that there was no strong significant correlation between MCM2 and DT. When comparing cleft 
types, MCM2 expression in fibroblasts from CLP(P) was significantly higher than fibroblasts 
from CP (p<0.05) (Figure 26A). Further, MCM2 expression differed based on cleft laterality as 
expression was significantly lower in BLCLP fibroblasts when compared with LUCLP and 
RUCLP (Figure 26B). 
MK167 expression was higher in most samples when compared with the HGF control, however 
there was large differences between fibroblasts with the highest expression being 5.47-fold and 
the lowest 0.83-fold (Figure 24A). Spearman’s rho analysis showed that there were there were 
no significant correlations between MKI67 and DT (Figure 24B). When comparing cleft types, 
on average CLP(L) fibroblasts had significantly lower expression than all other cleft groups, 
including: CLP(P) (p<0.05), CL (P<0.05) and CP (p<0.05). In addition, CLP(P) average 
expression of MKI67 was significantly lower than that of CP fibroblasts (p<0.05) (Figure 26C). 
Comparing MK167 expression in CLP patients according to laterality revealed that that 
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expression was significantly lower in BLCLP fibroblasts than LUCLP and RUCLP (Figure 
67D).  
PCNA expression varied widely across the cohort with a maximum expression, relative to the 
HGF control, of 4.51-fold and a low of 0.69-fold. As the data pertaining to PCNA expression 
was deemed to be non-parametric by means of shapiro-Wilk normality test, Spearman’s rho 
test revealed that there was a significant correlation between PCNA expression and DT (p<0.01) 
suggesting that patient expression of PCNA and the DT, determined from cell growth curves, 
may be related (Figure 25). Comparing PCNA expression between cleft types revealed that 
expression was significantly lower in CL fibroblasts when compared with both CLP(L) and 
CLP(P) whereas PCNA expression was significantly lower in CP fibroblasts when compared 
with CLP(P). Fibroblasts from the BLCLP phenotype had significantly lower PCNA expression 
when compared with those with RUCLP (Figure 26E and 26F).  
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Figure 23: Gene expression for MCM2. (A) MCM2 expression levels varied 
widely between samples with a maximum fold change of 5.74 and a minimum fold 
change of 0.65 but in general displayed higher expression than the HGF control. 
(B) Scatterplot comparing doubling times and MCM2 expression. Based on 
Spearman’s rho analysis there was no correlation observed between MCM2 
expression and DT (correlation coefficient = 0.093; p=0.39) (n=3). 
(A) 
(B) 
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Figure 24: Gene expression for MK167. (A) Gene expression levels varied 
between patient fibroblasts with a maximum fold change of 5.47 and a minimum 
fold change of 0.83 although the majority of samples expressed MK167 higher than 
the HG control. (B) Scatterplot comparing doubling times and MK167 expression. 
Based on Spearman’s rho analysis there was no correlation observed between 
MK167 expression and DT (correlation coefficient = 0.115; p=0.288) (n=3). 
 
(A) 
(B) 
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Figure 25: Gene expression for PCNA. (A) Gene expression varied between patient 
fibroblasts with a maximum fold change of 4.51 and a minimum fold change of 0.69 
however most samples displayed higher PCNA expression relative to the HGF control. 
(B) Scatterplot comparing doubling times and PCNA expression. Spearman’s rho 
analysis revealed there was a significant positive correlation observed between PCNA 
expression and DT (correlation coefficient = +0.401; p<0.01) (n=3). 
(B) 
(A) 
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Figure 26: Average expression of proliferation associated genes between cleft types. (A) Average MCM2 expression was significantly lower in CP fibroblasts 
when compared with CLP(P) fibroblasts. (B) Both LUCLP and RUCLP expression was significantly higher when compared with BLCLP. (C) Average MK167 was 
significantly lower in CLP(L) when compared with CLP(P), CL and CP, CLP(P) patient expression is also significantly lower when compared with to CP. (D) MK167 
expression was also higher in LUCLP and RUCLP when compared with the BLCLP phenotype. (E) Average PCNA expression was higher in CLP(L) when compared 
with CL in isolation, in addition, CLP(P) expression was significantly higher when compared with CL and CP. (F) MK167 expression was significantly higher in the 
RUCLP when compared with BLCLP. Data sets comprised of averaged data derived from all samples within the patient cohort that manifested a specific cleft 
phenotype. Gene expression values are calculated as fold changes in expression ratios relative to the HGF control. On the above graphs, cleft phenotypes were 
compared to each other individually, as opposed to a control with a single data point, in order to comparatively assess expression between cleft phenotypes. Significant 
differences were determined by means of student’s t-test where: # = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to 
CL (n=18); Ø = p<0.05 relative to CP (n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
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3.3.2 Hierarchical cluster analysis 
Hierarchical clustering, which groups data based on statistical similarity, was used to group 
cleft patient derived fibroblasts based on the data relating to cell growth, namely: growth curve 
data, DT, MTT absorbance at day four, MCM2 expression, MK167 expression and PCNA 
expression.  The resulting dendrogram revealed a data outlier, fibroblasts derived from patient 
S101603, which was significantly different from the rest of the cohort (cluster B) while the 
remaining samples (cluster A), split into two further clusters at a squared Euclidean distance of 
9: groups C with 13 samples and group D with 15 samples. Both groups contain fibroblasts 
derived from each cleft type; group C contains 13 samples with: 4 CLP(L), 2 CLP(P), 4 CL and 
3 CP; group D contains 15 samples with: 5 CLP(L), 6 CLP(P), 2 CL and 2 CP (Figure 27).  
However, there was a larger proportion of CLP(P) in cluster C (6) when compared with to 
cluster D (2). This clustering suggests that cleft fibroblasts display a high degree of similarity, 
in terms of proliferation associated data, and do not differ significantly based on the cleft 
phenotype of the patients from which they were isolated.  
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Figure 27: Dendrogram grouping patient fibroblasts following input of all cell 
growth and gene expression data. Hierarchical cluster analysis was employed to 
group samples based on growth curve data, DT, MTT absorbance at day four, 
MCM2 expression, MK167 expression and PCNA expression. The number of 
clusters were not predetermined thus cluster membership was based on the data 
alone. The clustering method employed was the centroid method and the data was 
measured using the squared Euclidean distance interval. The dendrogram revealed 
the presence of two statistically distinct clusters; group A comprising of 28 
samples and group B comprising of a single outlier. Group A bifurcates further but 
at a much smaller distance of 9 indicating the two groups share considerable 
similarity; group C comprises of 13 samples whereas group D comprises of 15 
samples.  
A 
B 
C 
D 
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3.4 Analysis of collagen production for all cleft patients 
Collagens are major structural proteins within developing embryological tissues as they permit 
ECM homeostasis, provide mechanical tissue stability and act as major scaffolds for cell 
adhesion and motility thereby permitting normal cellular activity. Further, it has been suggested 
collagen synthesis is critical to normal reorientation of the developing palatal shelves (Ben-
Khaial and Shah, 1994), thus collagen production and expression was assessed across the 
patient cohort in order to determine whether collagen synthesis may be a contributory factor in 
cleft phenotype manifestation. Sirius red staining was used to quantify the total collagen 
production for each cleft patients’ fibroblasts following 7 days in culture. The mean collagen 
production across all 29 patients’ fibroblasts was 167.98µg however; there was some variation 
across with the highest total collagen production of 218.82µg and the lowest 136.73µg (Figure 
28A). In order to establish whether the differences in collagen production were due to different 
cleft types, the data from each cleft type was grouped and plotted as an average. CLP(L) and 
CL fibroblasts produced similar amounts of collagen whilst with CLP(P) and CP derived 
fibroblasts shared similar levels of collagen production; this suggests collagen production may 
differ based on the anatomical origin of fibroblasts. CLP(P) and CP cleft phenotypes produced 
significantly lower amounts of collagen than the CLP(L) fibroblasts and CL fibroblasts 
respectively (p<0.05 and p<0.05) (Figure 28B). However, when comparing collagen production 
in CLP fibroblasts with varying laterality there were no significant differences in collagen 
production (Figure 28C).  
3.4.1 Analysis of collagen expression for all cleft patients  
Collagen expression by fibroblasts derived from differing cleft types was assessed. There was 
some variation in COL1A1expression across the sample cohort with a maximum 2.24-fold and 
a minimum fold change of 0.48-fold (Figure 29A). On average fibroblasts from the CL 
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phenotype expressed significantly higher levels of COL1A1 when compared with CLP(P) and 
CP (p<0.05) but not CLP(L). However, CLP(L) fibroblasts displayed significantly higher 
expression of COL1A1 when compared with the CP phenotype (p<0.05) (Figure 29B). CLP 
clefts with varying laterality expressed COL1A1 at similar levels with no significant differences 
between groups (Figure 29C).  
COL3A1 expression was variable with a number of fibroblasts expressing COL3A1 at levels 
similar to that of the HGF control whilst others displayed expression levels that were 
significantly higher suggesting patient derived fibroblasts may differ in production of collage 
type-3. The highest expression was 4.39-fold whereas the lowest was 0.75-fold (Figure 30A). 
When comparing cleft types, fibroblasts from CL patients expressed significantly lower levels 
of COL3A1 when compared with fibroblasts from CLP(L) and CLP(P) (p<0.05) but not CP 
(Figure 30B) suggesting when cleft lip and palate manifest together fibroblast expression of 
COL3A1 may be upregulated. Further, when comparing cleft laterality, it was found that 
fibroblasts from patients with the RUCLP phenotype expressed significantly lower amounts of 
CLO3A1 when compared with both LUCLP and BLCLP (p<0.05) (Figure 30C). 
COL5A1 expression varied widely between patient derived fibroblasts but all each sample 
expressed COL5A1 in amount greater than the control with a maximum of 12.19-fold and a 
minimum of 2.84-fold (Figure 31). When comparing cleft types, it was found that CLP(P) 
fibroblasts expressed significantly lower levels of COL5A1 when compared with both CLP(L) 
and C (P<0.05). In addition, RUCLP clefts expressed significantly lower levels of COL5A1 
when compared with both LUCLP and BLCLP (P<0.05).  
3.4.2 Correlations between collagen production and collagen expression 
Collagen production, COL1A1, and COL3A1 expression was not normally distributed therefore 
Spearman’s rho test was used to compute the correlation whereas COL5A1 data was normally 
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distributed therefore Pearson’s correlation was the appropriate correlation test. Spearman’s rho 
analysis revealed that there was a significant negative correlation between collagen production 
and COL3A1 expression (correlation coefficient = -0.390; p<0.01) and a significant positive 
correlation between COL1A1 expression and COL3A1 expression (correlation coefficient = 
+0.226; p<0.05). Pearson’s correlation revealed a significant positive correlation between 
COL3A1 and COL5A1 (correlation coefficient = +0.289; p<0.05)  
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Figure 28: Quantification of collagen production. (A) Collagen production between 
individual patient fibroblasts was varied with the maximum collagen production was 
218.82µg and the minimum was 136.73µg; NHDFF control fibroblasts produced 203.46 
µg which significantly greater than the majority of the sample cohort (n=3). (B) Collagen 
production was significantly higher in CLP(L) and CL when compared with CLP(P) and 
CP. (C) There was no difference in collagen production between clefts with varying 
laterality. Significant differences were determined by means of student’s t-tests where: 
# = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 
relative to CL (n=18); Ø = p<0.05 relative to CP (n=15). 
Collagen production: all cleft fibroblasts samples 
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Figure 29:  Gene expression of COL1A1. (A) Expression of COL1A1 were similar to 
the HGF control for the majority of cleft fibroblasts the highest expression was 2.24-fold 
and lowest was 0.48-fold (n=3). (B) COL1A1 expression was significantly higher in CL 
fibroblasts when compared with CLP(P) and CP groups but not CLP(L) however CLP(L) 
expression was shown to be significantly higher than that of CP. (C) There was no 
differences in COL1A1 expression between clefts of differing laterality. Significant 
differences were determined by means of student’s t-tests where: # = p<0.05 relative to 
CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); 
Ø = p<0.05 relative to CP (n=15). 
COL1A1 expression: all cleft fibroblasts samples 
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Figure 30: Gene expression of COL3A1. (A) A minority of fibroblasts displayed 
expression levels similar to that of HGF (minimum=0.75-fold) however most expressed 
COL3A1 in significantly higher amounts (maximum-3.64-fold) (n=3). (B) Expression of 
COL3A1 was significantly higher in both CLP(L) and CLP(P) fibroblasts when compared 
with CL. (C) COL3A1 expression was significantly lower in RUCLP cleft types when 
compared with LUCLP and BLCLP but there was no difference between LUCLP and 
BLCLP.  Significant differences were determined by means of student’s t-tests where: # 
= p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 
relative to CL (n=18); Ø = p<0.05 relative to CP (n=15); † = p<0.05 relative to LUCLP 
(n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
COL3A1 expression: all cleft fibroblasts samples 
¥ 
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Figure 31:  Gene expression of COL5A1. (A) Expression of COL5A1 varied widely 
but all fibroblasts exhibited expression significantly higher than that of the HGF control 
as the minimum was 2.84-fold and the maximum was 12.19-fold. (n=3). (B) COL5A1 
expression of CLP(P) was significantly lower than both CP and CLP(L) but not CL. (C) 
RUCLP expression of COL5A1 was shown to be significantly lower than both LUCLP 
and BLCLP. Significant differences were determined by means of student’s t-tests 
where: # = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ 
=p<0.05 relative to CL (n=18); Ø = p<0.05 relative to CP (n=15); † = p<0.05 relative 
to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to 
BLCLP (n=15). 
COL5A1 expression: all cleft fibroblasts samples 
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Figure 32: Scatter matrix comparing collagen production and expression of 
COL1A1, COL3A1 and COL5A1. Shapiro-Wilk test of normality revealed the data 
relating to collagen production, COL1A1 and COL3A1 were non-parametric (p<0.05, 
p<0.01 and p<0.01 respectively) whereas data relating to COL5A1 was parametric 
(p=0.101) thus required different tests for correlation analysis. Spearman’s rho 
analysis revealed there was a significant negative correlation between collagen 
production and COL3A1 expression (correlation coefficient = -0.390; p<0.01), a 
significant positive correlation between COL1A1 and COL3A1 (correlation 
coefficient = +0.226; p<0.05). Pearson correlation revealed a significant positive 
correlation between COL3A1 and COL5A1 (correlation coefficient = +0.289; 
p<0.05). 
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3.5 Analysis of sulphated glycosaminoglycan production 
Glycosaminoglycans (GAG’s) are negatively charged hydrophilic polysaccharides that 
contribute to tissue hydration, water retention caused by GAGs has been proposed to impart 
intrinsic hydrostatic force that contributes to the expansion, elevation and reorientation of the 
palatal shelves (Singh et al, 1994; Singh et al, 1997). Due to proposed critical role of GAGs in 
normal craniofacial development, GAG production and expression was assessed in populations 
of cleft fibroblasts to assess whether there were differences between cleft phenotypes. Alcian 
blue staining was utilised in order to quantify sulphated glycosaminoglycan (GAG) produced 
by cultures after 7 days by means of spectrophotometry. The highest absorbance observed was 
0.340 whereas the lowest absorbance value observed was 0.160 (Figure 33A). Across cleft 
types, absorbance was averaged which revealed that the CLP(L) group produced significantly 
lower GAG than the CLP(P) group (p<0.05) whereas there were no differences with or between 
CL and CP groups (Figure 33B). When comparing cleft laterality, the RUCLP group had 
significantly higher absorbance than LUCLP and BLCLP (p<0.05) thereby indicating increased 
GAG production (Figure 33C).  
3.5.1 Analysis of sulphated glycosaminoglycan expression  
Expression gene transcripts associated with sulphated GAG production were assessed. CSPG4 
expression was similar across the cleft fibroblast cohort however there was some variation as 
the lowest expression was 0.67-fold and the highest was 2.18-fold (Figure 34A). The CLP(P) 
fibroblasts had significantly lower CSPG4 expression when compared the CLP(L) and CP; it 
was also found that fibroblasts from CL also had significantly lower expression of CSPG4 than 
fibroblasts from CP (p<0.05) patients (Figure 34B). When grouping fibroblasts based on cleft 
laterality it was found that those with RUCLP has significantly lower expression of CSPG4 
when compared with those with LUCLP and BLCLP (p<0.05) (Figure 34C). 
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DSE expression was significantly upregulated in some cleft fibroblasts with a maximum 
expression of 6.36-fold however a number of samples expressed DSE in lower amounts but still 
significantly higher than the control. One sample was an outlier and expressed DSE in amounts 
comparable to the HGF control, as the lowest fold change observed was 1.01-fold (Figure 35A). 
DSE expression was significantly greater in fibroblasts from CP when compared with CLP(P) 
and CL derived fibroblasts (p<0.05) (Figure 35B). DSE expression was also shown to be 
significantly lower RUCLP compared LUCLP and BLCLP (p<0.05) (Figure 35C).  
HSPG2 was expressed in all cleft fibroblast samples in greater amounts than the HGF control 
as the lowest expression measured was 1.51-fold and the highest was 3.29-fold (Figure 36A). 
HSPG2 expression was significantly lower in CLP(P) fibroblasts when compared with both CL 
and CP (p<0.05) (Figure 36B). As seen with both CSPG4 and DSE expression, fibroblasts with 
RUCLP cleft laterality displayed significantly lower expression of HSPG2 when compared with 
both LUCLP and BLCLP (Figure 36C). This suggests that fibroblasts from RUCLP may 
express and produces different GAG’s in higher amounts that there LUCLP and BLCLP 
counterpart even though Alcian blue staining suggested higher amounts of sulphated GAG were 
produced by RUCLP fibroblasts. 
3.5.2 Correlations between GAG production and GAG expression 
Scatter matrix plots and correlation analysis were conducted in order to establish how 
production of sulphated GAG and expression of sulphated GAG associated genes were related 
between cleft fibroblast samples (Figure 37). It was found that there was a significant negative 
correlation between Alcian blue staining and HSPG2 expression (correlation coefficient = 
0.232; p<0.05). Likewise, there was a significant negative correlation between Alcian blue and 
DSE; this suggests that the increased production of GAG in some patient samples was not due 
to increased expression of DSE and HSPG2 and was potentially the result of CSPG4 and other 
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sulphated GAGs. A positive correlation was observed between CSPG4 and HSPG2 
(Correlation coefficient = +0.376; p<0.01) suggesting that it is possible that the genes are 
upregulated together in some cleft patients fibroblasts.  
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Figure 33:  Alcian blue staining for sulphated glycosaminoglycans. (A) Production of 
glycosaminoglycans was varied with a maximum absorbance was 0.34 and a minimum of 
0.16 which indicated there were large differences in GAG production between cleft 
fibroblasts; the NHDFF control was shown to produce significantly greater amounts of 
GAG when compared to all the cleft fibroblasts assessed here. (B) Absorbance was 
significantly higher in CLP(P) when compared with CLP(L) but there were no differences 
when compared with CL and CP. (C) RUCLP was shown to have significantly higher 
average absorbance when compared with both LUCLP and BLCLP. Significant differences 
were determined by means of student’s t-tests where: # = p<0.05 relative to CLP(L) (n=27); 
$ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø = p<0.05 relative 
to CP (n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) 
and + = p<0.05 relative to BLCLP (n=15). 
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Figure 34: Gene expression of CSPG4. (A) Expression of CSPG4 was similar across 
all cleft fibroblasts and exhibited amounts similar to that of the HGF control. (n=3). (B) 
CSPG4 expression was significantly higher in CLP(L) fibroblasts when compared with 
both CLP(P) and CL but not CP. Further, CL expression was significantly lower than 
that of CP fibroblasts. (C) Expression of CSPG4 in RUCLP fibroblasts was significantly 
lower than both LUCLP and BLCLP fibroblasts. Significant differences were 
determined by means of student’s t-tests where: # = p<0.05 relative to CLP(L) (n=27); 
$ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø = p<0.05 
relative to CP (n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to 
RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
CSPG4 expression: all cleft fibroblasts samples 
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Figure 35:  Gene expression of DSE. (A) Expression levels of DSE was variable across 
the patient cohort however most fibroblasts exhibited expression levels higher than that 
of the HGF control (n=3). (B) Fibroblasts from the CP phenotypes displayed significantly 
higher levels of expression of DSE when compared with both CLP(P) and CL but not 
CLP(L). (C)  DSE expression was shown to be significantly lower in RUCLP fibroblasts 
when compared with both BLCLP and LUCLP. Significant differences were determined 
by means of student’s t-tests where: # = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 
relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø = p<0.05 relative to CP 
(n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and 
+ = p<0.05 relative to BLCLP (n=15). 
DSE expression: all cleft fibroblasts samples 
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Figure 36: Gene expression of HSPG2. (A) Expression levels of HSPG2 were highly 
variable across the patient cohort however all samples exhibited expression levels higher 
than that of the HGF control. (n=3). (B) CLP(P) fibroblasts exhibited significantly lower 
average expression of HSPG2 when compared with both CL and CP but not CLP(L). (C) 
RUCLP fibroblasts had significantly lower average expression of HSPG2 when 
compared with both LUCLP and BLCLP. Significant differences were determined by 
means of student’s t-tests where: # = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 
relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø = p<0.05 relative to CP 
(n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and 
+ = p<0.05 relative to BLCLP (n=15). 
HSPG2 expression: all cleft fibroblasts samples 
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Figure 37: Scatter matrix comparing Alcian blue quantification and expression 
of HSPG2, CSPG4 and DSE. Shapiro-Wilk test of normality revealed the data 
relating to Alcian blue quantification and CSPG4 expression was parametric (p=1.49 
and p=0.606 respectively) whereas data relating to HSPG2 and DSE was non 
parametric (p<0.01 and p<0.01 respectively) thus required differing test for 
correlational analysis. Pearson correlation revealed a slight negative correlation 
between Alcian blue and CSPG4 though (correlation coefficient= -0.179; p= 0.098). 
Spearman’s rho analysis revealed a significant negative correlation between Alcian 
blue and HSPG2 expression (correlation coefficient = 0.232; p<0.05) and a 
significant negative correlation between DSE and Alcian blue staining (correlation 
coefficient = -0.241 (p<0.05). Further, a significant positive correlation was observed 
HSPG2 and CSPG4 (Correlation coefficient = +0.376; p<0.01).  
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3.6 Expression of FN1 by cleft fibroblasts  
FN1 expression was highly variable as the highest expression observed was 15.49-fold and the 
lowest was 3.22-fold, this suggested that in general cleft fibroblasts may produce fibronectin in 
higher amounts than their non-cleft NHDFF counterparts (Figure 38A). When patient 
expression was grouped based on cleft type it was found that CL fibroblasts expressed 
significantly lower amounts of FN1 when compared with CLP(L) and CLP(P) (p<0.05) Further, 
CP fibroblasts expressed significantly lower FN1 when compared with both CLP(P) and 
CLP(L); there was no difference between CLP(L) and CLP(P) or CL and CP (Figure 38B). This 
suggests cleft fibroblast fibronectin production may be significantly higher when cleft lip and 
palate manifest in conjunction as opposed to their isolated counterparts.  When comparing cleft 
laterality, it was again found that clefts that were RUCLP expressed significantly lower amounts 
of FN1 than both LUCLP and BLCLP (p<0.05), this suggests that RUCLP derived fibroblasts 
may produce fibronectin lower amounts than both LUCLP and BLCLP derived fibroblasts 
(Figure 38C).  
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Figure 38: Gene expression of FN1. (A) Expression of FN1 was highly variable across 
cleft fibroblast samples however samples exhibited expression in greater amounts than 
that of the HGF control as the maximum fold change was 15.49 and a minimum of 3.22 
(n=3). (B) FN1 expression was significantly higher in CLP(L) fibroblasts when compared 
with both CL and CP (p<0.05). In addition, CLP(P) fibroblasts also exhibited significantly 
higher expression of FN1 when compared with CL and CP; there was no differences 
between CLP(L) and CLP(P). (C) RUCLP fibroblasts exhibited significantly lower 
average expression of FN1 when compared with LUCLP and BLCLP. However, LUCLP 
fibroblasts had significantly higher expression of FN1 when compared with both RUCLP 
and BLCLP. Significant differences were determined by means of student’s t-tests where: 
# = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 
relative to CL (n=18); Ø = p<0.05 relative to CP (n=15); † = p<0.05 relative to LUCLP 
(n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
FN1 expression: all cleft fibroblasts samples 
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3.7 Expression of Transforming Growth Factor betas  
The TGF superfamily are a group of cytokines that can regulate processes such as: cell 
recruitment, proliferation, ECM deposition, differentiation and apoptosis (Penn et al, 2012), all 
of which are key to normal craniofacial development. TGFβ1, TGFβ2, and TGFβ3, have all 
been shown to be expressed either within the epithelium of the palatal shelves or the underlying 
mesenchyme where they are thought to play critical roles in palatal growth, fusion and 
epithelial-to-mesenchymal transition (EMT) of the medial edge epithelium (MEE) (Pelton et 
al, 1990; Kaartinen et al, 1997; Nawshad et al, 2004). Due to the elevation in expression of 
various TGFβs in key craniofacial structures during development coupled with their potent 
effects on cell behaviour, the expression of a number TGFβs, and their associated receptors, 
was assessed to establish potential differences in expression profiles between cleft phenotypes.  
Expression of TGFB1 was highly variable across the sample cohort as a number of samples 
upregulated TGFB1 whilst others were downregulated relative to the control; the maximum 
expression was 6.60-fold and the minimum was 0.51-fold. This sample variation this did not 
correlate with cleft type as there were no significant differences in TGFB1 expression between 
cleft types. However, there were significant differences between cleft fibroblasts derived from 
differing cleft literalities as LUCLP fibroblasts had significantly higher average expression 
when compared with both RUCLP (0<0.001) and BLCLP (p<0.05) (Figure 39A-C). Expression 
of TGFB2 was also highly variable but all samples expressed TGFB2 in significantly higher 
amounts than the control. Some samples exhibited TGFB2 in significantly higher amounts than 
the overall sample mean as the highest expression observed was 16.34-fold whereas the lowest 
was 1.92-fold thereby indicating large disparities between cleft fibroblasts. This variability did 
correlate to some degree with cleft type as TGFB2 expression was significantly greater in 
fibroblasts isolated from CLP(L) compared with CLP(P) (p<0.05). Further RUCLP fibroblasts 
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displayed significantly lowered expression when compared with LUCLP (p<0.05) and BLCLP 
(p<0.001) (Figure 40A-C).  Expression of TGFB3 was also variable, however a number of 
samples displayed expression comparable with the control although the maximum expression 
was 6.48-fold and the minimum was 0.64-fold. These differences in TGFB3 expression between 
samples were not based on cleft type or laterality though there was a significant difference in 
expression between CLP(L) and CP fibroblasts (Figure 41A-C). 
 
 
  
Figure 39: Expression levels of TGFB1. (A) Expression levels of TGFB1 were 
variable across the sample cohort however most fibroblasts expressed TGFB1 in 
significantly higher amounts than the control (n=3). (B) There was no differences in 
TGFB1 expression between cleft types. (C) Averages expression of TGFB1 was 
significantly in LUCLP relative to RUCLP and BLCLP. Significant differences were 
determined by means of student’s t-test where: † = p<0.05 relative to LUCLP (n=18); 
‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
 
 † 
 † 
(A) 
(B) (C) 
 123 
 
 
  
Figure 40: Expression levels of TGFB2. (A) Expression of TGFB2 was highly 
variable however all samples displayed fold changes significantly greater than the 
HGF control (n=3). (B) TGFB2 expression was significantly greater in CLP(L) when 
compared with CLP(P) but there were fibroblasts with high and low expression in 
each group. (C) TGFB2 expression was significantly lower in RUCLP relative to 
both LUCLP and BLCLP (n=3). Significant differences were determined by means 
of student’s t-test where: # = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative 
to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø = p<0.05 relative to CP 
(n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) 
and + = p<0.05 relative to BLCLP (n=15). 
‡ 
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Figure 41: Expression levels of TGFB3. (A) Expression of TGFB3 differed 
considerably across the sample cohort with some fibroblasts expressing TGFB3 in 
amounts comparable with the control and others in significantly greater amounts (n=3). 
(B) TGFB3 expression was significantly higher in CLP(L) relative to CP. (C) There 
were no significant differences in TGFB3 based on cleft laterality. Significant 
differences were determined by means of student’s t-test where: # = p<0.05 relative to 
CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); 
Ø = p<0.05 relative to CP (n=15).  
 
(A) 
(B) (C) 
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3.7.1 Expression of transforming growth factor beta receptors  
The expression of receptors associated with the TGFβ signalling pathway was assessed in order 
to determine how they differ between fibroblasts derived from different cleft patients. TGFBR1 
expression was comparable with the HGF control for a number of fibroblast samples, however 
the majority of fibroblast samples expressed TGFBR1 in significantly amounts as the maximum 
was 8.20-fold whereas the minimum was 0.63-fold. This difference did not correlate with cleft 
type as they all shared similar fold changes. However, in terms of cleft laterality it was shown 
that RUCLP fibroblasts displayed significantly lower expression when compared with LUCLP 
(Figure 42A-C).  
Expression of TGFBR2 was also varied but the majority of the samples displayed expression in 
greater amounts than the control as the maximum expression was 6.72-fold. However, a 
minority of samples shared expression comparable with or lower than the control as the 
minimum expression observed was 0.59-fold. In terms of cleft type, CLP(L) displayed 
significantly higher average expression of TGFBR2 when compared with CP but not other cleft 
types (p<0.05). As with expression of TGFBR1, expression of TGFBR2 was significantly down-
regulated in fibroblasts derived from RUCLP when compared with LUCLP derived fibroblasts 
(Figure 43A-C). 
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Figure 42: Expression levels of TGFBR1. (A) Expression of TGFBR1 was highly 
variable across the sample cohort as some fibroblasts exhibited expression levels 
comparable with the HGF control whereas others were significantly higher. (n=3). (B) 
There were no differences in TGFBR1 expression based on cleft phenotype. (C) Average 
expression of TGFBR1 was significantly higher in fibroblasts from patients with LUCLP 
relative to RUCLP. Significant differences were determined by means of student’s t-test 
where: † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and 
+ = p<0.05 relative to BLCLP (n=15). 
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Figure 43: Expression levels of TGFBR2. (A) Expression of TGFBR2 was varied, 
some samples exhibited expression comparable with the HGF control however the 
majority of fibroblast samples expressed TGFBR2 in significantly greater amounts 
(n=3). (B) Average expression of TGFBR2 was significantly greater in CLP(L) 
fibroblasts relative to CP. (C) Average expression was significantly higher in LUCLP 
fibroblasts relative to RUCLP. Significant differences were determined by means of 
student’s t-test where: # = p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to 
CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø = p<0.05 relative to CP (n=15); † 
= p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = 
p<0.05 relative to BLCLP (n=15).  
(A) 
(B) (C) 
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3.7.2 Expression of Transforming Growth Factor alpha  
Transforming growth factor alpha (TGFα), a potent epithelial mitogen that can also influence 
fibroblast activity, has been positively identified within the epithelium and the underlying 
mesenchyme at multiple stages of palatal development (Meng et al, 2009), TGFA expression 
was therefore assessed to determine whether its expression differed between cleft phenotypes. 
TGFA expression was less variable across the sample cohort. There were a number of samples 
that displayed significant down-regulation of TGFA relative to the control although this down-
regulation not correlate with cleft type. However, RUCLP fibroblasts displayed significantly 
lowered average expression of TGFA relative to both LUCLP and BLCLP (Figure 44A-C). 
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Figure 44: Expression levels of TGFA. (A) A subset of patient samples exhibited expression 
significantly lower than the control whereas others exhibited expression comparable with the 
HGF control. (n=3). (B) The expression of TGFA was similar for each cleft type. (C) TGFA 
expression was significantly lowered in RUCLP fibroblasts relative to LUCLP and BLCLP.  
(A) 
(B) (C) 
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3.8 Discussion 
The development of the face, including the lip and palate, is a precise tightly regulated process 
that encompasses complex interplay between a host of cell types and cell behaviours. The 
current mechanistic model suggests the morphogenesis of CLP may be due to pathological cell 
behaviours, including proliferation, adhesion, migration, differentiation and apoptosis, during 
the critical weeks of early craniofacial development, leading to deviation from the facial 
blueprint due to obstruction, malposition or failure of fusion facial growth centres as a result of 
genetic or environmental factors (Mossey et al, 2009). However, the precise mechanisms that 
give rise to the varying cleft phenotypes is currently poorly understood although it is possible 
that they may each be a result of differing pathological processes. The cornerstone of the facial 
developmental process is the rapid migration and proliferation of cranial neural crest cells 
(CNCCs) following delamination from the neural tube via the process of epithelial-to-
mesenchymal transition (EMT) (Strobl-Mazulla and Bronner, 2013). These cells migrate to 
sites that will become the facial processes and can differentiate into mesenchymal cells with 
the ability to give rise to diverse cell lineages, including fibroblasts, that contribute to the 
formation of facial cartilage, bone and connective tissue (Hay, 2005; Huang and Saint-Jeannet, 
2004). The formation of the face is a result of the action of these cell types at the five premature 
facial swellings where there continued proliferation lead to the outgrowth of these facial growth 
centres (Chai and Maxson, 2006; Jiang et al, 2008). CNCC derived mesenchymal cells, 
including fibroblasts, are the major secretors of ECM within these facial processes and 
contribute to their growth through there proliferative activity and continued secretion of ECM 
prior to fusion of the facial processes (Sun et al, 2000; Jiang et al, 2006). When in proximity, 
filopodial attachments from cells on the approaching opposing prominence begin to interact, 
this is followed by the generation and accumulation of larger cellular processes, including 
adhesion junctions, which lead to precise fusion of the facial processes (Sun et al, 2000). 
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Fibroblasts are key to these processes as reduced proliferation can lead to reduced cell packing 
within the facial processes, this could lead to a decrease in overall fibroblast ECM deposition 
thereby reducing the overall volume of the tissue. Further, due to acting as the biological 
scaffold, diminished ECM deposition can lead to a reduction in adhesion sites, which are 
required for cellular motility (Rozario and DeSimone, 2010). Controlled and tightly regulated 
fibroblast behaviour is therefore essential to normal facial development therefore perturbations 
in their activity may lead to CLP morphogenesis due to tissue malposition resulting in partial 
fusion of the facial prominences at various degrees of severity. Due to this, cleft fibroblast 
behaviour was assessed and compared between cleft patients as it is possible that differences in 
fibroblast activity may influence the type of cleft that manifests.  
3.8.1 Confirmation of the Fibroblast lineage  
To reliably compare fibroblasts derived from differing cleft phenotypes it was first necessary 
to confirm that samples comprised of homogenous fibroblast populations, this was achieved by 
both real time PCR and immunostaining methodologies. Vimentin (VIM) is an intermediate 
filament that is only found in cells of mesenchymal origin, such as fibroblasts, and has been 
successfully used as a fibroblast marker in a number of different studies (Ivey et al, 2017; 
Negmadjanov et al, 2015). It was found that all of the cells stained positive for VIM and 
displayed fibroblastic morphology thereby suggesting there was no epithelial contamination. 
Further, fibroblasts expressed four-fold increase in VIM relative to H400 squamous carcinoma 
epithelial cell line. Epithelial cells are of ectodermal origin and as result under normal 
circumstances do not express VIM unless undergoing epithelial-mesenchymal transition (EMT) 
(Abdulkareem et al, 2018) which is not be expected under normal cell culture conditions. It 
would be expected that homogenous populations of fibroblasts would express VIM whereas 
epithelial cells would exhibit null expression; however, it was shown here that H400 cells did 
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express VIM and this is likely due to being a transformed cancer cell line and not a true primary 
epithelial cell type. Further, the fibroblast phenotype is often confirmed by the absence of 
specific markers for other cell lineages (Chang et al, 2002), as epithelial cells had the highest 
potential to contaminate pure fibroblast cultures, pooled cleft fibroblasts were assessed for the 
expression of cytokeratin 5 (CK5) which is an epithelial marker (Corr et al, 2015). H400 cells 
were positive for CK5 whereas pooled cleft fibroblasts were negative. This data suggests 
cultures were homogenous fibroblast populations therefore any comparisons made between 
cleft types in subsequent assays would be with cells from the same lineage. 
3.8.2 The effect of increasing passage number on cleft fibroblast behaviour 
Two-dimensional cell culture involves growing cells onto a substrate with a finite surface area. 
As cells approach confluence, cell-substrate adhesion molecules are dissociated through use of 
chemical stimuli such as trypsin-EDTA. Following this, a sub-population of the dissociated 
cells are reseeded into a separate tissue culture vessel, this process is termed subculture, or 
passaging, every time this process is conducted the cell passage number is increased by one. 
Subculture is a traumatic process and can have a significant effect on normal cell behaviours 
(Hughes et al, 2018), thereby causing cells to behave differently at different passage numbers 
making comparisons between passages difficult and effecting results and data interpretation. 
To undertake valid comparative assessments between fibroblasts isolated from different cleft 
patients it was necessary to determine the effect of varying passage numbers on cell behaviour.  
It was found that passaging cells had a significant effect on the growth of cleft fibroblasts as 
after passage four as fibroblasts were shown to have a significant increase in DT (p<0.05). 
Others have found comparable results with primary human nasal epithelial stem progenitor cells 
(hNESPCs) which showed a marked increase in DT between passage one and three (Yu et al, 
2014). MCM2, a component of the mini chromosome maintenance (MCM) complex which acts 
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a replicative helicase for DNA replication, was significantly upregulated after passage two. 
MCM proteins are thought to be key regulators of cell proliferation during times of replicative 
stress (Quan Ge et al, 2007), which may occur as a result of repeated DNA replication at 
elevated cell passages.  Abundant MCM proteins are required for cells to survive replicative 
stress and proliferate normally (Ge et al, 2007) therefore their upregulation in cleft fibroblasts 
after passage two may be a response to the cell stresses caused by passaging and an attempt to 
maintain normal proliferative behaviour. Expression of MK167, a proliferative marker that is 
present in all of the active stages of the cell cycle including mitosis, was reduced after passage 
three, whilst PCNA expression, a cofactor to DNA polymerase, remained stable between 
passages zero to five. A study on human temporo-mandibular joint fibro-chondrocytes (TMJF) 
demonstrated that both MK167 and PCNA expression was similar between passage one and 
passage eight but there was a decrease in expression of both genes at passage nine which was 
suggested to result in reduced proliferation (Garzon et al, 2012). Downregulation of MK167 
after passage three and upregulation of MCM2 after passage two suggests this variance in 
expression may account for the significant increase in cleft fibroblast DT after passage three as 
it has been demonstrated that stable expression of proliferative markers is correlated with stable 
proliferation (Garzon et al, 2012). As fibroblast growth was shown to be unaffected at low 
passages, subsequent cell based assays were conducted with passage two fibroblasts thus any 
disruptions in cell behaviour would be consistent across the patient cohort. 
To determine the most appropriate passage number for PCR analysis it was necessary to 
establish the effect passaging on the expression of genes that are thought to be involved in cleft 
formation. Polymorphisms of interferon regulatory factor 6 (IRF6), a transcription factor that 
is elevated in the palatal shelves and is thought to regulate epithelial-to-mesenchymal transition 
during palatal fusion (Ke et al, 2015), are associated with CLP formation (Rahimov et al, 2008; 
Park et al, 2010). Cleft fibroblasts displayed stable expression of IRF6 between passage zero 
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and three followed by upregulation thereafter. Similarly, SOX9, a transcriptional regulator 
involved in craniofacial development (Lee et al, 2011), was downregulated after passage one; 
whereas TGFA, which influences the risk of cleft formation (Sull et al, 2009) displayed stable 
expression. Variability in expression of cleft associated markers at different passages may lead 
to false comparisons between samples that are no longer comparable leading to skewed results 
and to inaccurate conclusions (Hughes et al, 2018). Due to this, only passage one fibroblasts 
were utilised for PCR analysis; passage zero fibroblasts were required for cell stock expansion.  
3.8.3 Growth of cleft fibroblasts  
Despite DT varying between 26.11 and 32.41 hours, when grouping data there was no 
significant differences between fibroblasts derived from different cleft phenotypes. Further, the 
majority of samples displayed comparable DT to the NHDFF control. Conversely, others have 
shown NSCLP fibroblasts exhibited significantly higher thymidine incorporation (+151%) 
compared control fibroblasts isolated from patients with palatal trauma (Marinucci et al, 2009), 
this suggests that cleft fibroblasts may proliferate faster than their non-cleft counterparts. Gene 
expression of proliferation associated genes did vary significantly between cleft types therefore 
it is possible that in vivo cleft fibroblasts would proliferate differentially as opposed to their 
growth on an artificial two-dimensional surface. CLP(P) fibroblasts upregulated MCM2 relative 
to CP despite being derived from the same anatomical site. MCM2 proteins are a pre-requisite 
for DNA replication and commencement of the cell cycle (Kearsey and Labib, 1998). Elevated 
MCM expression has been identified in highly proliferative cells (Shetty et al, 2005; Torres-
Rendon et al, 2009) whereas quiescent cells display diminished MCM2 expression (Madine et 
al, 2000). Therefore, it is possible that CLP(P) fibroblast would proliferate faster in vivo 
compared to CP fibroblasts. Further, both types of CLP fibroblasts, CLP(L) and CLP(P), 
significantly upregulated of PCNA when compared with those with CL in isolation. PCNA is 
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also a key coordinator of DNA synthesis as it acts as a platform for recruitment of proteins 
associated with regulation of the cell cycle and repair of damaged DNA (Zhao et al, 2012). 
Taken together, this data suggests that fibroblasts from patients that have CLP in combination 
may proliferate significantly faster in vivo relative to their isolated counterparts, this may be a 
contributory factor in CLP as increased fibroblast proliferation would lead to increased cell 
packing within developing tissues coupled with the associated increase in ECM deposition both 
of which are factors that may lead to clefting (Sasaki et al, 2004; Moxham, 2003).  
BLCLP is more severe than unilateral CLP (UCLP), which has either left or right laterality, as 
clefts manifest on both sides of the lip often resulting in patients with a greater likelihood of 
developmental issues (Annigeri et al, 2012). The prevalence of BLCLP is significantly lower 
than that of UCLP, a study which assessed 583 cleft patients undergoing surgical repair found 
BLCLP was the most uncommon cleft type with a 3.8% prevalence rate whereas UCLP was far 
more common with a 42% prevalence rate (Jagomagi et al, 2010). Although it is possible that 
BLCLP is just a comparatively rare form of UCLP with the same causation it is also possible 
that BLCLP is a distinct cleft phenotype with distinct aetiological origins. However, despite 
this being speculated upon in the literature, there is currently little published evidence to support 
this suggestion although some have identified potentially distinct genetic origins for BLCLP 
(Ibitoye et al, 2015; Liu et al, 2005) and have shown variable gene expression between BLCLP 
and other cleft types (Francois et al, 2017). Here BLCLP fibroblasts presented statistically 
decreased expression profiles of the proliferative genes MCM2, MKI67 and PCNA compared 
with both RUCLP and LUCLP, suggesting the BLCLP cleft phenotype may be distinct and that 
the condition may be contributed to by decreased cell growth leading to malposition of the 
facial growth centres (Chai and Maxson, 2006; Jiang et al, 2008). 
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3.8.4 Cleft fibroblast production of extracellular matrix 
The extracellular matrix (ECM) is a complex meshwork of molecules that are secreted by 
mesenchymal cells, though fibroblasts are usually the principal secretors of ECM. During 
craniofacial development, the palatal mesenchyme expands due to the fundamental processes 
of proliferation and matrix deposition. It is currently thought proliferation and accumulation of 
ECM contribute equally to the increase in volume of craniofacial tissues prior to shelf adhesion 
(Ferguson 1998; Nik et al, 2016). Due to this, the accurate manufacture and erection of the 
facial processes, which lead to development of the lip and palate, are reliant on precise ECM 
production. Significant perturbations may lead shelf malposition and development of OFC as 
cleft formation is fundamentally a result of impediments to the processes of palatal shelf 
elevation, attachment to opposing shelves or failure of shelf fusion (Meng et al, 2009); it is the 
underlying cause of these pathological processes that are currently being explored.  
3.8.4.1 Collagen production  
Collagens are major constituents of the ECM, during craniofacial development many different 
types of collagens are expressed throughout the palatal mesenchyme. During shelf elevation the 
fibrillary collagen types I, III, and V have been shown to be upregulated throughout the 
developing palate (Kurisu et al, 1987; Morris-Wiman and Brinkley, 1992) and are critical in 
providing mechanical integrity throughout the developing shelves whilst influencing cell 
attachment and migration (Bode, 2000). Further, collagens which are distributed across the 
entirety of the palatal mesenchyme are thought to contribute to the force that results in both 
shelf elevation (Bodo et al, 1999) and reorientation (Ben-Khaial and Shah,1994) potentially by 
increasing tissue rigidity and contributing to the critical volume required before morphogenesis 
can occur (Ben-Khaial and Shah,1994); however, despite its elevated presence during these 
critical phases the precise role of collagen in craniofacial development is not fully understood. 
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The present study found that cleft fibroblast collagen production varied between 167.98µg and 
218.82µg. This variability seemed largely due to the anatomical origin of the fibroblasts as 
when grouped CLP(P) and CP patients, both of which were palatal fibroblasts, had significantly 
lower total collagen production when compared with both CLP(L) and CL which were lip 
derived fibroblasts. The behaviour of fibroblasts isolated from different regions can differ 
significantly (Chiquet et al, 2015). For example, when comparing oral fibroblasts, isolated from 
tonsil tissue, and dermal fibroblasts, isolated from foreskin, it was found that oral fibroblasts 
displayed marked differences in proliferation (Lee and Eun, 1999). In addition, fibroblasts 
isolated from different regions of the oral cavity can also differ in behaviour, it was found that 
gingival fibroblasts secreted significantly lower total ECM when compared with periodontal 
ligament fibroblasts (Hou et al, 1995); this suggests differences observed between cleft 
phenotypes may be due to anatomical origin. However, it is also possible decreased collagen 
production may be a contributing factor in clefts of the palate as both CLP(P) and CP derived 
fibroblasts had decreased production potentially leading to malposition of the palatal shelves 
during fusion, though there is not currently any other published evidence to support this. 
COL1A1 expression was also found to be significantly lowered in fibroblasts from CLP(P) and 
CP when compared with CL whereas COL3A1 expression was significantly higher in CLP(P) 
fibroblasts compared with CL. This is significant as during craniofacial embryogenesis the 
palatal mesenchyme has been shown to decrease production collagen type III and increase 
production of collagen type I (Morris-Wiman and Brinkley, 1993). Here the opposite pattern of 
expression was demonstrated by CLP(P) and CP. The ratio of collagen I and III within tissues 
can significantly impact tissue integrity, when compared with normal skin, hypertrophic scars 
comprise of significantly greater amounts of collagen III (Oliveira et al, 2009) leading to 
decreases in mechanical properties, including extensibility and toughness (Corr et al, 2009). 
Providing CLP(P) and CP elevated expression of COL3A1 translates to increased collagen III 
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within the palatal mesenchyme, palatal shelf tissues may exhibit reduced mechanical strength 
which could potentially interrupt the process of shelf elevation and reorientation which are 
processes that mediated by force distribution through collagen networks (Bodo et al, 1999; Ben-
Khaial and Shah,1994), thereby contributing to clefts of the palate. 
3.8.4.2 Glycosaminoglycan production 
Glycosaminoglycans (GAG’s) are major components of the ECM and, due to the presence of 
sulphate and uronic acid groups along the GAG chains, that are negatively charged. This makes 
GAGs hydrophilic and as a result interact with water molecules contributing to tissue hydration 
(Singh et al, 1994). During craniofacial development many have proposed a contributor to shelf 
elevation is the swelling of the palatal shelves, due the accumulation of water by GAGs within 
the mesenchyme, producing an intrinsic hydrostatic force that increases tissue volume leading 
to elevation (Ferguson, 1978; Brinkley and Moris-Wiman, 1987; Singh et al, 1997).  Quantities 
of GAG are elevated during shelf elevation and prior shelf fusion, when the orientation of 
palatal shelves is altered, followed by decreased total GAG after successful fusion (Singh et al, 
1994; Moxham, 2003). As hydration and subsequent GAG swelling is a major driving force 
during this process (Brinkley and Moris-Wiman, 1987), appropriate production of GAG’s is 
likely critical to typical craniofacial development. Cleft fibroblast production of GAGs varied 
considerably across the sample cohort. Despite this, there were samples with high and low 
production across all cleft types. However, CLP(L) fibroblasts produced significantly reduced 
GAG compared with CLP(P), it can be stipulated that differing anatomical origins may account 
for this disparity and not the tissue type as both CLP(P) and CLP(L) are derived from patients 
with both cleft lip and palate. In the UK, patients with CLP usually undergo lip repair at around 
3 months of age coupled with a secondary cleft palate repair in the following months (Sitzman 
et al, 2017). Thus the patients age at sample isolation may account for the differences in GAG 
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production observed between CLP(P) and CLP(L). Others have shown that fibroblasts isolated 
from the cleft lip of neonates, up to 16 days of age, and children, aged between 3 months and 6 
years old, displayed differential gene expression profiles, further both populations differed 
significantly from their adult counterparts (Zivicova et al, 2017); suggesting that the differences 
observed in GAG production in the present study may potentially be due to patient age.  
It is known that GAG’s, therefore their expression, is critical to craniofacial development as it 
has been shown that 5-fluoro-2-deoxyuridine (FUDR), an oncology drug, induces cleft palate 
by decreasing GAG production in developing embryos by 30% when compared with normal 
developing palates (Singh et al, 1997). Notably, it is clefts of the palate, not the lip, that FUDR 
induces (Ferguson, 1978), therefore it can be stipulated that GAG synthesis is more critical in 
the prevention of cleft palate as opposed to cleft lip. Due to this, it would be expected that there 
would be downregulation of GAG associated genes in CP patients when compared with those 
with CL. However, it has been shown here that CSPG4 and DSE are both upregulated in CP 
derived fibroblasts when compared with CL, it is therefore unlikely that there expression is 
associated with the cleft phenotype that was manifested. It is possible that expression of the 
unsulphated GAG Hyaluronic acid, which Alcian blue did not stain at the pH used here, could 
be downregulated in patients with CP due to its association with palate morphogenesis 
(Galloway et al, 2013), however this analysis was not conducted. RUCLP fibroblasts produced 
greater total sulphated GAGs compared to LUCLP and BLCLP; however, RUCLP fibroblasts 
downregulated CSPG4, HSPG2 and DSE thereby suggesting expression may not correlate with 
GAG production. As sulphated GAG’s are key to craniofacial development due to hydration of 
connective tissues, it is possible that the decreased expression may favour RUCLP 
manifestation; however, there is currently no other evidence to support this suggestion.  
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3.8.4.3 Fibronectin expression  
Directed CNCC migration is critical to normal development of the craniofacial region as it 
regulates the location of cell dense regions that that will subsequently differentiate and 
proliferate to form the facial growth centres. Fibronectin interacts with cellular transmembrane 
bound integrins and other ECM components including collagens and glycosaminoglycans. 
Fibronectin is abundant across the CNCC migratory path and is thought to contribute to their 
migratory directionality (Sternberg and Kimber, 1986). Saturation of CNCC-fibronectin 
binding domains, with complimentary peptides, leads to stunted migration (Boucaut et al, 1984) 
whilst presence of fibronectin supports CNCC attachment, spreading and migration (Perris et 
al, 1996). As CNCCs are the major pluripotent cell type within the craniofacial region it can be 
inferred that appropriate fibronectin expression is a prerequisite to normal craniofacial 
development (Snider and Mishina, 2014). Here CLP(L) and CLP(P) fibroblasts significantly 
upregulated FN1 when compared with both CL and CP in isolation. It has been shown in CP 
induced murine models that clefts were caused by perturbed fibronectin arrangements resulting 
in failure of palatal shelf elevation and midline fusion (Tang et al, 2015; Tang et al, 2016). 
Additionally, decreasing the efficacy of fibronectin through use of anti-fibronectin to adhere to 
binding domains also resulted in the formation of clefts (Sakai et al, 2003). This demonstrates 
that the presence of fibronectin is fundamental to normal craniofacial development; therefore, 
it is possible the downregulation observed in CP and CL fibroblasts, could be a contributing 
factor to the development of clefts in those patients. Alternatively, it is possible that the high 
expression of FN1 observed in both CLP(L) and CLP(P) could result elevated production of 
fibronectin thereby disrupting the regular fibronectin arrangement and contributing to the 
development of CLP in conjunction. However, larger samples sizes are required to confirm 
whether the expression of FN1 is related to the manifestation of specific cleft phenotypes.  
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3.8.5 Transforming growth factor beta expression  
Genes related to the transforming growth beta factor (TGFβ) superfamily have been repeatedly 
linked with cleft development (Funato and Nakamura, 2017; Kohli and Kohli, 2012). Due to 
this, the expression multiple TGF gene transcripts were assessed across the cleft sample cohort 
to determine if differences correlated with cleft type. TGFβ ligands are cytokines that can 
regulate: cell recruitment, proliferation, ECM deposition, differentiation and apoptosis (Penn et 
al, 2012), all of which are key to normal craniofacial development (Wu and Hill, 2009). During 
palatogenesis TGFβ ligands are expressed within the developing palatine shelves and 
surrounding craniofacial structures. TGFB1 and TGFB3 are significantly expressed in medial 
edge epithelium (MEE) of the developing palate prior to fusion whereas TGFB2 is expressed 
significantly in the underlying palatal mesenchyme; this expression increases further 
immediately following contact of the opposing shelves (Fitzpatrick et al, 1990). Following 
fusion, epithelial expression of TGFB1 and TGFB3 is decreased followed by upregulation 
within the underlying mesenchyme, this is associated with formation of the secondary palate 
and palatal bones (Fitzpatrick et al, 1990). The role of TGFβ in the formation of the upper lip 
is limited as there is yet to be study outlining the specific involvement of each isoform prior to 
fusion of the frontonasal and maxillary prominences. However, TGF signalling is thought to be 
involved as TGFBR1 murine knockout (KO) models have been observed with both unilateral 
and bilateral clefts of the lip (Li et al, 2008). Here it was shown that the majority of samples 
demonstrated significant upregulation of TGFB1, TGFB2 and TGFB3 relative to the non-cleft 
control with TGFB2 displaying the largest average fold change. Studies have shown that 
dysregulation of TGFβ expression leads to clefts in murine models. TGFB2 knockout mice 
develop clefts of the secondary palate, with extension from the hard palate into the soft palate, 
in 23% of pups (Sanford et al, 1997). Further, clefts were caused due to disruption of shelf 
growth and elevation resulting in malposition thus incorrect orientation for opposing shelf 
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fusion (Sanford et al, 1997), this suggests that patient dysregulation of TGFB2 may potentially 
disrupt palatal mesenchyme growth thereby contributing to cleft development. TGFB3 
knockout mouse models also presented the CP phenotype (Proetzel et al, 1995), however unlike 
with TGFB2 knockouts palatal shelf elevation and orientation was not disrupted. Rather, clefts 
were caused due a failure of fusion of opposing MEE surfaces (Proetzel et al, 1997), later it was 
shown that TGFB3 null mice display significantly reduced MEE filopodia distribution that 
potentially interfered with shelf adhesion (Taya et al, 1999). As TGFβ isoforms are structurally 
similar but functionally diverse, the expression of each is likely to contribute to differing modes 
of cleft development and potentially cleft phenotype. Here it was shown there was no direct 
correlation between TGFB1 and TGFB2 expression and different cleft types despite significant 
sample variation. However, as there was significant downregulation of TGFB3 in CP 
fibroblasts, when compared with CLP(L), downregulation of TGFB3 may contribute to CP 
manifestation, potentially as a result of a failed opposing MEE surface fusion (Proetzel et al, 
1997) although analysis with larger sample sized are required to confirm this.  
The majority of cleft samples here displayed upregulation of TGFBR1 and TGFBR2 relative to 
the non-cleft control although there were outliers with significantly reduced expression. 
TGFBR1 epithelium knockout models resulted in clefts of the soft palate with 100% penetrance 
due to failure of fusion (Dudas et al, 2006). Further, in CNCC specific TGFBR1 knockouts 
clefts were more significant as they encompassed both clefts of the lip and the hard and soft 
palate (Dudas et al, 2006).  In addition, others have demonstrated that deletion of TGFBR1 
within all of the developing facial prominences routinely led to clefts of the lip (Li et al, 2008). 
Similarly, CNCC specific TGFBR2 knockouts resulted in incomplete clefts of the secondary 
palate with 100% penetrance (Yoshihiro et al, 2003). These clefts were not a result of fusional 
deficiencies as when palatal shelves were artificially placed in proximity during in vitro organ 
culture they were able to fuse normally. Further, CNCC migration was not disrupted and it was 
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concluded that clefts formed due to perturbed proliferation resulting disruption to shelf growth 
leading to malposition (Yoshihiro et al, 2003). These knockout studies suggest appropriate 
expression and regulation of TGFβ receptors are critical to normal shelf growth, position and 
subsequent fusion, when their expression is disrupted there is the potential to develop clefts. 
Due to this, the variation in TGFBR1 and TGFBR2 expression observed across the sample 
cohort may have contributed to clefts in some patients. Further, as both receptors were 
downregulated in RUCLP when compared to LUCLP it is possible expression may be related 
to cleft laterality although there is currently no other supporting evidence. Although it is 
possible that disrupted TGFβ signalling contributed to cleft formation in some patients, as CLP 
is a pathology that can be caused by several different factors, the expression of single TGFβ 
genes are unlikely to be a good metric to assess why specific cleft phenotypes manifest. 
3.8.5.2 Transforming growth factor alpha expression 
Although TGFA polymorphisms have continually been associated with cleft development 
(Vieira, 2006), the assessment of basal expression between multiple patients to establish 
correlations with cleft phenotype manifestation was yet to be conducted. It was found here that 
the majority of cleft samples were comparable to the non-cleft control and although a subset 
presented significant downregulation, there were no significant differences between cleft 
phenotypes. Others have shown that there is an association between differing alleles of TGFA 
and the development of CP (Shiang et al, 1993), whilst patient polymorphisms have not been 
assessed here it was found that there were no differences in the basal expression between CP 
fibroblasts and other cleft types. During craniofacial development TGFA is expressed within 
the rapidly proliferating regions of the palatal shelves both prior to fusion and post fusion 
(Lamaroon and Diewert, 1996) thereby indicating it contributes to normal palatal development. 
However, TGFA null mice do not displays clefts of the lip or palate (Mann et al, 1993) thus 
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suggesting despite contributing to normal facial development it is not critical. Further, many 
studies have conflicting reports regarding the involvement of TGFA in cleft development 
(Vieira et al, 2006), although meta-analysis suggested significantly increased risk of CLP and 
CP development in individual with specific polymorphisms (Lu et al, 2014).Here RUCLP 
fibroblasts presented significant downregulation compared with LUCLP and BLCLP, this may 
have potentially contributed cleft laterality although currently no other studies to support this 
and it is likely that TGFA associated cleft development is a result of its interaction with related 
genes (Letra et al, 2012).  
3.9 Conclusion  
 Despite significant differences in DT, ECM production, TGF beta and TGF alpha expression 
between individual patients in the sample cohort, many of the differences could not be reliably 
attributed to cleft phenotype; rather, individual variation coupled with anatomical origin, or the 
age of the patient at the time of isolation, may have been contributory factors in the differences 
observed. However, palatal cleft fibroblasts derived from CLP(P) and CP patients displayed 
significantly reduced collagen production and COL1A1 expression coupled with increased 
COL3A1 expression when compared to CL fibroblasts. This suggests the normal collagen 
distribution and ratio of collagen 1:3 may be disrupted potentially contributing to clefts of the 
palate. Further, RUCLP fibroblasts were shown to display reduced expression of several genetic 
markers which may favour the manifestation of right laterality. However, repetition with larger 
patient cohorts are required to support the preliminary findings outlined here. 
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CHAPTER FOUR:  
ANALYSIS OF CLEFT FIBROBLAST MIGRATION
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4.1 Analysis of fibroblast wound closure rates between cleft patients 
As cell motility permits the re-localisation of cells to sites where they are needed, appropriate 
migration is fundamental to broad range of physiological processes including embryological 
development, wound healing and homeostasis. Perturbations to cell motility can have 
significant effects, particularly during the wound healing process, where the initial rate of 
migration is related to the degree of myofibroblast differentiation and  potentially contributes 
to fibrosis (Hinz and Gabbiani, 2003; Tomasek et al, 2002). Due to this, cleft fibroblast motility 
was assessed to determine if specific populations display motility indicative of pathological 
wound healing which could later be correlated with the cleft type from which they were derived.  
Cleft fibroblast closure of the defined cell free area produced by Ibidi inserts, hereafter referred 
to as a wound closure, was assessed using fibroblast isolated from each patient (Figure 45A-
H). It was identified that there was significant variance in wound closure between cultures from 
different patients (Figure 46). Following the initial removal of the insert at zero hours there was 
very little variation in uncolonised area between cultures from different patients within the 
cohort. However, after 12 hours, cells had started to migrate into the cell free region in all 
patient samples. The largest variance in uncolonised area between patient samples was seen 
after 24 hours (variance = 0.30mm2) whereas after 48 hours several cultures occupied the 
previously cell free region completely whilst others had not but a lower total variance was 
identified across the patient cohort (variance = 0.13mm2). After 48 hours a number of the 
wounds had been closed, due to this the 24-hour time-point was selected in order to calculate 
the remaining wound area (RWA%). The RWA% was calculated by division of the total 
uncolonised area at 24h by the initial uncolonised area at 0h and from this cell migration was 
inferred (Figure 48). More slowly migrating cells exhibited a higher RWA% whilst faster cells 
had a lower RWA%, hereafter cell migration will also be used to refer to RWA%.   
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Figure 45: Imaging of cleft fibroblast wound closure of a 500µm cell free 
region at 0 hours, 12 hours, 24 hours and 48 hours. Immediately following 
removal of the Ibidi insert there was a comparable well-defined cell free region in 
all cultures (A and E). At 12h all cultures exhibited some degree of cell migration 
into the wound (B and F). After 24 hours there was significant migration into the 
wound in all cultures. However, there were clear differences in the total area of 
the wound covered in cells with some cultures exhibiting nearly complete wound 
closure (C), which were labelled fast migrating fibroblasts, whereas others 
displayed significantly less (G) and were labelled slow migrating fibroblasts. After 
48 hours a number of the wounds had been completely closed (D) whereas others 
still had a large amount of the wound still uncolonised (H). Scale bars = 200μm. 
(A) 
(B) 
(C) 
(D) 
(E) 
(F) 
(G) 
(H) 
0
 H
o
u
rs
 
1
2
 H
o
u
rs
 
2
4
 H
o
u
rs
 
4
8
 H
o
u
rs
 
Fast migrating fibroblasts Slow migrating fibroblasts 
 147 
 
Figure 46: Quantification of cleft fibroblast wound closure for all patients. The total cell free area following removal of the Ibidi insert (0 Hours) was 
similar for all patients though there were slight non-significant differences. At 0h the maximum area was 3.32mm2 and the minimum area was 2.89mm2 
thereby demonstrating some slight initial variability in wound area (variance = 0.01mm2) thus necessitating calculations of RWA% which would account for 
initial wound variability. Uncolonised area decreased for all patients after 12 hours as fibroblast had begun to migrate into the previously cell free wound, 
the maximum area was 3.06mm2 and the minimum was 2.05mm2, this demonstrated a lack of uniformity in cell migration between fibroblast populations as 
even at earliest time point assessed here there was significant patient variability. The largest differences in area between patients was observed following 24h 
after removal of the insert, the maximum area observed was 2.61mm2 and the minimum was 0.82mm2 thereby demonstrating large disparities in the wound 
closure between cleft patient derived fibroblasts; neonatal human dermal foreskin fibroblast (NHDFF) control cells displayed an average remaining area of 
1.44mm2 at 24h thereby displaying an intermediate rate of wound closure. As the variance between all samples was largest at 24 hours post insert removal 
(variance = 0.301mm2) this time point to make comparisons between patient-to-patient differences in wound closure. After 48 hours some cleft fibroblasts 
had completely covered the wound whereas others still had a significant area uncolonised. The maximum area was 1.51mm2, the NHDFF control had 
0.72mm2 remaining whilst others completely closed (0.00mm2), suggesting some fibroblasts require significantly longer to complete wound closure thus 
demonstrating their clear differences in the ability of cleft fibroblasts to migrate into a wound between different cleft patients. This data demonstrates that 
despite initial similarity in the wound area at 0h cleft fibroblasts derived from different patients cover the wound at significantly different rates (n=9). 
Cleft fibroblast wound closure following removal of Ibidi inserts 
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4.1.2 Hierarchical cluster analysis based on the percentage remaining wound area after 
24 hours (RWA%) for all cleft patients  
In order to analyse the differences and similarities in inferred fibroblast migration rates across 
the patient cohort, all data for each time point was subject to hierarchical cluster analysis which 
grouped patients according to the similarity of the data sets depicting results as a dendrogram 
(Figure 47). The data pertaining to the percentage remaining wound area after 24 hours 
(RWA%) was clustered into two statistically distinct groups; group A which comprised 17 
patient samples and group B of 12 patient samples. Within group A sample RWA% ranged 
between 49.53%-83.34% whereas in group B RWA% ranged between 26.72%-48.88% thereby 
demonstrating considerable variation within clusters (Figure 48). When the RWA% for each 
patient’s fibroblasts within their respective cluster was averaged it was found that group A had 
an average RWA% of 68.34% whereas group B had an average RWA% of 37.48% thereby 
demonstrating that fibroblasts in group A migrated more slowly when compared with those in 
group B (p<0.001) (Figure 49). As the slow migrating fibroblasts in group A comprised of 17 
patient samples and the fast migrating fibroblasts in group B comprised of 12 patient samples, 
when averaging all of the experimental data for analysis and comparison of fast and slow cell 
populations, based on cluster membership, there was an n number of 51 for the slow group and 
an n number of 36 for the fast group as assays for each cleft sample were conducted in triplicate.   
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Figure 47: Dendrogram grouping patients based on the wound closure by cleft 
fibroblast at each time point. Hierarchical cluster analysis was employed to group 
patients based on the total area of wound closure of the initial 500µm wound at 0h, 
12h, 24h and 48h. The number of clusters was not pre-determined thus cluster 
membership was based on data alone. The clustering method employed was the 
average linkage method and data was measured using the squared Euclidean 
distance interval. The dendrogram revealed the presence of two statistically distinct 
groups, Group A, which comprised 17 samples and group B, which comprised 12 
samples and the age matched NHDFF control. This data suggests that cleft 
fibroblasts differ significantly based on wound closure and can be categorised as 
fast migrating fibroblasts, which is group B, and slow migrating fibroblasts, which 
is group A. For ease of comparison, the slow group was coloured yellow and the 
fast group was coloured red and this was used for all future comparisons.  
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Figure 48: Remaining wound area after 24 hours for all cleft fibroblast samples. Cell 
migration was expressed as a percentage of the wound area uncolonised at 24 hours when 
compared with total area at 0 hours, thus accounting for the slight variance in initial starting 
area. The fibroblast samples have been ordered from fastest migrating (smallest RWA%) 
to slowest migrating (largest RWA%).  The two groups determined by cluster analysis have 
been coloured based on cluster membership (red = fast; yellow = slow). The NHDFF 
control was clustered into the fast group however it was the slowest migrating sample 
within the fast group due to having the largest RWA% after 24 hours (n=9).  
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Figure 49: Average RWA% for all cleft fibroblast samples in fast and slow 
migrating groups. The average RWA% of the fast migrating group was 37.48% 
whereas the slow group had an average RWA% of 68.34%. This difference in average 
RWA% was shown to be significant (p<0.001) as determined by an independent 
samples t-test with a two tailed distribution (Fast group: n=36; slow group: n=51). 
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4.1.3 Analysis of RWA% and cluster membership between cleft types 
When comparing the RWA% from fibroblasts derived from patients with different cleft types 
it was found that fibroblast samples derived from patients with CL displayed significantly lower 
RWA% when compared with fibroblasts derived from CLP(L) (p<0.01), CLP(P) (p<0.01) and 
CP (p<0.01) patients (Figure 50A). In addition, all fibroblasts derived from CL patients were 
clustered within the fast migrating cluster (Figure 50B) thus demonstrating that all CL derived 
fibroblasts have low RWA% and share a degree of similarity. This data suggests that, in terms 
of inferred motility rates derived from RWA%, fibroblasts derived from the CL phenotype may 
be physiologically distinct from fibroblasts derived from other cleft phenotypes due to their 
elevated migration rates. In addition, cells from CLP(L) patients, which were shown to have 
significantly less average RWA% when compared with the anatomically similar CL, 
demonstrated significantly higher RWA% when compared with cells from CLP(P) (p<0.05) 
and CP patients (p<0.05). Despite this, cluster analysis placed 3 CLP(L) derived fibroblasts in 
the fast cluster and 6 in the slow cluster thus demonstrating variability in migratory speeds 
within this group. Cluster analysis also placed 4 CP derived fibroblasts in the slow cluster and 
1 in the fast cluster whereas fibroblasts derived from CLP(P) had 7 in the slow cluster but only 
2 in the fast cluster thus suggesting a greater degree of similarity in the RWA% between patients 
of these cleft types. This data suggests the differences in RWA% observed in fibroblast samples 
derived from CLP(L), CLP(P) and CP may be potentially due to individual biological variation 
of primary cells and not the cleft phenotype from which they were derived. Additionally, 
fibroblasts derived from patients with RUCLP demonstrated significantly lower RWA% when 
compared with BLCLP (P<0.05) but not LUCLP (Figure 50C-D). 
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Cleft phenotype  Cleft laterality 
Type Fast Slow  Type Fast Slow 
CLP (L) 3 6  LUCLP 2 4 
CLP (P) 2 7  RUCLP 1 6 
CL 6 0  BLCLP 2 3 
CP 1 4   
Figure 50: Average RWA% between cleft types. (A) Fibroblasts isolated from CLP(P) and 
CP cleft patient tissues demonstrated significantly slower overall migration when compared 
with both CLP(L) and CL derived fibroblasts; CL fibroblasts migrated at significantly faster 
rates than all other cleft types. (B) Fibroblasts from each cleft type were present in both fast 
and slow migrating groups except CL fibroblasts which were all grouped into the fast 
migrating cluster. (C) Migration rates between LUCLP and RUCLP patients were similar 
whilst fibroblasts derived from BLCLP patients were significantly faster than RUCLP but not 
LUCLP. (D) Fibroblasts were present in both slow and fast clusters regardless of cleft 
laterality; however, most RUCLP derived fibroblasts were clustered into the slow migrating 
group. Significant differences were determined by means of student’s t-test where: # = p<0.05 
relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL 
(n=18); Ø = p<0.05 relative to CP (n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 
relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
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4.2 Assessment of the potential effect of cell proliferation on RWA% 
 
To assess whether cell proliferation contributed to the differences in RWA% observed between 
cells from the different cleft patients, the RWA% was compared with the doubling time (DT) 
for each patient (which were previously established through growth curve analysis). It was 
found that there was significant overlap in the DT between patients in the fast and slow group; 
the DT in the fast group ranged between 26.32 hours and 30.68 hours whereas the slow group 
DT ranged between 26.11 and 32.41 (Figure 51A-B). It was shown that there were no 
significant differences in the average DT between the fast and slow groups. Further, Pearson’s 
correlation analysis revealed that there were no significant correlations between RWA% and 
DT (correlation coefficient = 0.189) suggesting that DT does not influence RWA%. In addition, 
an Ibidi wound healing assay was repeated with both Mitomycin C, an agent known to inhibit 
cell proliferation, treated and untreated fibroblasts and the RWA% was compared (data not 
presented here). No significant difference between the treated and untreated groups was 
identified with a student’s t-test with two-tailed distribution (p = 0.901).  
 
 
  
Figure 51: Scatterplots of RWA% vs doubling time. (A) The RWA% and 
population doubling time for each patient. (B) When patients were clustered based on 
migratory speed there was significant overlap in the DT between fast and slow groups.  
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4.3 Analysis of cytoskeletal related components in fast and slow groups 
As actin is a major component of the cell cytoskeleton and is fundamental to the processes 
involved in cell motility, the intracellular cytoskeletal F-actin levels were quantified in 
fibroblasts from three patients in each of the fast and slow migrating groups. The F-actin levels 
were normalised to cell number and whilst total F-actin was variable, there was significantly 
more total F-actin found on average in the fast migrating fibroblasts when compared with the 
slow migrating fibroblasts (p<0.001) as determined by an individual samples t-test with a two 
tailed distribution (Figure 52A-H). When comparing cleft types, it was shown that there were 
no significant differences in the total F-actin levels within tissue samples when comparing CP 
and CL (Figure 53A-G). This suggests that although increased actin may be associated with 
elevated fibroblast migration, it is unlikely that differences in actin are associated with cleft 
phenotype and the significantly increased RWA% observed in CL derived fibroblasts relative 
to other cleft types.    
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Figure 52: Quantification of total cytoskeletal F-actin levels in both fast and slow cleft 
fibroblast groups using phalloidin staining. Three patients from both the fast and slow 
groups were selected for analysis. Representative images from the fast group (A-C) and the 
slow group (D-F) depicted the locations of individual cell nuclei (DAPI staining cell nuclei 
blue) the distribution of F-actin within individual cellular cytoskeletons (FITC staining F-
actin green). (G) Each patient’s actin levels were quantified in terms of integrated density and 
presented as a ratio of total F-actin to cell number. (F) Averaging data from each group 
revealed there was a significant difference (p<0.001) in F-actin levels between fast and slow 
groups as determined by an individual samples t-test with a two tailed distribution (n=9).  
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Figure 53: Quantification of total cytoskeletal F-actin levels in both cleft lip and cleft 
palate tissue sections. (A-C) Mucosal tissue sections from cleft lip and mucosal tissue sections 
from patients with cleft palates (D-F) were stained with DAPI (blue) and phalloidin bound 
fluorescein conjugates (green) to reveal the distribution of F-actin within each section. (G) 
Quantification of F-actin revealed no significant difference in the amount of F-actin present 
when comparing cleft lip and cleft palate tissue section (n=6).   
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4.3.1 Assessment of ACTA1 and TUBA1 expression 
As there were significantly greater total amounts of F-actin per cell within fast migrating 
fibroblasts relative to slow migrating fibroblasts, actin expression (ACTA1) was assessed by 
means of real time PCR in cleft fibroblasts for all cleft patients. There was considerable 
variability in the expression levels of ACTA1 in fibroblasts from the 29 patients as the highest 
fold change, relative to the age-matched control, was 8.61 whereas the lowest was 1.42. When 
the patients were grouped according to migratory speed no significant differences were 
identified between the fast group and the slow group suggesting that ACTA1 expression was 
not related to migratory speed (Figure 54A-B). TUBA1 expression was also assessed as tubulin 
is also major component of the cytoskeleton and often works in conjunction with actin filaments 
to aid in motility. Tubulin expression was variable with the fold changes, relative to control, 
ranging between 5.09 and the lowest being 0.75 thereby suggesting significantly lower 
expression in some cleft patients. When TUBA1 expression levels were grouped based on 
fibroblast migratory speeds the fast migrating fibroblasts generated significantly higher overall 
expression when compared with the slow migrating fibroblasts (p<0.01) as determined by an 
independent samples t-test with a two-tailed distribution, this suggests that TUBA1 expression 
is higher in patients in fast migrating fibroblasts (Figure 55A-B). Spearman’s rho analysis 
showed no correlation between ACTA1 and TUBA1 expression (correlation coefficient = 0.041) 
nor differences in expression of ACTA1 or TUBA1 between cleft phenotypes. TUBA1 
expression did differ based on cleft laterality as RUCLP patients exhibited significantly lower 
expression when compared with both LUCLP and BLCLP (p<0.01) (Figure 56A-D). 
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Figure 54: Expression levels of ACTA1. (A) Expression levels of ACTA1 were variable in 
cells from the whole patient cohort yet the expression levels were all higher than found in 
the HGF control. The maximum fold change was 8.61 and the minimum was 1.42 indicating 
considerable patient-to-patient variability. (B) Average expression levels between fast and 
slow migratory groups revealed that there was no significant difference in ACTA1 
expression as determined by an independent samples t-test with a two tailed distribution. 
(Fast group: n=36; slow group: n=51). 
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Figure 55: Expression levels of TUBA1. (A) Expression levels of TUBA1 in fibroblasts 
from the entire patient cohort were variable. Most expression levels were greater than 
found in the HGF control though there were a number of outliers with lower expression 
levels. The maximum fold change was 5.09 and the minimum was 0.75 indicating 
considerable variability between cleft patients. (B) Average expression levels of TUBA1 
revealed that there is a significant difference between fast and slow groups (p<0.01) as 
determined by an independent samples t-test with a two-tailed distribution. (Fast group: 
n=36; slow group: n=51). 
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Figure 56: ACTA1 and TUBA1 expression between cleft types. (A)   ACTA1 expression was 
comparable between both cleft types (B) and laterality. (C) There were no significant 
differences in TUBA1 expression between cleft types (D) TUBA1 expression was significantly 
lower in fibroblasts from patients with RUCLP when compared with both LUCLP and BLCLP. 
Significant differences were determined by means of student’s t-test where: † = p<0.05 relative 
to LUCLP (n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP 
(n=15). 
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4.3.2 Expression of RAC1, RHOA and CDC42 
Regulation of cytoskeletal dynamics, including reorganization of actin and tubulin, is largely 
controlled by the Rho family of GTPases which interact with downstream effectors to stimulate 
conformational change; RAC1, RHOA and CDC42 are the primary influencers in terms of 
migration. RAC1 expression in fibroblasts from each cleft patient revealed large differences in 
expression levels between samples. Some fibroblasts demonstrated fold changes greater than 
nine relative to the HGF control, whilst others showed expression levels similar to the control 
resulting in large standard deviations. There was no significant correlation between RWA% 
and RAC1 expression (correlation coefficient = -0.328). It was shown that the RAC1 expression 
in fibroblasts from patients with both CL and CP were significantly higher than the cells from 
patients that demonstrated the CLP(L) phenotype despite CL and CLP(L) both being lip derived 
fibroblasts (Figure 57A-C). The expression of RHOA was just as variable and there was no 
significant correlation identified between RHOA expression and RWA% (correlation 
coefficient = 0.054). The variability in terms of RHOA expression was not identified to be due 
to the cleft phenotype (Figure 58A-C). The expression of CDC42 was less variable when 
compared with RAC1 and RHOA and there was no correlation between CDC42 expression and 
RWA% (correlation coefficient = -0.196). With data averaged, CL and CP cleft phenotypes 
demonstrated significantly higher CDC42 expression when compared with CLP(P) despite CP 
and CLP(P) both being palatal derived fibroblasts (Figure 59A-C). When comparing cleft 
laterality, fibroblasts from patients with RUCLP consistently demonstrated significantly 
lowered expression of RAC1, RHOA and CDC42 when compared with both LUCLP and 
BLCLP and interestingly, RWA% was also significantly higher in cultures from patients with 
RUCLP when compared with those with BLCLP suggesting a possible negative correlation. 
When patients were grouped based on migratory speed, it was found that, despite average 
expression of RAC1 being higher in the slow group (p=0.06), there were no significant 
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differences in RAC1, RHOA and CDC42 expression between fast and slow migrating fibroblasts 
(Figure 60A-C).  
 
 
  
Figure 57: Expression of RAC1 between cleft patients. (A) expression of RAC1 was highly 
variable between cleft patients with a maximum fold change of 9.41 and a minimum of 1.19 
indicating considerable differences between patients. (B) CL and CP patients shared similar 
expression levels RAC1 both of which were significantly higher than CLP (L).  (C) RAC1 
expression was significantly lower in patients with RUCLP when compared with both LUCLP 
and BLCLP. Significant differences were determined by means of student’s t-test where: # = 
p<0.05 relative to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to 
CL (n=18); Ø = p<0.05 relative to CP (n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 
relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
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Figure 58: Expression of RHOA between cleft patients. (A) overall RHOA expression 
differed considerably in fibroblasts from different cleft patients. The highest fold change was 
8.16 and the lowest was 0.77 indicating large patient variation. (B) There were no significant 
differences in RHOA expression between cleft phenotypes. (C) RHOA expression was 
significantly lower in patients with RUCLP relative to both LUCLP and BLCLP. Significant 
differences were determined by means of student’s t-test where: † = p<0.05 relative to LUCLP 
(n=18); ‡ = p<0.05 relative to RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
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Figure 59: Expression of CDC42 between cleft patients. (A) There were large variations 
observed in CDC42 expression between samples established from different cleft patients 
outlined by the differences between the highest fold change was of 7.96 and the lowest of 1.29. 
(B) Patients with CL and CP shared similar levels if expression both of which were shown to 
be significantly higher than that of CLP (P) but not CLP (L). (C) Patients with RUCLP had 
significantly lower overall expression when compared with both LUCLP and BLCLP. 
Significant differences were determined by means of student’s t-test where: # = p<0.05 relative 
to CLP(L) (n=27); $ = p<0.05 relative to CLP(P) (n=27); ¥ =p<0.05 relative to CL (n=18); Ø 
= p<0.05 relative to CP (n=15); † = p<0.05 relative to LUCLP (n=18); ‡ = p<0.05 relative to 
RUCLP (n=21) and + = p<0.05 relative to BLCLP (n=15). 
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Figure 60: Average expression of RAC1, RHOA and CDC42 between patient fibroblast 
samples clustered into fast and slow migrating groups. (A) Although slow migrating cleft 
fibroblasts expressed higher RAC1 on average this was shown to be not statistically significant 
(p = 0.06). (B) RHOA expression was similar between fast and slow clusters, as was expression 
of CDC42 (C). (Fast group: n=36; slow group: n=51). 
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4.4 Analysis of ECM production and expression between fast and slow groups 
ECM production and expression was compared between fast and slow migrating fibroblasts. 
Average total collagen protein production, determined by staining mitomycin C treated 
fibroblast samples with Sirius red after seven days in culture, was greater in fast migrating 
fibroblasts (mean = 174.53μg) when compared with slow migrating fibroblasts (mean = 
162.60μg) and this difference was shown to be significant by means of an independent samples 
t-test with two-tailed distribution (p<0.001). Further, expression of COL3A1 was significantly 
lower in the fast group when compared with the slow group thereby suggesting that whilst more 
rapidly migrating fibroblasts secreted more total collagen overall than the slower migrating 
fibroblasts, the expression level of COL3A1 was lower than the slow group.  No significant 
differences were identified between fast and slow migrating fibroblasts for expression of any 
other collagen types assessed here (Figure 61A-C). Pearson’s correlation analysis between 
RWA% and collagen production reinforced earlier findings as there was a significant negative 
correlation between RWA% and collagen production (correlation coefficient = -0.454; p<0.01) 
which suggested that cultures with higher RWA%, which migrated at slower rates, also 
synthesised less collagen whereas cultures with lower RWA%, which had faster migrating 
fibroblasts, secreted greater amounts of collagen (Figure 62). Glycosaminoglycan production 
was shown to be similar between fast and slow migrating groups. However, expression of 
CSPG4 was significantly lower in the fast group relative to the slow group whereas both DSE 
and HSPG2 were similar between migratory groups (Figure 63A-D). Whilst expression of 
elastin was comparable between and slow migrating groups, expression of FN1 was 
significantly lower in fast migrating cleft relative to their slow migrating counterpart (Figure 
64A-B).  
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Figure 61: Comparison of collagen production and gene expression between fast and 
slow migratory groups. (A) Collagen production was generally higher in the fast migratory 
group when compared with the slow migratory group. This difference was deemed significant 
(p<0.001) by means of Welch’s t-test with a two tailed distribution. (B) COL1A1 expression 
was similar in both the fast group and slow group with no significant difference. (C) COL3A1 
expression was lower in the fast migratory group when compared with the slow migratory 
group, this difference was significant (p<0.01) as determined by an independent samples t-
test with a two tailed distribution. (Fast group: n=36; slow group: n=51). 
(A) (B) (C) 
** 
*** 
COL1A1: Fast vs Slow 
G
e
n
e
 e
x
p
r
e
ss
io
n
 (
r
a
ti
o
 t
o
 h
o
u
se
k
e
e
p
e
r
) 
COL3A1: Fast vs Slow 
G
e
n
e
 e
x
p
r
e
ss
io
n
 (
r
a
ti
o
 t
o
 h
o
u
se
k
e
e
p
e
r
) 
Collagen production 
C
o
ll
a
g
en
 p
r
o
d
u
c
ti
o
n
 (
μ
g
) 
Figure 62: RWA(%) vs collagen production. (A) RWA% and collagen production for all 
patients compared by means of a scatterplot. (B) RWA% and Collagen production when 
patient fibroblasts are clustered based on their migratory speed. Data was determined to be 
non-parametric by means of a shapiro-wilko normality test. Bivariate correlation using 
Spearman’s rho analysis revealed there was a significant negative correlation between 
RWA% and collagen production (correlation coefficient = -0.454; p<0.01). Suggesting 
patients with a higher RWA%, thus slower migrating cells, have lower total collagen 
production.  
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Figure 63: Comparison of sulphated glycosaminoglycan production and expression 
between fast and slow migratory groups. (A) Sulphated glycosaminoglycan production 
was similar for both fast and slow groups with no significant difference. (B) CSPG4 
expression was lower in the fast group when compared with the slow group, this difference 
was significant (p<0.01) as determined by the independent samples t-test with two tailed 
distribution. (C) DSE expression was comparable for both the fast and slow migrating groups 
with no significant difference. (D) HSPG2 expression was also statistically similar in both 
the fast and slow migrating. (Fast group: n=36; slow group: n=51). 
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Figure 64: Comparison of ELN and FN1 expression levels between fast and slow migrating 
groups. (A) ELN expression was similar in both fast and slow migrating groups no significant 
difference. (B) FN1 expression was lower in the fast migrating group when compared with the 
slow migrating group, this difference was significant as determined by an independent samples 
t-test with a two-tailed distribution (p<0.001). (Fast group: n=36; slow group: n=51). 
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4.5 Differences in cytokine release profiles between fast and slow groups 
 
The bicinchoninic acid assay (BCA assay) was employed in order to assess the total amount of 
protein within serum free cultures of cleft fibroblasts; fibroblasts from three patients in each of 
the fast and slow migrating groups were assessed so that any differences could be measured. It 
was found that overall the fast migrating fibroblasts secreted lower total amounts of protein 
when compared with the slow migrating fibroblasts, this difference was shown to be significant 
by means of Welch’s t-test with two-tailed distribution (p<0.001) (Figure 65A-B).  
  
Figure 65: Quantification of total protein secreted by fast and slow migrating 
fibroblasts. (A) In general, the fast migrating fibroblast secreted lower total protein when 
compared with slow migrating cells (n=12). (B) When averaged total secreted protein was 
shown to be significantly lower in the fast migrating group (p<0.001) when compared with 
the slow migrating group as determined by Welch’s t-test with two tailed distribution (n=36). 
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4.5.1 Analysis of the effect of secretome substitution on RWA% 
Due to the differences in total secreted protein observed within serum free medium, it was 
thought that fast and slow migrating cells may have secreted different types and quantities of 
proteins that could potentially have influenced their behaviour. Secretome substitution assays 
were conducted whereby fast migrating cells were cultured in the secretome of slow migrating 
fibroblasts for 24 hours prior to induction of wound healing assays whilst the reverse was also 
conducted as slow migrating cells were treated with fast migrating fibroblast secretome. It was 
found that when treated with the fast secretome, slow fibroblast RWA% significantly decreased 
from 77.56% to 42.63% (p<0.001) due to increased wound closure (Figure 66A-C). Conversely, 
fast migrating fibroblasts were shown to decrease in speed with the RWA% increasing from 
29.77% to 44.15% (p<0.001) (Figure 67A-C). This data suggested that the variation in the 
secretome between cleft fibroblasts had a significant effect on the cells ability to migrate into 
cell free wound area which could have potentially accounted for the significant differences 
observed in cultures established from the patient cohort. 
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Figure 66: RWA% in slow migrating cells supplemented with fast migrating 
fibroblast secretome (FS). Following supplementation with FS the RWA% after 24 
hours in slow migrating fibroblasts significantly decreased (p<0.001) demonstrating 
an increase in migratory speed (n=9). Scale bars = 100μm. 
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Figure 67: RWA% in fast migrating cells when supplemented with slow migrating 
fibroblast Secretome (SS). Following supplementation with SS the RWA% after 24 
hours in fast migrating fibroblast was significantly increased (p<0.001) demonstrating a 
decrease in migratory speed (n=9). Scale bars = 100μm. 
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4.5.2 Analysis of fibroblast secretome through use of cytokine arrays 
A cytokine array, which assess the relative abundance of 105 different cytokines, was used in 
order to compare the serum free secretome of fast and slow migrating fibroblasts. Densitometry 
revealed that there were a number of significant differences (Figure 68A-B). It was found that 
in the fast group there were a number of cytokines that were present in significantly higher 
amounts when compared with the slow group, these included: Insulin-like growth factor-
binding protein-2 (IGFB2) (p<0.001), Growth differentiation factor 15 (GDF15) (p<0.001), 
Dickkopf-related protein 1 (DKK1) (p<0.001). Further, Interleukin 6 (IL-6), Interleukin 8 (IL-
8), Complement factor D (CFD) and Endoglin (ENG) were absent in the slow group were only 
secreted by the fast migrating fibroblasts (Figure 69A-G). Conversely, there were a number of 
cytokines that were produced in significantly higher amounts in the slow migrating group, these 
included: Monocyte chemoattractant protein 1 (MCP-1) (p<0.001), Chitinase-3-like protein 1 
(CHI3L1) (p<0.001) and Stromal cell-derived factor 1 (SDF-1) (p<0.05) (Figure 70A-C). 
 
 
 
 
  
Figure 68: Scans of nitrocellulose membranes following exposure to fast and slow 
fibroblast Secretome. Different densities were observed at varying location along the 
membrane that were quantified via densitometry.  Each cytokine is spotted in duplicate and 
two membranes were used for both the fast and slow group (n=4).  
Fast Slow (A) (B) 
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Figure 69: Higher cytokine secretion by fast migrating fibroblasts.  A number of 
cytokines were shown to be secreted in significantly higher amounts from the fast migrating 
cleft fibroblasts relative to their slow migrating counterparts. These included (A) Insulin-like 
growth factor-binding protein 2 (IGFB2) (B) Growth differentiation factor 15 (GDF15) and 
(C) Dickkopf-related protein 1 (DKK1), these differences were significant (p<0.001, 
p<0.001 and p<0.001 respectively. Furthermore, (D) Interleukin 6 (IL-6), (E) Interleukin 8 
(IL-8), (F) Complement factor D (CFD) and (G) Endoglin (ENG) were absent in the slow 
group were only secreted by the fast migrating fibroblasts, thereby suggesting fast migrating 
fibroblasts differ considerably in their cytokine release profiles when compared there slow 
migrating counterparts (Fast group n = 4; slow group n = 4).  
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Figure 70: Higher cytokine production by slow migrating fibroblasts.  A number of 
cytokines were secreted in significantly greater amounts by the slow migrating cleft 
fibroblasts when compared with their fast migrating counterparts. (A) These included: 
Chitinase-3-like protein 1 (CHI3L1) (p<0.001), (B) Monocyte chemoattractant protein 1 
(MCP-1) (p<0.001) and (C) Stromal cell-derived factor 1 (SDF-1) (p<0.05). This data 
suggests that the cytokine release profiles in fibroblasts derived from the slow migratory 
group are distinct from there fast migrating counterparts.  Fast group n=4; slow group (n=4). 
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4.6 Human cell motility PCR array analysis 
As the fast and slow fibroblasts were shown to differ significantly in their cytokine release 
profiles and a number of genes involved in cell migration and ECM production, a PCR array 
comprising 84 genes involved in cell motility was conducted in order to establish how fast and 
slow groups differed in their expression across a larger gene cohort. Expression levels for the 
majority of the genes assessed were comparable between fast and slow groups though there 
were a number of significant differences, these included: Actinin alpha 4 (ACTN4) (p<0.05), 
ARP2 actin-related protein 2 homolog (ACTR2) (p<0.05), Hepatocyte growth factor (HGF) 
(p<0.05), Integrin alpha 4 (ITGA4) (p<0.05), Matrix metallopeptidase 9 (MMP9) (p<0.05), 
Moesin (MSN) (p<0.01), Myosin heavy chain 9 (MYH9) (p<0.05) and Ras homolog gene 
family member B (RHOB) (p<0.05). In addition, there were a number of other genes with 
average fold changes greater than two but not significantly different statistically due to the 
variation in expression between the members of the fast and slow groups assessed, these genes 
included: Colony stimulating factor 1 (CSF1), Diaphanous homolog 1 (DIAPH1), Epidermal 
growth factor receptor (EGFR), Insulin-like growth factor 1 (IGF1), Insulin-like growth factor 
1 receptor (IGF1R), Met proto-oncogene (MET), Matrix metallopeptidase 14 (MMP14), Matrix 
metallopeptidase 2 (MMP2), P21 protein (Cdc42/Rac)-activated kinase 4 (PAK4), Paxillin 
(PXN) and Ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein 
Rac2) (RAC2). The fold changes and p-values for the aforementioned genes, as well as the 
genes that were comparable between the fast and slow group, are shown in the table below.  
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Gene name 
Gene 
symbol 
Accession 
number 
Fold 
change 
p-
value 
Relative to Fast 
migratory group 
Actinin, alpha 1 ACTN1 NM_001102 1.12 0.560 
Actinin, alpha 3 ACTN3 NM_001104 1.35 0.890 
Actinin, alpha 4 ACTN4 NM_004924 2.09 0.034 
ARP2 actin-related protein 2 
homolog 
ACTR2 NM_005722 -1.31 0.045 
ARP3 actin-related protein 3 
homolog 
ACTR3 NM_005721 -1.26 0.224 
V-akt murine thymoma viral 
oncogene homolog 1 
AKT1 NM_005163 1.21 0.800 
ADP-ribosylation factor 6 ARF6 NM_001663 1.89 0.265 
Rho GDP dissociation inhibitor 
(GDI) alpha 
ARHGDIA NM_004309 1.87 0.102 
Rho guanine nucleotide exchange 
factor (GEF) 7 
ARHGEF7 NM_003899 1.26 0.800 
BAI1-associated protein 2 BAIAP2 NM_006340 1.32 0.552 
Breast cancer anti-estrogen resistance 
1 
BCAR1 NM_014567 1.44 0.709 
Calpain 1, (mu/I) large subunit CAPN1 NM_005186 1.86 0.279 
Calpain 2, (m/II) large subunit CAPN2 NM_001748 -1.71 0.065 
Caveolin 1, caveolae protein CAV1 NM_001753 -1.33 0.424 
Cell division cycle 42 CDC42 NM_001791 1.05 0.517 
Cofilin 1 (non-muscle) CFL1 NM_005507 1.14 0.241 
V-crk sarcoma virus CT10 oncogene 
homolog 
CRK NM_016823 1.16 0.655 
Colony stimulating factor 1 CSF1 NM_000757 2.14 0.252 
Cortactin CTTN NM_005231 -1.07 0.668 
Diaphanous homolog 1 DIAPH1 NM_005219 2.14 0.125 
Dipeptidyl-peptidase 4 DPP4 NM_001935 1.55 0.422 
Epidermal growth factor EGF NM_001963 -1.43 0.420 
Epidermal growth factor receptor EGFR NM_005228 2.39 0.258 
Enabled homolog ENAH NM_001008 1.64 0.112 
Ezrin EZR NM_003379 -1.14 0.588 
Fibroblast activation protein, alpha FAP NM_004460 1.44 0.503 
Fibroblast growth factor 2 FGF2 NM_002006 1.20 0.447 
Hepatocyte growth factor 
(hepapoietin A; scatter factor) 
HGF NM_000601 2.95 0.013 
Insulin-like growth factor 1 IGF1 NM_000618 6.52 0.394 
Insulin-like growth factor 1 receptor IGF1R NM_000875 2.51 0.189 
Integrin-linked kinase ILK NM_004517 1.63 0.112 
Integrin, alpha 4 ITGA4 NM_000885 -2.43 0.026 
Integrin, beta 1 ITGB1 NM_002211 1.41 0.348 
Integrin, beta 2 ITGB2 NM_000211 -1.29 0.428 
Integrin, beta 3 ITGB3 NM_000212 1.17 0.507 
LIM domain kinase 1 LIMK1 NM_002314 1.96 0.143 
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Mitogen-activated protein kinase 1 MAPK1 NM_002745 1.07 0.639 
Met proto-oncogene MET NM_000245 3.27 0.072 
Matrix metallopeptidase 14 MMP14 NM_004995 3.32 0.150 
Matrix metallopeptidase 2 MMP2 NM_004530 2.66 0.223 
Matrix metallopeptidase 9 MMP9 NM_004994 1.87 0.010 
Moesin MSN NM_002444 2.10 0.009 
Myosin, heavy chain 10, non-muscle MYH10 NM_005964 1.75 0.159 
Myosin, heavy chain 9, non-muscle MYH9 NM_002473 3.15 0.010 
Myosin, light chain 9, regulatory MYL9 NM_006097 1.55 0.102 
Myosin light chain kinase MYLK NM_053025 -1.24 0.668 
P21 protein (Cdc42/Rac)-activated 
kinase 1 
PAK1 NM_002576 -1.28 0.126 
P21 protein (Cdc42/Rac)-activated 
kinase 4 
PAK4 NM_005884 2.52 0.188 
Profilin 1 PFN1 NM_005022 -1.52 0.113 
Phosphoinositide-3-kinase, catalytic, 
alpha polypeptide 
PIK3CA NM_006218 1.38 0.267 
Plasminogen activator, urokinase 
receptor 
PLAUR NM_002659 -1.50 0.440 
Phospholipase C, gamma 1 PLCG1 NM_002660 1.56 0.426 
Phospholipase D1, PLD1 NM_002662 1.32 0.709 
Protein kinase C, alpha PRKCA NM_002737 1.78 0.142 
Phosphatase and tensin homolog PTEN NM_000314 1.59 0.494 
PTK2 protein tyrosine kinase 2 PTK2 NM_005607 1.02 0.927 
PTK2B protein tyrosine kinase 2 beta PTK2B NM_004103 1.01 0.561 
Protein tyrosine phosphatase, non-
receptor type 1 
PTPN1 NM_002827 1.60 0.322 
Paxillin PXN NM_002859 4.15 0.071 
Ras-related C3 botulinum toxin 
substrate 1 (rho family, small GTP 
binding protein Rac1) 
RAC1 NM_006908 1.15 0.586 
Ras-related C3 botulinum toxin 
substrate 2 (rho family, small GTP 
binding protein Rac2) 
RAC2 NM_002872 -2.48 0.279 
RAS p21 protein activator (GTPase 
activating protein) 1 
RASA1 NM_002890 1.01 0.985 
Radixin RDX NM_002906 -1.14 0.665 
Rhodopsin RHO NM_000539 -1.05 0.801 
Ras homolog gene family, member A RHOA NM_001664 1.01 0.882 
Ras homolog gene family, member B RHOB NM_004040 2.49 0.027 
Ras homolog gene family, member C RHOC NM_175744 1.21 0.175 
Rho family GTPase 3 RND3 NM_005168 1.21 0.696 
Rho-associated, coiled-coil containing 
protein kinase 1 
ROCK1 NM_005406 1.42 0.372 
SH3 and PX domains 2A SH3PXD2A NM_014631 1.76 0.403 
V-src sarcoma (Schmidt-Ruppin A-2) 
viral oncogene homolog = 
SRC NM_005417 1.51 0.296 
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Signal transducer and activator of 
transcription 3  
STAT3 NM_003150 1.68 0.352 
Supervillin SVIL NM_003174 1.66 0.528 
Transforming growth factor, beta 1 TGFB1 NM_000660 1.52 0.494 
TIMP metallopeptidase inhibitor 2 TIMP2 NM_003255 1.90 0.273 
Talin 1 TLN1 NM_006289 1.84 0.112 
Vasodilator-stimulated 
phosphoprotein 
VASP NM_003370 1.60 0.276 
Vinculin VCL NM_003373 1.93 0.150 
Vascular endothelial growth factor A VEGFA NM_003376 -1.62 0.391 
Vimentin VIM NM_003380 -1.05 0.975 
WAS protein family, member 1 WASF1 NM_003931 1.05 0.982 
WAS protein family, member 2 WASF2 NM_006990 1.58 0.198 
Wiskott-Aldrich syndrome-like WASL NM_003941 1.02 0.738 
WAS/WASL interacting protein 
family, member 1 
WIPF1 NM_003387 1.79 0.234 
 
  
Table 7: Summary of fold changes in gene expression between fast and slow migrating 
fibroblasts obtained by PCR arrays. Three patients from both the fast and slow migrating 
group were selected for PCR array analysis, the data was pooled and expressed in terms of 
an average fold change in the slow migrating group relative to the fast migrating group. 
Positive fold changes greater than two are marked in red whereas high negative fold changes 
greater than two are marked in blue. All p-values have also been recorded and any significant 
differences were marked in red (n=3).  
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4.7 Analysis of transforming growth factor beta and alpha on cell growth 
In order to assess the effect of recombinant TGF’s on the growth of cleft fibroblasts, cultures 
were supplemented with 5nM or 20nM of each growth factor followed by generation of growth 
curves. It was found that supplementation with both 5nM and 20nM TGFβ1 increased cell 
growth leading to significantly decreased DT (p<0.05 and p<0.001 respectively). Conversely, 
supplementation with TGFβ3 at 5nM decreased cell growth rate leading to significantly 
increased DT (P<0.05) which increased further following supplementation with 20nM 
(p<0.001). Supplementation with both TGFβ2 and TGFα did not significantly influence growth 
of cleft fibroblasts at any of the concentrations used here (Figure 71A-D).  
4.7.1 Comparison of transforming growth factor beta and alpha expression between fast 
and slow migrating cleft fibroblasts 
To asses if there were any differences in the expression of various TGF beta and alpha between 
the fast and slow migrating fibroblasts, samples were grouped and their gene expression was 
averaged. It was found that TGFA expression was significantly upregulated in the fast group 
when compared with the slow (p<0.001).  No other TGF gene transcripts were up-regulated in 
the fast migrating fibroblast group. Conversely, expression of TGFB3 was significantly 
downregulated in the fast group when compared with the slow (p<0.05). Similarly, TGFBR1 
was also significantly down-regulated in the fast group when compared with the average 
expression of the slow group (p<0.05) thereby suggesting that TGFA, TGFB3 and TGFBR1 
may be involved in the differences observed in wound closure (Figure 72).   
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Figure 71: The effect of Transforming growth factor beta and alpha on the population 
doubling times of cleft fibroblasts. (A) Supplementation with 5nM TGFβ1 significantly 
decreased DT (p<0.05), this is decreased further following supplementation with 20nM 
(p<0.001) demonstrating that TGFβ1 supplementation at the concentrations used here 
increased the growth of cleft fibroblasts. (B) 5nM TGFβ2 led to an increase in DT however 
this increase was non-significant, DT did increase further following supplementation with 
20nM (p<0.05). (C)  Supplementation with 5nM TGFβ3 significantly increased DT 
(p<0.05) this increase was maintained following supplementation with 20nM (p<0.001). 
(D) Treating cleft fibroblasts with either 5nM or 20nM TGFA did not significantly 
influence their DT.  
(A) (B) 
(C) (D) 
* 
*** 
* 
* * 
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* 
* 
Figure 72: Transforming growth factor beta and alphaexpression between fast and 
slow migrating fibroblasts. Expression of TGFA was significantly higher in the fast 
group relative to the slow (p<0.001). There were no differences between the two groups 
based on expression of TGFB2 and TGFBR2. However, both TGFB3 and TGFBR1 were, 
on average, expressed in significantly higher amount in the slow group relative to the fast 
(p<0.05). (Fast group n=36; slow group=51).  
TGF beta and alpha expression: 
Fast vs. Slow 
 184 
 
4.7.2 Analysis of TGF beta and alpha on wound closure after 24 hours 
As it was previously shown that expression of TGFB3 and TGFA differed significantly based 
migratory group, the effect of TGF supplementation at 20nM on the RWA% of cleft fibroblasts 
was assessed. It was found that supplementation with 20nM TGFβ1 and TGFβ2 did lead to a 
decrease in wound closure though this not significant relative to the unsupplemented control. 
Supplementation with 20nM TGFβ3 did lead to a significant increase in the RWA% relative to 
the control (p<0.05). In contrast, the RWA% was very significantly decreased following 
supplementation of cultures with 20nM TGFα (p<0.001) (Figure 73).  
 
  
Figure 73: Effect of Transforming growth factor beta and alpha supplementation of 
on cleft fibroblast RWA%. Supplementation with 20nM TGFβ1 and 20nM TGFβ2 
decreased RWA% however this was not statistically significant. Supplementation with 
20nM TGFβ3 did lead to a significant decrease in the RWA% (p<0.05) suggesting the 
presence of TGFβ3 decreases the migratory rates of cleft fibroblasts.  The RWA% was 
very significantly decreased following supplementation with 20nM TGFA (p<0.001) 
suggesting that the presence of TGFA significantly increases cell migratory speed in cleft 
fibroblasts (n=9).  
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4.7.3 TGF beta and alpha on expression of myofibroblast differentiation markers 
ACTA2 expresses alpha smooth muscle actin (α-SMA) which is a commonly used marker for 
fibroblast to myofibroblast differentiation and was used here to assess the effect of TGF 
supplementation on cleft fibroblasts differentiation. It was shown here that supplementation 
with recombinant TGFβ1, TGFβ2, TGFβ3 and TGFα at concentration of 5nM and 20nM all led 
to significant upregulation of ACTA2 when compared with the unsupplemented control. The 
largest increase in ACTA2 expression was observed following TGFβ1 supplementation, this 
was shown to increase by 7.87-fold following 5nM supplementation and increased to 14.60- 
fold after treatment with 20nM TGFβ1 (Figure 74). In addition, vimentin (VIM), a commonly 
used fibroblast marker that has also been shown to be upregulated following fibroblast to 
myofibroblast differentiation, expression was assessed. As with ACTA2, VIM expression was 
shown to be significantly upregulated in all TGF supplementation conditions. Further, as with 
ACTA2, the greatest upregulation was observed following TGFβ1 supplementation which 
increased by 5.76-fold under the 5nM condition and 6.32-fold following treatment with 20nM. 
This data indicates that TGF supplementation can induce cleft fibroblast-to-myofibroblast 
differentiation and TGFβ1 was the most potent inducer of this differentiation (Figure 75). 
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*** 
*** 
  * 
 * 
*** 
***   * *** 
Figure 74: Effect of transforming growth factors beta and alpha on ACTA2 
expression. Supplementation with 5nM TGFβ1 significantly increased the expression of 
ACTA in cleft fibroblasts (p<0.001); this increased further following supplementation with 
20nM (p<0.001) suggesting that the presence of TGFβ1 induced cleft fibroblast to 
myofibroblast differentiation. Supplementation with TGFβ2 (5nM and 20nM) both 
resulted in significant upregulation of ACTA2 but not the extent of TGFβ1 (p<0.05). 
TGFβ3 (5nM and 20nM) and TGFA (5nM and 20nM) also significantly increased 
expression of ACTA2 by however this increased expression was significantly lower than 
that of TGFβ1 treated cultures (n=3).  
*** *** 
*** 
***  * 
*** 
 * 
Figure 75: Effect of transforming growth factor beta and alpha on VIM expression. 
Cultures treated with 5nM and 20nM TGFβ1 displayed significant upregulation of VIM 
when compared with the untreated control (p<0.001); there was no significant difference 
between the 5nM and 20nM treatment conditions. VIM was also upregulated in cultures 
treated with 5nM TGFβ2, this was upregulated further with 20nM (p<0.001). Cleft 
fibroblasts treated with 5nM TGFβ3 did not significantly upregulate VIM however 
significant increases were observed with 20nM supplementation (p<0.05). Treatment 
with 5nM TGFA significantly increased expression of VIM relative to the control 
(P<0.05); this expression was increased further following treatment with 20nM 
(P<0.001) (n=3).  
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4.7.4 TGF beta and alpha and cleft fibroblast collagen production and expression 
Total collagen production by mitomycin C growth inhibited cleft fibroblasts following 
supplementation with TGF’s was assessed by means of Sirius red staining. Both TGFβ1 and 
TGFα supplementation at 5nM led to significantly increased production of collagen when 
compared with the unsupplemented control (p<0.001 and p<0.001 respectively), TGFβ1 did 
not cause collagen production to increase further following treatment with 20nM although 
20nM TGFα did lead to increased collagen production when compared with its 5nM 
counterpart. TGFβ2 did not significantly influence collagen production in concentrations of 
5nM or 20nm, however supplementation with 5nM TGFβ3 led to a significant decrease in 
collagen production (p<0.001) which was shown to decrease further following treatment with 
20nM (p<0.05) (Figure 76). 
Supplementation with TGFβ1 at concentration of 5nM and 20nM resulted in significant 
upregulation of both COL1A1 and COL3A1, this was also observed following supplementation 
with TGFβ2 however both genes were not upregulated to the extent observed following 
treatment with TGFβ1. Supplementation of cleft fibroblasts with TGFβ3 at 5nM led significant 
downregulation of COL1A1 but not COL3A1, COL3A1 expression was significantly decreased 
following TGFβ3 treatment at 20nM as was COL1A1. COL1A1 expression was comparable 
with the control following treatment with both 5nM and 20nM TGFA whereas both of these 
concentrations resulted in significant upregulation of COL3A1 (Figure 77 and Figure 78).  
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*** 
*** 
  * 
*** 
Figure 76: Effect of transforming growth factor beta and alpha on collagen 
production Supplementation with TGFβ1 (5nM and 20nM) significantly increased the 
total collagen, produced by mitomycin C growth inhibited cleft fibroblasts, relative to the 
control which comprised of growth inhibited cleft fibroblasts that were not supplemented 
with exogenous transforming growth factors (p<0.001 and p<0.001 respectively); there 
was no significant difference between the 5nM and 20nM conditions. There were no 
significant differences in collagen production between fibroblasts treated with TGFβ2 and 
the control.  Cultures treated with 5nM TGFβ3 produced significantly decreased levels of 
collagen (p<0.001); this decreased further following supplementation with 20nM (p<0.05). 
Treatment with 5nM TGFA led to significantly increased collagen production (p<0.05) 
which increased further following supplementation with 20nM (p<0.001) (n=6).  
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*** *** 
Figure 77: Effect of transforming growth factor beta and alpha on COL1A1 
expression. TGFβ1 supplementation had the greatest effect on COL1A1 expression. 
COL1A1 was significantly upregulated following supplementation with 5nM (p<0.001); 
expression was increased further with 20nM (p<0.001). COL1A1 was also upregulated 
following supplementation with both 5nM and 20nM TGFβ2 (p<0.001). Supplementation 
with 5nM TGFβ3 significantly decreased COL1A1 expression (p<0.001); this was 
decreased further 20nM. Cultures supplemented with 5nM and 20nM TGFA displayed 
expression profiles comparable to that of the unsupplemented control (n=3).  
*** 
*** 
*** 
  * 
  * 
*** 
  * 
Figure 78: Effect of transforming growth factor beta and alpha on COL3A1 expression. 
COL3A1 was significantly upregulated following treatment with 5nM TGFβ1 (p<0.001); 
this was increased further with 20nM (p<0.01). COL3A1 was also upregulated following 
treatment with 5nM and 20nM TGFβ2. Supplementation with 5nM TGFB3 did not lead to 
any significant change in expression of COL3A1 however expression was significantly 
decreased in the presence of 20nM TGFβ3 (p<0.05). COL3A1 was significantly upregulated 
following 5nM TGFα supplementation (p<0.001), this was also increased with 20nM 
however due to larger stdev the significance relative to the control decreased (p<0.05) (n=3). 
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4.8 Discussion  
Following cleft repair, a subset of patients develop post-operative complications. For example, 
oronasal fistula (ONF) is characterised by reinstatement of the link between the oral and nasal 
cavities postoperatively and on average effects approximately 8.6% of cleft patients, although 
patients with combined CLP are at increased risk (Hardwicke et al, 2014). The cause of post-
operative complications can be varied and a number of potential contributory factors have been 
suggested, which include: size and width of the cleft (Khanna et al, 2012), surgical protocol 
(Zhang et al, 2017), differences between clinicians (Sitzman et al, 2017), age (Williams et al, 
2001) and body weight (Fillies et al, 2007). However, although multiple factors can influence 
the risk of post-operative complications, it has been suggested that pathological wound healing 
may be the principle contributor (Chitturi et al, 2015; Beyeler et al, 2014). Hypertrophic 
scarring (HTS), which affects approximately 25% of cleft patients (Soltani et al, 2012), is a 
result of persistent pathological deposition of ECM by local fibroblast which contribute to post-
operative complications through pathological wound contracture, increased tension at suture 
lines and reduced tissue integrity at the site of the repair. As many of the genes associated with 
cleft development are also involved in wound healing (Dixon et al, 2011), it is possible that the 
abnormal wound healing observed in some patients may be due to the disruption of normal 
fibroblast behaviour caused by the genetic predisposition that led to the formation of CLP. 
4.8.1 Cleft fibroblasts and cell migration  
Fibroblasts are central to normal wound healing, migrating into a wound from surrounding 
tissues thereby exerting tractional forces between their cell body and ECM molecules to which 
they are attached, leads to increased rigidity between fibroblast-ECM contacts and increased 
intercellular stress resulting in a myofibroblast differentiation response (Hinz and Gabbiani, 
2003). Myofibroblasts are also key secretors of ECM macromolecules, including collagens, and 
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are the major contributors to wound contracture. As the initial fibroblast migration rate is 
directly related to the rate of myofibroblast differentiation, which in turn is associated with 
mechano-transduction of contractile forces that lead to wound contracture, the initial fibroblast 
migration rate is central to ECM deposition and wound contraction (Tomasek et al, 2002). To 
date, one other study has compared cell migration of fibroblasts isolated from different cleft 
patients (Beyeler et al, 2014). However, only cleft lip fibroblasts, isolated from patients with 
CLP, were assessed, thereby limiting the data to a single cleft type. Further, scratch wound 
assays, which have significant drawbacks that can influence analysis of cell migration, were 
utilised to calculate a rate of wound closure (RWC%). Beyeler et al (2014) found that of the 16 
primary cleft fibroblast cell lines assessed, 10 shared comparable RWC%, whereas 5 migrated 
significantly faster and 1 migrated significantly slower. The patients were separated into three 
distinct groups which were: fast, intermediate and slow, as only one patient was in the slow 
group it was deemed an outlier and excluded from analysis. It was found that average RWC% 
between fast and intermediate groups were statistically different (p<0.001) (Beyeler et al, 
2014). Similarly, the present study identified two distinct groups in terms of cell migration, fast 
and slow, which were also statistically distinct. However, these migratory groups did not 
correlate with cleft type although CL derived fibroblast were all clustered into the fast group 
and demonstrated elevated motility.  As fibroblasts isolated from different cleft patients migrate 
at differing rates, this variance in motility could potentially be a significant contributory factor 
in the pathological wound healing found in some cleft patients; particularly CL patients which 
present a 25% risk of HTS (Soltani et al, 2012). Further, this may account for why different 
patients undergoing the same cleft repair by the same surgeon often display distinct surgical 
outcomes (Soltani et al, 2012). Cell migration is accelerated in fibroblasts isolated from HTS 
(Deng et al, 2018); in addition, fibroblasts isolated from keloid scar tissue also have 
significantly increased migratory rates compared with both extralesional fibroblasts, at the 
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periphery of the keloid scar and normal dermal fibroblasts within the same patient (Syed and 
Bayat, 2012). As both HTS and keloid scars arise as a result of pathological wound healing, it 
is significant that both of these tissue types contain fibroblasts with increased migration rates. 
It may be possible that cleft fibroblasts that demonstrate faster migration, could also contribute 
to defective wound healing due to greater exertion of tractional forces leading to elevated 
myofibroblast differentiation thus greater secretion of ECM and potentially HTS formation. 
4.8.2 ECM deposition and expression by cleft fibroblasts 
The provisional ECM secreted by fibroblasts comprises largely of collagen and fibronectin 
(Werner and Grose, 2003), this process is similar in both normal and pathological wound 
healing, however, the hallmarks of pathological healing, such as fibrosis and subsequent 
formation of HTS, include excessive myofibroblast differentiation and collagen production. As 
stated previously, the increased migration rates in the fast migrating cleft fibroblast group could 
potentially lead to greater myofibroblast differentiation; however, it was also shown here that 
the fast migrating fibroblasts secreted a significantly higher amount of total collagen. This 
increased collagen production is important as it has been shown that HTS tissue histologically 
contains a significant overabundance of collagen when compared with normally healed tissue 
(Gauglitz et al, 2010). This increase in production primarily comprises of Collagens type I and 
III (Niessen et al, 1999); however, here it was shown that fast migrating fibroblasts, despite 
secreting more total collagen, expressed COL1A1 at levels comparable with the slow group 
whereas COL3A1 had significantly lower overall expression in the fast group when compared 
with the slowly migrating fibroblasts. Although many studies report increased collagen I and 
III in HTS (Zhang et al, 1995), there are many conflicting reports, with some suggesting that 
only type III is upregulated and not type I (Oliveira et al, 2009). However, some have reported 
that HTS consist primarily of type I collagen and type III collagen is found at higher ratios in 
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normal tissues (Grieb et al, 2011; Cheng et al, 2011), which correlates with results obtained 
here. This potentially suggests that patients with faster migrating fibroblasts may be at elevated 
risk of pathological wound healing. The conflicting reports regarding collagen composition and 
HTS may be due to innate differences between oral and dermal fibroblasts (Shannon et al, 2006) 
as some report oral fibroblasts demonstrate an enhanced ability to re-organise ECM (Stephens 
et al, 1996).  Coupled with increased motility, cleft lip fibroblasts produced significantly greater 
total collagen and COL1A1 expression relative their palatal counterparts. As these are both 
hallmarks of pathological wound healing and HTS, it could be stipulated that patients with the 
CL phenotype may be at elevated risk of pathological wound healing. This correlates with 
others demonstrating that patients with CL develop HTS in 25% of patients (Soltani et al, 2012) 
as opposed to the 8.6% risk of ONF formation following CP repairs (Hardwicke et al, 2014).  
Cleft fibroblasts from the slow migrating groups demonstrated significant upregulation of 
fibronectin (FN1) compared with their fast counterparts. Fibronectin is a glycoprotein that is 
assembled into the ECM, where it functions as a scaffold and a signalling molecule, to aid in 
cell adhesion and migration (Ishise et al, 2015). During early wound healing fibronectin is 
fundamental to the production of the fibrin clot (Fieguth et al, 2003), this provisional matrix is 
essential for initial fibroblast migration into the wound as when absent fibroblast migration into 
the wound bed is decreased by 80% (Greiling and Clark, 1997). Although fibronectin is critical 
to normal wound healing, histological sections of HTS tissue display significant deposition of 
fibronectin with HTS derived fibroblasts secrete significantly greater amounts of fibronectin 
(Kischer and Hendrix, 1983; Kischer et al, 1989). Contrary to what would be expected, the 
present study demonstrated that slow migrating fibroblasts exhibited upregulation of FN1 
suggesting it may contribute to HTS in those patients. Equally, decreased expression of FN1 by 
the fast group, which is the presumed pathological group, could be significant as there are likely 
many compounding factors that converge and contribute to abnormal wound healing. 
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4.8.3 Involvement of cytoskeletal components in cleft fibroblast migration rates 
In order to establish why cleft fibroblasts presented significantly different RWA%s, structural 
differences in the cell cytoskeleton were investigated.  It was found that fast migrating cleft 
fibroblast, on average, contained significantly more total cellular f-actin when compared with 
the slow migrating cleft fibroblasts (p<0.001), although this did not correlate with increased 
actin expression. Similarly, others have shown that fast migrating cleft fibroblasts have 
significantly larger lamellipodia, due to a more organised actin network within the fibroblasts, 
compared with their slower migrating counterparts (Beyeler et al, 2014), however total actin 
was not quantified and differences were determined by analysis of a single patient from each 
group. The cell cytoskeleton is also comprised of polymers of tubulin, which form microtubules 
that are critical to normal locomotion of adherent cells. Microtubules are dynamic and are in a 
constant state of polymerisation and depolymerisation to regulate locomotion. These structures 
are present in large concentrations at the rear of the cell and are pivotal in the disassembly of 
focal adhesion complexes with underlying matrix (Ezratty et al, 2005) in response to contractile 
forces produced by actin at the leading edge of the cells. It was found in the present study that 
TUBA1 was significantly downregulated in slow fibroblasts when compared with the fast 
counterparts, due to the critical role of tubulin in cell dynamics this down regulation may have 
resulted in decreased tubulin production by slow migrating cell and potentially contributed to 
the decreased migration rates. Chinese hamster ovary (CHO) cells treated with nocodazole, a 
microtubule inhibitor, have demonstrated the importance of tubulin in directed cell migration. 
Treatment with 1nM nocodazole, a concentration that supresses microtubule dynamics, led to 
a significant decrease in migration rates. However, in the presence of 70nM nocodazole, a 
concentration that leads to complete breakdown of the microtubule network, cells were still 
able to migrate, although the directionality of migration was significantly perturbed as cells did 
not migrate towards a scratch wound due to disrupted cellular polarity (Ganguly et al, 2012; 
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Baudoin et al, 2008). As slow migrating fibroblasts downregulated tubulin it is possible that the 
cells may have disrupted directional motility. This could lead to fewer cells migrating into the 
empty area created by the Ibidi insert, meaning the differences observed in migration rates were 
not due to migratory speed but rather an inability to control the direction of motility towards 
uncolonised areas, thereby generating a perceived decrease in migratory rate.  
Cytoskeletal dynamics, including reorganisation of actin and tubulin, is regulated by the Rho 
family of GTPases, which are proteins that act as molecular switches within the cell where they 
stimulate cytoskeletal conformational change through interaction with downstream effectors 
(Zhao and Manser, 2005). In terms of fibroblast motility RAC1, RHOA and CDC42 are the 
primary influencers (Nobes and Hall, 1995; Lawson et al, 2017), however here it was shown 
that their expression was comparable between fast and slow groups therefore are unlikely 
contributory factors in the disparity seen in RWA%.Intracellular regulation of cytoskeletal 
dynamics is achieved by the above GTPases interacting with the downstream effectors Wiskott–
Aldrich syndrome protein (WASP), which are effectors for CDC42, and WASP-family verprolin 
homologue (WAVE), which are involved in RAC-induced actin dynamics (Bompard and Caron, 
2004; Symons et al, 1996). This interaction induces effector protein conformational change 
which subsequently activates the Arp2/3 complexes that mediates f-actin polymerisation 
through formation of nucleation cores which are precursors to actin filaments (Kurisu and 
Takenawa, 2009). This process contributes to cell polarity in the initial stages of cell migration 
through formation of lamellipodia at the leading edge of the cell, which help propel the cell in 
a forward direction (Steffen et al, 2013). Despite their being no differences in the expression of 
WASP and WAVE between fast and slow groups, the main function of WASP and WAVE 
proteins is to activate the ARP2 and ARP3 proteins thereby permitting formation of the ARP2/3 
complex, it was shown here that ARP2 gene expression was significantly downregulated in the 
slow migrating fibroblasts (see table 7). The ARP2/3 complex is the principal component in the 
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formation of new actin filaments at the leading edge of the cells. The complex binds to the 
lateral borders of existing filaments where it acts as a nucleation core by anchoring at 70° angle, 
relative to the parent filament and acts as a site for continued actin polymerization leading to 
formation of new filaments. Growth of the daughter filament is halted by capping proteins, 
when the filament reaches the desired length, allowing the daughter filament to act as a new 
binding site for ARP2/3 thereby exponentially expanding the actin network at the leading edge 
of the cell and aiding in propelling the cell forward (Mullins et al, 1998; Pollard and Beltznar, 
2002). As slow migrating cleft fibroblasts were shown to express significantly lower amounts 
of ARP2, a critical component of the ARP2/3 complex, it is possible that decreased migration 
rates were a result of decreased nucleation of new actin filaments at the leading edge, this would 
also correlate with reduced total actin observed in slow migrating fibroblasts by phalloidin 
staining. This is supported by recent research that has found that ARP2 depleted murine 
fibroblasts demonstrated a loss of lamellipodial formation and reduced migration rates, both of 
which were normalised following ARP2 restoration (Congying et al, 2012). RHOB is a small 
GTPase that coordinates interaction with several complexes which contribute to: actin 
polymerisation, membrane protrusion, cell migration and cell adhesion (Vega and Ridley, 
2018). RHOB downregulation has been reported to have an inverse correlation cell motility in 
multiple cell types with RhoB depletion leading to elevated motility but reduced cell spreading 
and lamellipodial extension; potentially due to perturbed focal adhesion contact with the 
underlying substratum (Vega et al, 2012). As PCR array analysis revealed that RHOB 
expression was significantly upregulated in the slow migrating cleft fibroblasts it is possible 
that the potential increased production of RHOB proteins by slow cells could have contributed 
to their decreased migratory capabilities. 
Patients with CL demonstrated significantly faster RWA% when compared with all other cleft 
types although expression of ACTA1, TUBA1, RAC1, RHOA and CDC42 were not shown to be 
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significantly different when compared with all other cleft types. Due to this the mechanism 
behind the increased RWA% of CL patients is currently unknown, although the other 
cytoskeletal regulators such as upstream regulators of ARP 2/3 complex activity should be 
assessed as potential contributors. When comparing clefts of the lip with differing laterality, it 
was found that RUCLP derived fibroblasts had significantly decreased CDC42 and RHOA 
expression relative to LUCLP and BLCLP whilst also demonstrating significantly lower RAC1 
expression relative to LUCLP. These differences are of note as RUCLP fibroblasts also had 
slower RWA% compared with LUCLP and BLCLP fibroblasts. Therefore, it is possible that 
the decreased RWA% observed in RUCLP was due to disrupted cytoskeletal dynamics due to 
decreased expression of RAC1, CDC42 and RHOA though further assessment of downstream 
effectors should also be assessed and compared between clefts of differing laterality. Increased 
migratory speed may be associated with pathological wound healing, as RUCLP have slower 
RWA%, from which decreased migration rates can be inferred, it is possible that these patients 
may be at decreased risk of post-operative complications. However, one study has shown that 
there is no difference in HTS formation between patients with ULCLP and BLCLP with relative 
incidence rates of 24.1% and 28.6% respectively, although no distinctions were made between 
RUCLP and LUCLP (Soltani et al, 2012) which should be addressed in future studies. 
4.8.4 Differences in protein production between fast and slow cleft fibroblasts  
Due to the involvement of fibroblasts in multiple physiological behaviours they are able to 
secrete an array of diverse cytokine that can influence cell behaviour. It was shown here that 
the fast migrating fibroblast group secreted greater total protein relative to the slow. Further, 
secretome substitution assays demonstrated that secreted cytokines were able to both increase 
and decrease the RWA% of slow and fast migrating fibroblast respectively. Others have also 
demonstrated the stimulatory effects of conditioned media, human dermal fibroblasts (HDF) 
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treated with conditioned media from human immortalized keratinocytes (HaCaT) stimulated 
cell migration (Li et al, 2014). Further, HDF supplementation with bone marrow mononuclear 
cell (BM-HNC) secretome significantly increased migration thus closure of scratch wounds 
(Menendez et al, 2017).  The inhibitory effect of conditioned media has also been demonstrated 
as mesenchymal stem cells (MSC) secretome significantly decreased the migration of corneal 
fibroblasts (Watson et al, 2009). This demonstrate the secretome derived from different cell 
types can influence fibroblast behaviour. However here, secretome substitution from cells of 
the same type, significantly influenced RWA%, suggesting the presence of differing cytokines 
within the secretome could have influenced cleft fibroblast motility in an autocrine fashion. 
Cytokine arrays were conducted to identify how fast and slow fibroblasts differed in terms of 
their secreted cytokine profiles. Fast migrating cleft fibroblasts produced significantly greater 
amounts of Insulin-like growth factor (IGF) binding protein-2 (IGFbP2) when compared with 
their slow counterparts. IGFBP2 is a secreted cytokine that is involved in the regulation of the 
cell behaviours induced by IGF-1 through its antagonistic function (Firth and Baxter, 2002). 
IGF-1 has repeatedly been shown to potent stimulator of cell migration in multiple cell types 
(Guvakova, 2007), whilst the main function of IGBP2 is to compete for IGF-1 receptor binding 
sites, recent research has shown that it can also stimulate cell motility. HDF’s that were cultured 
with both IGFBP2 and IGFBP2 fragments were shown to increase cell migration rates by 50% 
compared with controls (Brandt et al, 2014); further, inhibition of IGFB2 in fibroblast-like 
synoviocytes (FLS) were shown to significantly decrease their rate of migration (Wang et al, 
2017). Though the precise mechanism of the stimulatory effect of IGBP2 on cell migration is 
currently undefined, it has been shown that IGFBP2 potently binds to proteoglycans and 
glycosaminoglycans (Kawai et al, 2011). Further, when IGFBP2 treated fibroblasts were pre-
treated with α5β1, an integrin that binds to ECM macromolecules, motility deceased to levels 
comparable with that of the control, suggesting that the mechanism behind increased migration 
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rates was due to alteration to the way cells adhered to the surrounding ECM (Brandt et al, 2015). 
Therefore, increased IGBP2 secretion observed in fast cleft fibroblasts may contribute to their 
elevated motility due to alteration to cell-ECM interactions. Growth differentiation factor 15 
(GDF15), was also shown to be secreted in higher amounts by fast fibroblasts. Although the 
precise role of GDF15 remains undefined, it is known to be upregulated in response to cellular 
stress and disease thereby stimulating changes in cell behaviours including growth, apoptosis 
and invasion (Baek and Eling, 2019. For example, GDF15 contributes to malignant progression 
of a number of cancers by stimulating tumour cells to migrate into surrounding tissues (Corre 
et al, 2013). SNU-216 cells, a gastric cell line, displayed increased invasiveness due to 
overexpression of GDF15 (Lee et al, 2003) whereas prostate cancer cells displayed increased 
motility due to reorganization of the cytoskeletal actin network in response to GDF15 (Senapati 
et al, 2010). Due to this, increased GDF15 secretion may have contributed to the elevated 
motility observed in the fast fibroblast group potentially due to influences on the actin 
cytoskeleton as it was also shown here that they contained greater intercellular actin. Dickkopf-
related protein-1 (Dkk1), which plays a critical role in craniofacial development due to its 
function as an antagonist to Wnt signalling molecules (Nie, 2005), was elevated in the fast 
migrating group. Wnt signalling molecules are potent inducers of cell migration in a range of 
cell types, including neural crest cells which are involved in development of the lip and palate 
(Schambony and Wedlich, 2013); thus, variation in Dkk1 production may contribute to the 
development of CLP. Pax9 negative mice, which exhibit the CP phenotype, demonstrated 
corrected palatal fusion thus inhibition of the CP phenotype, following intravenous delivery 
Dkk1 inhibitors to prenatal mice during the palatogenesis developmental period (Jia et al, 
2017). It was suggested that corrected palatal fusion was likely due to restoration of Wnt 
signalling within the palatal mesenchyme as Dkk1 inhibitors acted as Wnt agonists. Further, as 
overproduction of Dkk1 increased the motility of carcinoma cell lines by interference with Wnt 
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signalling (Chen et al, 2013; Pang et al, 2017) it is possible that increased Dkk1production by 
the fast group may have contributed to their elevated motility via disruption to wnt signalling. 
The slow cleft fibroblast group secreted increased monocyte chemoattractant protein-1 (MCP-
1), a potent inflammatory chemokine produced by multiple cells types including fibroblasts 
(Yoshimura and Leonard, 1990). Whilst the main function of MCP-1 is to regulate monocyte 
migration during an inflammatory response, MCP-1 has also been shown to exert an anti-
fibrotic effect in human foetal fibroblasts by downregulation of ECM proteins involved in 
fibrosis, including: collagen-1 by 75%, and fibronectin by 40% (Kalderen et al, 2014). Further, 
MCP-1 treated fibroblasts significantly downregulated α-Smooth muscle actin (α-SMA), a 
myofibroblast differentiation marker, relative to control samples (Kalderen et al, 2014). This 
suggests MCP-1 is an inhibitor of excessive ECM production and fibroblast-to myofibroblast 
differentiation, which are both contributors to fibrotic scar formation. As slow cleft fibroblasts 
secreted lower total collagen when compared with their fast counterparts, it is possible that an 
increased MCP-1 production was a contributory factor. Further, as slow migrating fibroblasts 
exert less tractional force on the surrounding ECM, which reduces subsequent myofibroblast 
differentiation, it is possible that patients with decreased migratory rates may be at lowered risk 
of pathological wound healing therefore subsequent development of HTS and ONF. As the 
cytokine release profiles between fast and slow cleft fibroblast differed considerably, with a 
number shown to significantly influence motility, the disparity between migratory groups may 
have due to variability in intrinsic cytokine release followed by autocrine responses. 
4.8.5 Effect of transforming growth factor beta and alpha on cleft fibroblast behaviour  
Transforming growth factors are critical to normal wound healing as they stimulate or inhibit 
key processes including cell recruitment, proliferation, ECM deposition and wound contracture 
(Penn et al, 2012).  Pathological wound healing following cleft repair is a considerable issue as 
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it can lead to the formation of hypertrophic scars (HTS) and contribute to the formation of 
oronasal fistulae.  Myofibroblasts are critical to normal wound healing but their overabundance 
can be pathological and contribute considerably to fibrosis. As outlined previously the initial 
rate of fibroblast migration into and across a wound contributes to myofibroblast differentiation 
due to increased tractional force at the wound site, this increased mechanical stress leads to 
ECM stiffness and stimulate differentiation (Hinz and Gabbiani, 2003). However, transforming 
growth factor β1 (TGFβ1) can also contribute to differentiation to the myofibroblast phenotype 
(Thannickal et al, 2003) which is characterised by upregulation of ACTA2 (α-SMA) (Evans et 
al, 2003). Here cleft fibroblasts treated with TGFβ1 at concentration significantly upregulated 
ACTA2 in a dose dependant manner thus indicating fibroblast-to-myofibroblast differentiation 
similar to what other have shown (Evan et al, 2003). As TGFβ1 is a potent differentiation factor 
in cleft fibroblasts it is possible that the cleft patients with increased TGFβ1 expression, across 
the highly variable cohort, may be at increased risk of HTS due to premature differentiation as 
a result of increased TGFB1 production. Fibroblasts isolated from HTS also upregulate TGFB1 
relative to their normal counterparts (Wang et al, 2001). In addition, following treatment with 
TGFβ1, cleft fibroblasts produced greater amounts of total collagen which coincided with 
upregulation of COL1A1 and COL3A1, which is comparable to what other have found (Petrov 
et al, 2002). This is interesting as myofibroblast are associated with increased ECM production 
(Hinz et al, 2007) and increased collagen is a hallmark of HTS thereby offering further evidence 
that patients with elevated TGFB1 expression may be at greater risk of fibrosis.  
TGFA expression was significantly higher in fibroblasts isolated from patients in the fast group 
compared with the slow. Further, cleft fibroblast supplementation with 20nM TGFA resulted in 
drastically increased RWA%, relative to unsupplemented controls, thereby demonstrating its 
stimulatory effect on cleft fibroblast migration. One other study has assessed cleft fibroblast 
motility, findings correlate with the present study as TGFA was significantly upregulated in fast 
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migrating cleft fibroblasts and the addition of TGFα at 5nM significantly increased the wound 
closure of slow migrating fibroblasts (Beyeler et al, 2014). In addition, supplementation with 
TGFα inhibitors, resulted in reduced wound closure of fast migrating fibroblasts thus it was 
concluded that TGFα plays an important role in cleft fibroblast motility which could potentially 
translate to reduced fibrosis in some patients (Beyeler et al, 2014). The present study also 
demonstrated that supplementation with TGFα led to increased collagen production and 
COL3A1 expression. Others have shown mature hypertrophic scars, within which increased 
collagen deposition is characteristic, expressed significantly higher collagen type III within the 
dermis relative to non-hypertrophic scars (Oliveira et al, 2014). This suggests that elevated 
TGFα is likely involved in cleft fibroblast motility and stimulates increased collagen secretion 
which could result in greater likelihood of HTS formation in some patients.  
Following supplementation with TGFβ3 cleft fibroblasts demonstrated significantly decreased 
RWA%, others have also shown that TGFβ3 has an anti-motility effect on dermal fibroblasts 
(Bandyopadhyay et al, 2006). This anti-motility effect potentially accounts for why fibroblasts 
in the slow cluster exhibited increased expression of TGFβ3 which potentially contributed to 
their decreased wound closure. As migration rates are related to myofibroblast differentiation 
it is also possible that these patients are at decreased risk of fibrosis due to increased production 
of TGFβ3 potentially reducing wound site migration rates. TGFβ3 has been shown to have an 
antagonistic effect in the formation of scars as it was shown that intradermal delivery of TGFβ3 
at a murine wound sites led to a decreased presence of fibrotic markers (Waddington et al, 
2010). Further, delivery of exogenous TGFβ3 to the wound site following cleft lip repair on a 
murine model resulted in decreased expression of smooth muscle actin and reduced collagen 
deposition (Hosokawa et al, 2003). This supports the results found here as following 
supplementation with TGFβ3, COL1A1 expression was downregulated as was expression of 
COL3A1, both of which correlated with significantly decreased total collagen production. This 
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data suggests that TGFβ3 potentially has a protective role against fibrosis and resultant HTS. 
Due to this, the increased expression of TGFB3 seen in some fibroblasts may result in a 
decreased risk of pathological wound healing in the patients from which they were isolated. 
However, HTS is a complex process and is likely not the result of expression of single genes 
rather the interaction and regulation multiple associated genes are the likely cause. Long-term 
follow-up assessments following cleft repair are required, with larger patient cohorts, to assess 
if there are any significant correlations with TGF expression and patient outcome.  
4.9 Conclusion  
Fibroblasts isolated from cleft patients differed significantly in terms of their RWA% and were 
grouped into two distinct migratory clusters: fast and slow, with fibroblasts from the fast group 
secreting greater total collagen. The non-cleft NHDFF control was clustered into the fast group 
but due to the fundamental differences between oral and dermal fibroblasts they may not be 
comparable. Although migratory speed did not correlate with cleft phenotype, CL derived 
fibroblast all presented elevated motility and were all clustered into the fast group. Further, CL 
fibroblast secreted greater total collagen and upregulated COL1A1. As increased migration and 
collagen secretion are hallmarks of HTS, it is possible patients with faster migrating fibroblast, 
including those derived from CL, may be at greater risk of pathological wound healing, this 
correlates with the elevated risk of HTS in patients following CL repair (Soltani et al, 2012). 
Although fast migrating fibroblasts did not differ in terms of expression of the cytoskeletal 
regulators RAC1, RHOA and CDC42, they contained increased intercellular actin which 
correlated with upregulation of ARP2, a component of the ARP 2/3 complex which acts as an 
actin nucleator, thereby suggesting elevated motility may be due to altered cytoskeletal 
dynamics. However, the two migratory groups also differed in terms of their cytokine release 
profiles which could have potentially influenced cell motility in an autocrine manner, thereby 
suggesting distinct physiological differences between the two groups.  
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CHAPTER FIVE: 
 THE INFLUENCE OF FOLIC ACID ON CLEFT FIBROBLAST BEHAVIOUR 
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5.1 Folic acid and cell growth 
Folate deficiency has been repeatedly associated with the development of orofacial clefts 
(Jahanbin et al, 2019); however, despite this, the underlying physiological function that folic 
acid (FA) contributes to in order to induce its protective role is undefined. Here a broad range 
of cell responses to FA supplementation was assessed in vitro to identify cell behaviours that 
are induced by the presence of elevated FA thereby identifying potential underlying cell 
behaviours that may contribute to cleft prevention. To assess the effect of FA concentration on 
the growth of cleft fibroblasts, isolated from the fast (S101596) and slow (S101597) migratory 
groups established previously, growth curves were generated with an FA negative control (FA-
ve), which had the same DMEM formulation but excluded FA, and in the presence of FA at 
concentrations of: 20nM, 10µM, 20µM and 30µM from which doubling times were calculated. 
Fibroblasts supplemented with physiological concentrations of FA (20nM) generated 
comparable cell numbers to that of the FA-ve control, throughout the assay period, indicating 
that at this concentration FA did not appear to influence cell growth. Despite all cultures being 
seeded at the same concentration (5x104), fibroblast growth following culture with 10µM FA 
was accelerated (p<0.01), cell number increased further in the presence of 20μM FA, though 
not significantly (Figure 79A-B). However, growth was significantly reduced in medium 
containing 30μM FA (p<0.01). Fibroblasts derived from the fast and slow migratory groups 
shared similar responses to the presence of FA. The growth increases observed in the presence 
of 10μM and 20μM FA was also observed in the non-cleft neonantal human dermal foreskin 
fibroblasts (NHDFF) control (figure 79C), indicating this folate response was not specific to 
cleft fibroblasts. Population doubling times (DT) mirrored growth curve models. Physiological 
concentrations (20nM) FA did not influence DT. However, 10μM and 20μM resulted in 
significant (p<0.01) decreases in DT in both fast (figure 80A) and slow groups (figure 80B) 
relative to the control. Fibroblasts treated with 30μM displayed significantly longer DT in both 
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migratory groups (P<0.001). This general trend was also observed in the NHDFF control (figure 
80C).   
(A) (B) 
(C) 
Figure 79: Effect of folic acid on the growth of cleft fibroblasts. At day 0 the same 
number of cleft fibroblasts were seeded with the only differences between cultures being 
the concentration of FA provided. After 2 days in culture there were marginal (non-
significant) increases in the cell numbers present in cultures treated with 10µM and 20µM 
FA.  After 4 days in culture cells treated with 20nM FA displayed cell numbers comparable 
with those of control cells whereas fibroblast treated with 10µM and 20µM FA were 
significantly higher in cell number (p<0.05 and p<0.05, respectively) however cultures 
treated with 30µM displayed significantly lower cell number (p<0.01). This increased 
growth rate in cultures treated 10µM and 20µM FA continued up until day 8 whereas 
growth in 30µM was significantly decreased. This general trend was observed in both fast 
and slow migrating fibroblasts as well as in non-cleft control cells (NHDFF) (n=12).  
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(A) (B) 
(C) 
Figure 80: Effect of folic acid on cleft fibroblast doubling time. (A) Doubling times 
were comparable between untreated control cells and cells treated with 20nM FA, which 
demonstrated that at physiological concentration FA did not influence cleft fibroblast 
growth rates. Doubling times were significantly lower in cultures treated with 10µM and 
20µM (p<0.01 and p<0.01 respectively) thus demonstrating an increase in cell growth 
however there was no significant difference between 10µM and 20µM treated cultures. 
Cleft fibroblasts treated with 30µM FA displayed significantly decreased population 
doubling times (p<0.001) when compared with the control group demonstrating that at this 
concentration FA had an adverse effect on cell growth. This general trend was observed in 
both the fast (S101596) and slow (S101597) (B) migrating fibroblasts as well as in non-
cleft NHDFF control (C) (n=3). 
*** 
*** 
*** 
** ** ** ** 
** ** 
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5.2 Influence of folic acid on formazan production by cleft fibroblasts  
In the absence of FA fast migrating cells exhibited lower overall absorbance values, this was 
increased in the presence of physiological concentrations of FA (20nM)(non-significant). When 
cleft fibroblasts were cultured with 10μM and 20μM FA, absorbance values were significantly 
higher than both the control (p<0.01 and p<0.01) and the 20nM condition (p<0.01 and p<0.01). 
Supplementation with 30μM led a marked decrease in metabolic activity when compared with 
the 10μM FA (p<0.05) and 20μM (p<0.01) conditions although absorbance values were still 
significantly greater than the FA-ve control (p<0.05) (figure 81A). Slow migrating fibroblasts 
(S101597) displayed a different response to FA. Following 10μM supplementation, fibroblasts 
exhibited significantly increased absorbance relative to both the control (p<0.01) and the 20nM 
group (p<0.01). However, both 20μM and 30μM conditions displayed absorbance comparable 
with the control and significantly lower than 10μM FA (p<0.01 and p<0.05) (figure 81B).  
 
 
Figure 81: Effect of folic acid on formazan production by cleft fibroblasts. (A) The 
metabolic activity per cell in the fast migrating group was comparable for untreated control 
cells and cells treated with 20nM FA, however treating cells with 10µM, 20µM and 30µM FA 
significantly increased the metabolic activity per cell (p<0.01, p<0.001 and p<0.05 
respectively). (B) Following treatment with 10µM FA metabolic activity was significantly 
increased (P<0.05) when compared with the control however there was no significant 
difference between the control and the 20µM FA and 30µM FA treated cleft fibroblasts.  
(A) (B) 
*** ** 
* * 
MTT assay: S101596 MTT assay: S101597 
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5.3 Influence folic acid supplementation on wound closure 
Changes in wound closure in the presence of a range of concentrations of FA was measured by 
means of an Ibidi migration assay. Cleft fibroblast from the fast migratory group were found to 
exhibit similar migratory rates between the control and the 20nM FA supplemented group 
indicating that despite being the normal physiological concentration of FA it did not have any 
significant effect on migration rates in vitro.  Cleft fibroblast migration in the presence of 10μM 
FA was significantly decreased when compared with both the control (p<0.01) and 20nM FA 
(P<0.01) exposure. Treatment with 20μM and 30μM FA led to a further reduction in migratory 
speed and was significantly slower than the 10μM FA exposure group (p<0.05) (figure 82A). 
This data demonstrated that the addition of FA to fast migrating fibroblasts, in concentrations 
of 10μM, 20μM or 30μM, led to a significant decrease in migratory speed over a duration of 24 
hours.  Slow migrating fibroblasts did not demonstrate any significant change in RWA% in 
response to FA (figure 82B).  
 
 
 
Figure 82: Effect of folic acid supplementation on RWA%. (A) Supplementation with 
20nM FA did not lead to any significant change in wound closure However, supplementation 
with 10μM, 20μM and 30μM FA significantly increased RWA% due to decreased migratory 
speed when compared with untreated controls (p<0.001). Supplementation with 20µM FA led 
to a significant decrease in RWA% when compared with 10µM (p<0.05), there was no 
significant difference between 20µM and 30µM treated groups. (B) In the slow migrating 
group supplementation with 20nM, 10µM, 20µM and 30µM FA did not lead to a significant 
decrease in migratory speed (n=9).  
(A) (B) 
*** 
*** 
*** 
* 
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5.3.1 Effect of folic acid on genes related to cell migration 
Exposure to a range of concentrations of FA prior to RNA isolation from cultured fibroblasts 
resulted in a number of changes to the expression levels of ACTA1 and TUBA1, which are 
regulators of actin and tubulin production and are involved in the mechanical process of cell 
migration. Supplementation with 10μM FA led to a significant decrease in the expression of 
both ACTA1 (p<0.01) and TUBA1 (p<0.01) in fast migrating cleft fibroblasts (Figure 83A-B). 
However, increasing concentrations of FA to 20μM and 30μM did not have any significant 
effect on ACTA1 or TUBA1 expression levels relative to the 10μM treatment condition. Slow 
migrating fibroblasts had decreased ACTA1 expression in response to 10μM FA though this 
decrease was not significant. Increasing FA concentrations to 20μM and 30μM resulted in a 
significant downregulation of ACTA1 compared with the FA-ve control (p<0.05 and p<0.01 
respectively). Furthermore, cleft fibroblasts treated with 10μM and 20μM FA had significantly 
decreased expression of TUBA1 (p<0.05 and p<0.05). However, supplementation with 30μM 
FA did not lead to a significant decrease in TUBA1 expression, relative to the control, despite 
minimal downregulation (Figure 83C-D). These data indicated that ACTA1 and TUBA1 
expression was downregulated in response to relatively high concentrations of FA.  
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(A) (C) 
(B) 
(D) 
Figure 83: Effect of folic acid on gene expression of cytoskeletal-related molecules. 
(A) ACTA1 expression and TUBA1 expression (B) was significantly decreased in the 10µM 
FA treated groups (p<0.001 and p<0.001). This decrease was also detected in both 20µM 
and 30µM groups, though all treated groups displayed similar expression levels. (C) 
ACTA1 expression in fibroblasts from the slow migrating group was lower when treated 
with 10µM FA however this was non-significant. Supplementation with 20μM and 30μM 
FA led to a significant decrease in expression levels when compared with an untreated 
control (p<0.05 and p<0.01 respectively). (D) Supplementation with 10µM and 20µM FA 
resulted in a significant decrease in TUBA1 expression (p<0.05 and p<0.05) however 
supplementation with 30µM FA did not lead to a significant decrease in TUBA1 expression 
levels (n=3).  
*** 
* 
*** 
*** *** *** 
* 
*** 
* * 
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5.4 Effect of folic acid on cell adherence and cell non-adherence  
 
To determine the effect of FA on the adhesion of cleft fibroblast, cells were seeded at 5x105 
with range of concentrations of FA and after 24 hours and the number of adherent and non-
adherent cells were counted. Two controls were used, one comprised of the normal formulation 
of DMEM (which contains approximately 9μM FA) whilst the second was the modified FA-ve 
culture medium that has been used for all other folate supplementation assays. 
In terms of cell adhesion, fast migrating fibroblasts (S101596) exhibited significantly higher 
numbers of adherent cells in the FA+ve control when compared with the FA-ve control 
(p<0.01). These data were supported by quantification of the numbers of non-adherent cells 
which were significantly higher in the FA-ve control when compared with FA+ve (p<0.01), 
indicating that the presence of FA within the normal formulation of culture medium was critical 
for optimal cell adhesion. Supplementation with 20nM FA did not significantly influence the 
number of adherent cells as values were comparable with those of the FA-ve control 
demonstrating that this concentration did not have a significant effect on cell adhesion. 
However, supplementation with 10μM and 20μM FA caused significantly greater numbers of 
cells to be adherent after 24 hours when compared with the FA-ve control (p<0.05) although 
values were comparable with the FA+ve control (Figure 84A-C). This was mirrored in the 
quantification of the number of non-adherent cells as both conditions produced significantly 
lower number of non-adherent cells when compared with the FA-ve control. Though somewhat 
unexpected the presence of 30μM FA significantly decreased cell adhesion rates, the numbers 
of adherent cells were significantly lower than the 10μM and 20μM FA conditions (p<0.01 and 
p<0.01 respectively). In addition, the presence of 30μM FA led to numbers of non-adherent 
cells that were significant higher than all other FA treated groups and the FA-ve control 
(p<0.01). The same general trends were observed in the slow migrating cells (S101597), though 
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the numbers of non-adherent cells in the 30μM condition were comparable with that of the FA-
ve group. Non-cleft cells also exhibited a similar response to FA in the concentration ranges 
used. Taken together these data demonstrated that the presence of FA was critical for cell 
adhesion in both cleft and non-cleft fibroblasts although 30uM FA had an adverse effect on cell 
adhesion (Figure 85A-C).   
  
Figure 84: Effect of folic acid supplementation on cell adherence. (A) The number of 
adherent cells was significantly lower (p<0.05) in the FA negative control (FA-ve) when 
compared with the FA positive control (FA+ve) suggesting that FA is important for optimal 
cell adhesion. The number of adherent cells was comparable between the FA-ve control 
and the cells supplemented with 20nM FA, however the supplementation with 20nM did 
lead to lower total adherent cells when compared with the FA+ve control (p<0.01). 
Following supplementation with 10µM and 20µM the number of adherent cells were 
comparable to that of the FA+ve control but significantly higher than the FA-ve control 
(P<0.05). When treated with 30µM FA cleft fibroblasts exhibited lower levels of cell 
adherence when compared with the cells supplemented with 10µM (p<0.01) and were 
similar to that of the FA-ve control. This general pattern of adhesion was also observed in 
the slow migrating group (B) and the non-cleft cells (C) (n=3).  
(A) (B) 
(C) 
* ** ** 
* 
** 
** ** 
** 
** 
* 
** ** ** 
** 
** 
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Figure 85: Effect of folic acid supplementation on cell non-adherence. (A) The number 
of non-adherent cells was significantly lower in the FA+ve control when compared with the 
FA-ve control (p<0.01). Supplementation with 20nM FA did led to non-adherent cell 
number comparable to the FA-ve control but significantly higher than that of the FA+ve 
control (P<0.001). Cultures supplemented with 10µM and 20µM led to significantly fewer 
non-adherent cells when compared with FA-ve (P<0.01) however cell numbers were 
comparable to that of the FA+ve control. Cleft fibroblasts treated with 30µM FA were 
significantly more non-adherent when compared with both the FA-ve control and FA+ve 
control (p<0.01 and p<0.05 respectively). (B) Similar trends were observed in slow 
migrating fibroblasts (S101597) and in NHDFF (C) however in S101597 there was no 
significant difference between supplementation with 30µM FA and the FA-ve control (n=3). 
(A) (B) 
(C) 
** 
** 
*** 
** ** ** ** 
*** *** 
*** 
** 
** 
** 
** 
** 
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5.4.1 Effect of folic acid on cell-to-cell adhesion 
The effect of FA on cell-cell adhesion was assessed by seeding 5x104 fluorescently labelled 
cleft fibroblasts onto confluent monolayers of the same cell type followed by measuring the 
relative fluorescence of the supernatant, which contained all of the labelled non-adherent cells, 
after 24 hours.  The FA-ve control exhibited the highest fluorescence which indicated the largest 
number of non-adherent cells (Figure 86A) this was confirmed following quantification of cell 
numbers using a standard curve (Figure 86B). Supplementation with 20nM FA led to a 
reduction in fluorescence relative to the control, following quantification this decreased signal 
translated to significantly decreased non-adherent cell number (p<0.05). Exposure to 10μM, 
20μM, and 30μM FA significantly lowered fluorescence compared with the control (p<0.01). 
This data suggests that the presence of FA within the culture medium improved the ability of 
cleft fibroblasts to adhere to cells of the same type. 
  
Figure 86: Effect of folic acid supplementation on cell-cell adhesion. (A) FA negative 
control cultures exhibited the highest RFU based on the number of remaining stained non-
adherent cells in the cell supernatant after 24 hours. Supplementation with 20nM FA did not 
lead to any significant differences in RFU relative to the control. However, supplementation 
with 10µM, 20µM and 30µM led to a significant reduction in RFU when compared with the 
FA-ve control (p<0.001, p<0.001 and 0<0.001 respectively), indicating the presence of FA 
increases cell-to-cell adhesion rates. (B) 20nM FA did lead to significant reduction in the 
number non-adherent cells after 24 hours when compared with the control (P<0.05). 10µM, 
20µM and 30µM FA led to a greater decrease in non-adherent cells when compared with both 
the control and the 20nM group (p<0.001, p<0.001 and p<0.001 respectively). There were no 
significant differences between 10µM, 20µM and 30µM FA conditions (n=6).  
(A) (B) 
*** *** *** 
*** *** *** 
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5.4.2 Effect of folic acid on expression of genes related to cell adhesion 
Due to the effect of FA on the adhesive ability of cleft fibroblast, gene expression analysis was 
conducted on a number of transcripts that are associated with cell adhesion. In the fast migrating 
group (S101596) intercellular adhesion molecule-1 (ICAM1) was significantly upregulated 
(p<0.01) following supplementation with 10μM FA with a 4-fold change relative to the FA-ve 
control. Increasing FA concentration to 20μM and 30μM did not lead to further increases in 
expression (Figure 87A). Vascular cell adhesion molecule 1 (VCAM1) was also significantly 
upregulated in the presence of 10μM and 20μM FA (p<0.01 and p<0.01) with an approximate 
4-fold change relative to the control, 30μM FA led to a further increase in expression of VCAM1 
with an approximate 5-fold change which was significantly higher than both the 10μM and 
20μM conditions (Figure 87B). Paxillin (PXN) expression was shown to be significantly higher 
than the FA-ve control following exposure to 10μM and 20μM FA however the fold change of 
1.5 was much lower than the increase observed with ICAM1 and VCAM1, supplementation with 
30μM FA did not lead to a significant increase in PXN expression relative to the control (Figure 
87C). Fibroblasts from the slow migrating group (S101597) also showed upregulation of 
ICAM1 in the presence of 10μM FA; however, this was increased further to a 5-fold change in 
the presence of 20μM FA (Figure 87D). VCAM1 was also upregulated in all experimental 
conditions though the fold change was lower (approximately 3.5) (Figure 87E). PXN expression 
was not affected by FA in any of the concentrations assessed with expression levels comparable 
with that of the FA-ve control.  
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  (A) (D) 
(B) (E) 
(C) (F) 
Figure 87: Effect of folic acid supplementation on cell adhesion related gene expression. 
Fast migrating cells: (A) ICAM1 expression was significantly increased following 
supplementation with 10µM, 20µM and 30µM FA (p<0.001); there was no significant 
differences between supplemented conditions. (B) VCAM1 expression was significantly 
upregulated in all supplemented conditions when compared with the control (p<0.001), 
however 30µM FA led to significantly higher expression when compared with 10µM and 
20µM exposure (p<0.05). (C) PXN expression was significantly higher in the 10µM and 20µM 
FA conditions when compared with the control however there was no significant difference 
between 30µM FA exposure and the control.  Slow migrating cells: (D) All experimental 
conditions displayed significantly higher ICAM1 expression compared with the untreated 
control (p<0.01) however 20µM FA exposure resulted in significantly higher expression levels 
when compared with 10µM and 30 µM FA exposure. (E) VCAM1 expression was significantly 
higher in the 10µM, 20µM and 30µM exposure conditions when compared with the FA-ve 
control, there were no differences between groups.  (F) There were no differences between 
PXN expression in the control and the FA treated conditions (n=3). 
*** *** *** 
*** 
*** 
*** 
*** *** 
*** 
*** 
*** 
*** 
* * 
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5.5 Effect of folic acid on expression of RAC1, RHOA and CDC42 
As FA influences both cell adhesion and cell motility, expression of genes associated with these 
cell activates were determined. Rac family small GTPase-1 (RAC1) was significantly down-
regulated, when compared with the control, in response to 10μM, 20μM, and 30μM FA 
(p<0.01) in the fast migrating groups (Figure 88A). Ras-homolog gene family member-A 
(RHOA) was significantly upregulated (p<0.01) with an average 2.5-fold change relative to the 
control following supplementation with 10Μm, 20μM, and 30μM FA (Figure 88B). Cell 
division control protein 42 (CDC42) expression was also significantly up-regulated in response 
to 10μM (p<0.01) 20μM (p<0.05) and 30μM (p<0.01) FA however, the average fold-changes 
were only approximately 1.5 (Figure 88C). Although the slow migrating fibroblast sample 
shared a similar pattern of expression there were a few differences. RAC1 was significantly 
down-regulated in response to 10μM and 20μM FA exposure and expression was down-
regulated further in response to 30μM FA (Figure 88D). RHOA was upregulated in response to 
10μM and 20μM FA exposure with an average 3-fold change this was reduced to 2.5-fold in 
the 30μM FA group (Figure 88D). CDC42 was upregulated in response to 10μM FA (fold-
change approximately 1.5) and expression increased further following exposure to 20μM and 
30μM FA (fold change approximately 2) (Figure 88F). These data suggested that the expression 
levels of RAC1, RHOA and CDC42 genes were significantly influenced by FA exposure at high 
concentrations, which may have exerted an effect on cell adhesion and migration.                     
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(A) 
(B) (E) 
(C) (F) 
(D) 
Figure 88: Effect of folic acid supplementation on RAC1, RHOA and CDC42 gene 
expression. Fast migrating cells: (A) RAC1 expression was significantly down-regulated 
following supplementation with 10µM, 20µM and 30µM FA (p<0.01; p<0.001; p<0.01); 
there were no significant differences between treated groups. (B) RHOA expression was 
significantly up-regulated in all FA treated groups (p<0.05; p<0.001; p<0.001) however 
there were no significant differences between treatment conditions. (C) CDC42 expression 
was upregulated in the 10µM (p<0.01), 20µM (p<0.05) and 30µM (p<0.001) treated 
groups when compared with the control. Upon supplementation with FA, similar patterns 
of RAC1, RHOA and CDC42 expression were observed in the cells from the slow 
migrating group (D-F) (n=3). 
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5.6 Influence of folic acid on collagen production and expression 
The response of cleft fibroblasts to FA in terms of collagen production was assessed by means 
of Sirius red staining followed by quantification of the adherent dye. With S101596 cells, it was 
found that supplementation with the physiological concentration of FA (20nM) did not result 
in any significant change in collagen production relative to the FA-ve control. However, FA in 
concentrations of 10μM led to a significant increase in total collagen production (p<0.01) while 
increasing the concentration to 20μM and 30μM did not lead further increased (Figure 89A). 
Despite producing a greater amount of collagen overall, S101597 cells shared a similar response 
to FA supplementation. Treatment with 20nM produced similar levels of collagen as the 
control, whereas, supplementation with 10μM, 20μM and 30μM FA led to significantly higher 
total collagen but no differences between FA exposure concentrations (Figure 89B).  
The influence of FA on collagen gene expression was also measured by means of real-time 
polymerase chain reaction. In S101596 cleft fibroblasts the addition of 10μM FA resulted in a 
significant increase (p<0.01) COL1A1 expression which increased further in the presence of 
20μM (p<0.05) but not 30μM (Figure 90A). COL3A1 was significantly upregulated in the 
presence of 10μM FA (p<0.05) though to a lesser degree than COL1A1, this was increased 
further in response to 20μM and 30μM FA though not significantly (Figure 90C). In S101597 
cleft fibroblasts cultures COL1A1 expression was also upregulated in response to 10μM FA 
(p<0.01) although to a much greater degree; there was no significant change in COL1A1 
expression following exposure to 20μM and 30μM FA groups relative to the 10μM FA (Figure 
90B).  COL3A1 was significantly upregulated (p<0.01) in response to 10μM and 20μM FA 
(approximately 2.5-fold change relative to the FA-ve control), this decreased to an approximate 
2-fold change in response to 30μM FA (Figure 90D).  
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(A) (B) 
(C) (D) 
Figure 90: Folic acid supplementation and cleft fibroblast collagen gene expression. 
(A-B) Supplementation at 10µM, 20µM and 30µM FA significantly increased COL1A1 
expression in both the fast (S101596) and slow (S101597) migrating groups (P<0.001 and 
p<0.001 respectively). (C) Supplementation with 10µM FA caused a significant increase 
in COL3A1 expression in the fast group (p<0.05), this upregulation increased at elevated 
FA exposures (p<0.01 and p<0.001). (D) Upon FA supplementation, COL3A1 expression 
was higher in the slow migrating groups; 10µM and 20µM FA significantly increased 
COL3A1 expression though this decreased following supplementation with 30µM. (n=3).  
*** 
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(A) (B) 
Figure 89: Folic acid supplementation and cleft fibroblast collagen production.  (A) 
Supplementation with 20nM FA did not significantly alter collagen production in both 
cell types. However, elevated FA exposure (10μM, 20μM and 30Μm) significantly 
increased collagen production (p<0.01), though there were no significant differences 
between treatment conditions. (B) Similar trends were observed in the slow migrating 
group (S101597) although overall collagen production was higher in this group.   
*** *** *** 
*** *** *** 
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5.6.1 Effect of folic acid on sulphated GAG production and gene expression 
Alcian blue staining was assessed following incubation of with varying concentrations of FA 
to quantify the amount of sulphated glycosaminoglycans (GAGs) produced over a seven-day 
period. S101596 fibroblasts demonstrated comparable absorbance values between the FA-ve 
control and the 20nM FA supplemented condition, indicating that at this concentration FA did 
not influence GAG production. Incubation with 10μM caused a significant increase in sulphated 
GAG production (p<0.01), this increased further following supplementation with 20μM though 
not significantly. Exposure to 30μM FA led to a significant decrease in GAG production with 
levels lower than that of the FA-ve control (Figure 91A). The S101597 cleft fibroblasts 
produced significantly lower amounts of sulphated GAGs although a similar response to FA 
was observed. The FA-ve control and the 20nM condition produced similar amounts of GAG 
whereas production was increased following the addition of 10μM FA. However, unlike 
S101596 absorbance was decreased following the addition of 20μM and this was decreased 
further following the addition of 30μM (Figure 91B). These data indicated that although 
physiological concentration of FA did not appear to influence sulphated GAG production the 
application of 10μM FA may have had a positive effect on production whilst higher 
concentrations may have caused to a significant reduction in GAG production.  
Expression of markers associated with sulphated glycosaminoglycan production was assessed 
to ascertain cell responses to FA. Chondroitin sulphate proteoglycan 4 (CSPG4) expression was 
significantly downregulated in response to 10μM, 20μM and 30 FA (p<0.01) in both S101596 
and S101597 although the latter produced lowered expression overall; there was no significant 
difference in expression between treated groups (Figure 92A-B). Heparin sulphate proteoglycan 
2 (HSPG2) was not downregulated in response to 10μM FA in the S101596 group. However, 
expression was significantly downregulated in response to 20μM and 30μM FA 
supplementation (p<0.01) (Figure 92C). Similarly, HSPG2 expression remained comparable 
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with the FA-ve control in the S101597 group in response to 10μM and 20μM FA but was 
downregulated in response to 30μM (p<0.01) (Figure 92D). Dermatan sulphate epimerase 
(DSE) expression was not significantly influenced by the presence of FA at any of the 
concentrations used in both S101596 and S101597 cleft fibroblasts (Figure 92E-F).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 91: Effect of folic acid supplementation on glycosaminoglycan production. (A) 
Supplementation with 20nM FA did not significantly affect the amount of GAGs produced 
based on absorbance readings. However, following supplementation with 10µM and 20µM 
FA absorbance was significantly increased (p<0.01); absorbance was again decreased to 
levels comparable with that of the control in the 30µM condition. (B) The slow migrating 
cell types assessed here produced lower overall GAGs when compared with the fast group. 
GAG production significantly increased following supplementation with 10µM FA 
(p<0.001) it was also increased in the presence of 20µM and 30µM but to a lesser degree 
than that of 10µM.   
(A) (B) 
** ** 
*** 
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Figure 92: Effect of folic acid supplementation on glycosaminoglycan gene expression.  
(A-B) CSPG4 was significantly downregulated following supplementation with 10µM, 
20µM and 30µM FA (p<0.01) in both the fast and slow migrating groups however the slow 
migrating group exhibited lower overall expression; there was no significant differences 
between treatment conditions. (C) Supplementation with 10µM does not lead to any 
significant change in HSPG2 expression however supplementation with 20µM and 30µM 
led to a significant decrease in HSPG2 expression (p<0.01). (D) In the slow migrating 
groups HSPG2 expression was not significantly different following supplementation with 
10µM or 20µM FA however treatment with 30 µM FA resulted in a significant 
downregulation of HSPG2. (E-F) Supplementation with 10µM, 20µM and 30µM did not 
cause any significant change in DSE expression in either the fast or slow migratory groups 
(n=3). 
(A) (B) 
(C) 
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5.6.2 Expression of other extracellular matrix related molecules in response to folic 
acid 
Fibronectin 1 (FN1) expression was not significantly influenced by the presence of FA in 
S101596 fibroblast cultures (Figure 93A). However, FN1 expression was significantly 
upregulated in S101597 fibroblasts in response to 10μM, 20μM and 30μM FA (P<0.05) (Figure 
104B). Elastin (ELN) expression was significantly downregulated in S101596 fibroblasts in 
response to 10μM FA (p<0.01) but at concentrations of 20μM and 30μM FA expression levels 
were comparable with that of the control (Figure 93C). Conversely, in S101597 fibroblasts 
supplementation with 20μM and 30μM FA led to a significant downregulation of ELN (p<0.01) 
(Figure 93D). Laminin subunit alpha 1 (LAMA1) expression was not affected by the presence 
of FA as expression levels were comparable with those of the FA-ve control in both cell 
populations (Figure 93E-F).   
5.7 Effect of folic acid on expression of markers associated folate with metabolism  
Folate hydrolase 1 (FOLH1) was upregulated in both S101596 and S101597 with increasing 
FA concentrations. However, the fast migrating cell type had higher fold changes in FOLH1 
expression relative to the slow group. Further, there were no differences observed in expression 
based on FA concentrations as 10μM, 20μM and 30μM had similar fold changes (Figure 94A-
B). Methylenetetrahydrofolate reductase (MTHFR) expression was also upregulated following 
supplementation with 10μM, 20μM and 30 FA relative to the FA-ve control in both S101596 
and S101596. However, as with FOLH1, fold changes were higher in the fast group whilst there 
were no significant differences between FA treated groups (Figure 94C-D).  
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(C) (D) 
(E) (F) 
Figure 93: Effect of folic acid supplementation on expression of extracellular matrix 
related molecules. (A) FN1 expression was comparable between 10µM, 20µM and 
30µM FA treated cleft fibroblasts and the FA-ve control. (B) In the slow migratory group 
treatment with 10µM, 20µM and 30µM FA leads to a significant increase in FN1 
expression (p<0.05); there were no significant differences between treatment conditions. 
(C) ELN expression was significantly downregulated following supplementation with 
10µM however there was no significant difference between the control and the 20µM and 
30µM treatment conditions. (D) Supplementation with 10µM led to a non-significant 
decrease in ELN expression in the slow migratory group, this expression decreased 
significantly following treatment with 20µM and 30 µM (p<0.01). (E-F) There were no 
significant differences in LAMA1 expression between the FA-ve control and FA treated 
cultures for both the fast and slow migratory groups (n=3).  
** 
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(A) (B) 
(C) (D) 
Figure 94: The effect of folic acid supplementation on genes involved in folate 
metabolism. (A) FOLH1 expression was significantly upregulated following 
supplementation with 10µM, 20µM and 30µM FA in the fast migrating cells (fold change 
approximately 6-7) (p<0.001); there was no significant difference between supplemented 
groups. (B) FOLH1 was also upregulated in the slow cells however the fold changes were 
smaller than in S101596 (fold change of approximately 3-3.5) with no differences between 
FA treatment conditions. (C) MTHFR was significantly upregulated relative to the FA 
control in all 3 experimental conditions (p<0.001) (fold change approximately 3.5-4). (D) 
MTHFR was also upregulated in the slow migrating groups following FA supplementation 
(p<0.01) (fold change approximately 2-2.5); variation in FA conditions did not influence 
expression.  
*** 
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5.8 Discussion  
Maternal dietary intake of folic acid (FA) has been continually associated with potential 
preventative roles in cleft development (Van-Rooji et al, 2004) with a recent comprehensive 
meta-analysis concluding maternal FA supplementation significantly reduced the risk of all 
cleft phenotypes (Jahanbin et al, 2019). Despite this, there is currently little data pertaining to 
the regulatory and behavioural influences FA may have on cleft fibroblasts which could be 
altered and potentially influence clefting during foetal development. Therefore, the purpose of 
this study was to identify a broad array of behaviours that may be influenced by the presence 
of FA thus providing new insights into the potential cellular and molecular mechanisms by 
which FA may be involved in cleft prevention. Overall, the data indicated that FA can affect a 
range of cell activities including: growth, migration, adhesion, ECM deposition and gene 
expression. However, FA supplementation in normal physiological concentrations (20nM), did 
not induce significant change in the aforementioned cell responses, suggesting physiological 
concentrations of FA might be too low to bring about an observable cellular response in the 
assays used. However, elevated concentrations of FA induced measurable differences in cell 
behaviour relative to controls. This is important as pregnant mothers are advised to supplement 
their diets with a much higher folate intake than normal, (up to 1000µg/day as opposed to 
400µg/day (WHO, 2004), both periconceptually and during their first trimester of pregnancy 
which would likely increase serum folate levels significantly (Chitayat et al, 2016). Despite the 
potential benefit of excess dietary folate, it was found here that supplementation with 30μM FA 
often caused a decrease in the positive effects observed at other FA concentrations, which may 
be due to potential cytotoxicity of FA at this concentration.  However, it is important to note 
these assays were conducted in vitro thus any effect folate supplementation had on cell cultures 
may not translate to altered physiological behaviours during foetal development in utero, thus 
the results may not translate to any preventative roles in cleft development.  
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5.8.1 Effect of folic acid supplementation on cell growth, migration and adhesion 
During craniofacial development pluripotent cranial neural crest cells (CNCCs) delaminate and 
migrate from the neural tube into regions that will form the frontonasal prominence, maxillary 
and mandibular prominences. CNCCs undergo rapid proliferation and differentiation, causing 
prominences to increase in size resulting in formation of the craniofacial structures. Controlled 
cell migration, through the process of adhesion and detachment, to the correct anatomical site 
followed by proliferation are therefore critical to normal facial development. Thus, factors that 
can influence these behaviours must be carefully regulated to ensure normal development. Cleft 
fibroblast growth of was increased in the presence of 10μM and 20μM; further, non-cleft control 
cells (NHDFF’s) also responded to FA by increasing proliferative rate.  This stimulatory effect 
is likely due to the cellular requirement of FA to act as a carbon donor for de novo nucleotide 
synthesis of thymidine and the purines, adenine and guanine (Stover and Field, 2011). As the 
rate of proliferation is elevated during development, FA deficiency may be a limiting factor due 
to reduced cellular nucleotide concentrations which are required for DNA replication (Bailey 
et al, 1999). Others have shown proliferation is reduced in FA deficient cultures whereas growth 
is stimulated by the presence of FA (Hwang et al, 2018). Further, murine knockout models, 
which develop neural tube defects due to impairment in neuro-epithelial proliferation, presented 
rescued proliferation, comparable to controls, in the presence of FA (Ichi et al, 2010). As neuro-
epithelial cells are CNCC precursors and FA has been shown to simulate proliferation in a range 
of cell types, including cleft fibroblasts and NHDFFs, it is possible maternal FA deficiency may 
perturb CNCC proliferation within the facial growth centres, thereby contributing to cleft 
development due to the embryos reliance on maternal FA intake.  
Changes in the adhesive ability of local cell populations is required during CNCC delamination 
from neural tube and during migration towards the sites that will become the facial growth 
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centres. Here it was demonstrated that the presence of FA had a positive effect on cell-substrate 
and cell-cell adhesion relative to FA-ve controls; further, this correlated with upregulation 
genes associated with cell adhesion. FA within culture medium has been shown to influence 
cell adhesion in multiple studies; however, it usually induces decreased adhesion, or has no 
effect, as opposed to the increase observed with cleft fibroblasts here. Indeed, Hoover (1977) 
found that populations of embryonic neural retinal cells had significantly decreased cell 
adhesion in the presence of 3.5mM FA (75%) and 0.7mM (43%). Branda and Tracy (1990) 
found that there were greater numbers of adherent melanoma cells in FA deficient cultures, 
relative to FA supplemented, whereas carcinoma colon epithelial cells were unaffected in terms 
of adhesion when exposed to 10uM FA (Ting et al, 2018). Although much of the literature 
seems to suggest FA has a negative impact on adhesion, the present study represents the first 
instance that the influence of FA on cleft fibroblast adhesion has been assessed and it was shown 
to have a positive effect. As GTPases are pivotal to cellular adhesion and motility, there 
activation/deactivation may significantly affect the adhesiveness of fibroblasts. The actin 
cytoskeleton interacts with the underlying substrate primarily through actin stress fibres which 
transmit mechanical forces between the substrate and the cell at focal adhesions. It was shown 
in 3T3 fibroblasts that RhoA drives the formation of stress fibres and focal adhesions, which 
anchor the cell to the substrate; further, stress fibre and focal adhesion formation was blocked 
when RhoA activity was inhibited (Ridley and Hall, 1992). As RHOA was upregulated in cleft 
fibroblasts in the presence of FA, it is possible that FA stimulates RHOA mediated actin 
formation leading to the production of focal complexes which improve their adhesiveness  
The migratory route adopted by CNCCs during migration from the neural folds is guided by a 
highly preserved molecular blueprint that ensures migration towards developing craniofacial 
sites through induction of a number of molecular pathways coupled with regulation of cellular 
responses to the extracellular milieu (Hall, 2009). The presence of elevated FA within cleft 
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fibroblast cultures significantly reduced migration; this was coupled with downregulation of 
ACTA1 and TUBA1. Actin filaments and microtubules comprise the major components of the 
cell cytoskeleton which is pivotal in controlling cell locomotion, this appears to be especially 
important during craniofacial development as altered cytoskeletal polymerization has been 
shown to lead to alterations to cell shape disrupting neural tube closure and consequently facial 
development (Sadler et al, 1982; Moephuli et al, 1997). Downregulation of both actin and 
tubulin may account for the decreased cell migration rates especially when considering that 
there is a direct association between intercellular actin and folate metabolism as it was shown 
following disruption of the actin cytoskeleton there was an increase in the number of cellular 
folate surface receptors followed by increased intercellular folate metabolism (Lewis et al, 
1998). As maternal FA intake has been associated with cleft prevention, altered expression of 
actin and tubulin, coupled with the resultant influence on migratory rates, in response to folate, 
may influence CNCC migration from the neural tube. However, further research is needed to 
identify the precise CNCC response to FA in terms of migration. Others have concluded that 
FA has a similar anti-migratory effect thereby supporting the results obtained here as 10μM FA 
was shown to inhibit endothelial cell migratory rates and decrease lamellipodial formation as a 
result of modulation of RhoA activity (Hou et al, 2013; Chou et al, 2013). Rho GTPases are 
major regulators of cytoskeletal dynamics thereby influencing the behaviours of actin and 
tubulin during cell locomotion. FA supplementation led to significant downregulation of RAC1 
in cleft fibroblasts relative to FA-ve controls. RAC1 is ubiquitously expressed and is pivotal to 
cell locomotion as Rac proteins are reportedly expressed at the front of the cell and drives cell 
motility via formation of lamellipodial extensions which function to interact with the 
extracellular environment, direct cell polarity and propel the cell in a forward direction (Thomas 
et al, 2010). Due to this, downregulation of RAC1 in the presence of FA may have contribute 
to the decreased migratory rates observed in FA treated fibroblasts. Furthermore, as RAC1 
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expression was altered in both cleft and non-cleft NHDFF fibroblasts it is plausible that CNCCs 
may have similar responses to FA during craniofacial formation which may potentially 
contribute to OFC prevention though this needs to be explored further. If the pluripotent CNCCs 
present disrupted motility in response to FA deficiency, it could influence fibroblast 
concentrations within that facial growth centres, potentially perturbing ECM deposition thereby 
disrupting normal tissue expansion potentially contribute to cleft development.  
5.8.2 The effect of folic acid on the production of extracellular matrix  
The ECM comprises the local microenvironment that cells must interact with to carry specific 
cellular functions whilst providing a medium through which adhesion, migration, proliferation 
and extracellular signalling can occur. Collagens are the major fibrillary component of the ECM 
and impart mechanical integrity to the surrounding cells and tissues whilst also acting as point 
of guidance for directed cell migration (Zetter and Brightman, 1990). This is achieved through 
collagens contribution to tissue rigidity as cellular mechano-sensing can identify substrate 
rigidity and adjust motility through the process of durotaxis (Lo et al, 2000); however, chemo 
attractive forces also contribute to CNCC migrational directionality (Rogers et al, 2012). The 
presence of FA was shown here to significantly increase collagen production and expression of 
both COL1A1 and COL3A1.  Providing similar folate responses occur during embryological 
development, fibroblasts could be stimulated to express and secrete elevated fibrillar collagens 
in utero. This could potentially contribute to the CNCC motility, which display rapid migration 
that is stimulated by the underlying ECM (Henderson and Copp, 1997). This is due to the 
presence of collagens and fibronectin, which are expressed and synthesised along the precise 
pathways of CNCC migration thereby permitting directed motility to the facial growth centres 
through continued attachment and detachment with underlying fibres (Henderson and Copp, 
1997; Perris, 1997). Others have also demonstrated the stimulatory role of FA in terms of 
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collagen production, although the mechanism has not yet been determined. For example, FA 
supplementation in collagen embedded dermal fibroblasts significantly increased collagen 
synthesis expression of COL1A1 (Fischer et al, 2011). Further, diabetic mice, which 
demonstrated impaired wound healing and reduced collagen deposition, were shown to display 
cell proliferation, collagen deposition and tissue regeneration comparable to that of their non-
diabetic counterparts following daily 3mg/KG FA dosing (Zhao et al, 2018). As during 
embryological development of the palate collagen type I is highly expressed in CNCCs within 
the palatal mesenchyme thereby significantly contributing towards development of the hard and 
soft palate (Oka et al, 2012).Fibronectin (FN1) was also to be upregulated by cleft fibroblasts 
in the presence of FA. As with collagen, cell attachment and guided migration of early 
embryonic cells is contributed to by the presence of underlying fibronectin as it has been shown 
that FN is present along the migratory pathways taken by neural crest cells (Nawgreen and 
Thiery, 1980) and that integrin mediated NCC binding to FN is critical for normal motility 
(Strachan and Condic, 2008). In addition, following the injection of peptides, that were 
complimentary to fibronectin binding domains, into chick embryos, the migratory path of 
CNCCs was significantly perturbed due to the saturation of fibronectin binding sites thereby 
preventing their interaction with CNCC leading to abnormal craniofacial development 
(Boucaut et al, 1984). This demonstrates the critical importance of appropriate fibronectin 
regulation to normal development. As the presence of FA has been shown to lead to 
upregulation of collagen and fibronectin, it is possible that the potential protective role FA has 
in the prevention of clefts is, in part, due to its stimulation of ECM deposition 
5.8.3 The effect of folic acid on genes related to folate metabolism 
Closely linked with the folate metabolism cycle, which is required to permit FA derivatives to 
function as acceptors and a donors of carbon units thereby enabling: synthesis of nucleotides, 
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amino acid metabolism and oxidation reactions (Blom et al, 2006), is the methionine cycle, 
which leads the production of homocysteine (HCY) and is required to form cysteine and other 
related proteins.  Plasma HCY levels are largely determined by plasma concentrations of FA as 
it is required to convert HCY back into methionine; this is relevant as elevated HCY (hyper-
homocysteinemia) is linked to perturbed foetal development (Taparia et al, 2007) including 
neural tube defects (Imbard, 2013) and orofacial clefts (Wong et al, 1999). In the present study, 
following supplementation with FA, MTHFR, which is responsible for conversion of 5,10–
MTHF to 5-MTHF, was significantly upregulated. MTHFR upregulation is significant as it 
regulates serum HCY concentrations by inducing demethylation of 5-MTHF to THF thereby 
converting HCY into methionine as part of a secondary reaction (Selhub, 1999). HCY has been 
shown to be elevated in non-syndromic CLP patients relative to control patients (Abdulla et al, 
2016; Rooji et al, 2003; Kumari et al, 2013) and elevated maternal serum HCY was associated 
with increased risk of both CLP and CPO (Little et al, 2007). One study demonstrated the serum 
HCY was 9.5μ/L in control group whereas it was significantly higher in the cleft groups 
(18.4μ/L) (Abdulla et al, 2016).  Elevated HCY levels were also shown to affect the behaviour 
of CNCC by altering their growth and migration from the neural tube coupled with CNCC 
differentiation; FA supplementation was shown to reverse this due to reduction in HCY levels 
by conversion to methionine (Boot et al, 2003). Furthermore, FOLH1 which contributes to 
cellular uptake of 5-MTHF, was also upregulated here following supplementation of cleft 
fibroblasts with FA, this would suggest more efficient cellular folate delivery. As folate 
deficiency has been shown to alter expression of genes relating to cell signalling, cytoskeletal 
components and the ECM (Katula et al, 2007) it is possible that the increased FA uptake as a 
result of FOLH1 upregulation may contribute to normal cell behaviour. Taken together these 
data suggest that the presence of FA increases expression of MTHFR which, coupled with the 
presence of elevated serum folate levels, promotes the conversion of HCY into methionine. As 
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HCY concentrations have repeatedly been shown to be elevated in both mothers who are FA 
deficient it is possible that the protective effect against cleft formation that is observed 
following FA supplementation is due, at least in part, to reduction of HCY by means of the 
folate and methionine pathways. Although homocysteine has been repeatedly associated with 
cleft formation, most of the studies conducted have suffered from small sample sizes and low 
statistical power therefore large scale studies are needed within which HCY levels within FA 
deficient and FA sufficient mothers are assessed and correlated with the risk of foetal OFC.   
5.9 Conclusion 
The presence of folic acid was shown here to influence a range of cleft fibroblast behaviours. 
FOLH1, which contributes to cellular folate metabolism, was upregulated thereby suggesting 
the presence of FA may result in more efficient cellular folate delivery.  In addition, adhesion 
of cleft fibroblasts was elevated whilst their migratory speed was reduced, this may have been 
due to the variations observed in Rho GTPase expression in the presence of FA; specifically, 
upregulation of RHOA, which is involved in the formation of adhesive focal complexes, and 
downregulation of RAC1, which contributes lamellipodial extension thus directed cell motility. 
The expression of ECM associated genes, including regulators of collagen and fibronectin, were 
also upregulated. This could potentially result in elevated ECM deposition during development 
which could play a protective role as both collagen and fibronectin are required along cellular 
migratory pathways and are also essential to the mechanical integrity of developing tissues. As 
FA stimulated a diverse range of cell behaviours within populations of cleft fibroblasts it is 
possible that CNCCs, which are the principle cell type in craniofacial development, would also 
be influenced in a similar manner. Perturbations to these behaviours within FA deficient 
mothers may contribute to OFC development thereby suggesting that FA plays a protective role 
by contributing to normal cell behaviour; however further research is required into the FA 
response of human CNCCs before such a conclusion can be made. 
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CHAPTER SIX: 
GENERAL DISCUSSION AND CONCLUDING REMARKS 
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6.1 General discussion 
Due to the high incidence of cleft lip and cleft palate forming in isolation, there has been 
considerable speculation as to whether CP, CL and CLP are disparate clinical entities with 
differing physiological aetiologies. Normal facial development occurs in a regulated sequential 
pattern. Following delamination from the neural tube, the rapidly migrating and proliferating 
CNCCs migrate to the sites that will become frontonasal prominence and into the pharyngeal 
arches. Outgrowth of the first pharyngeal arch eventually leads to its separation into the paired 
mandibular processes and the paired maxillary processes. Medial growth of the mandibular 
processes leads to fusion at the midline, forming the mandible, whereas medial growth of the 
maxillary processes leads to fusion with the lateral nasal process, which differentiates from the 
frontonasal process, eventually forming the intermaxillary segment which gives rise to the 
philtrum, upper lip and the primary palate (Senders et al, 2003; Lan et al, 2015); disruption 
during this process can lead to the formation of either unilateral or bilateral clefts lip. Following 
this, bilateral outgrowths from the maxillary processes form the palatal shelves, which fuse to 
form the midline epithelial seam and eventually the definitive palate (Yu et al, 2009); disruption 
at this stage can lead to clefts of the palate. Due to the formation of the lip and palate being 
distinct embryological events, it is possible that formation of cleft lip and the palate are formed 
due to physiologically distinct mechanisms. However, it is also possible that cleft lip and palate, 
when forming in conjunction, is a more severe manifestation of the same physiological defect, 
with the same causation, but at a greater degree of severity (Shkoukani et al, 2013).  
The present study is the first to characterise and compare fibroblasts derived from differing cleft 
phenotypes, in terms of their behaviour in vitro, to determine whether fibroblasts isolated from 
differing cleft types are physiologically distinct. It was highlighted here that there were many 
behavioural and genetic differences between fibroblast isolated different patients within the 
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cohort. However, these differences often did not correlate with cleft type; therefore, the 
variation in fibroblast behaviour could not be attributed to the potential genetic deviations that 
resulted in the manifestation of the cleft type. Rather, the differences observed in fibroblast 
behaviour were likely due to the distinct individual genetic profiles of the patients undergoing 
the repair. However, RUCLP fibroblasts were shown to consistently downregulate a number of 
genes associated with ECM production and TGF expression compared with both LUCLP and 
BLCLP. It is thus possible fibroblasts derived from the CL with right laterality are genetically 
distinct and potentially have distinct aetiological origins. Left laterality is more common than 
right laterality (Nagase et al, 2011; Conway et al, 2015) and currently it is unknown why there 
is left dominance with regards cleft lip development (Vieira and Dattilo, 2018). It is possible 
that the down-regulation of ECM associated genes observed here may lead to interference with 
the normal positioning of the facial processes prior to fusion thereby contributing to formation 
of RUCLP. However, samples sizes for the present study were small; therefore, the results 
obtained here are preliminary and cannot be deemed conclusive or representative of all cleft 
patients. Large-scale studies that analyse an array of genetic markers associated with cleft 
development are required to definitively determine if RUCLP fibroblasts are genetically distinct 
from their LUCLP and BLCLP counterparts. Determination of aetiological differences between 
cleft types is important, as if clefts of differing types and laterality are aetiologically distinct 
they should be studied as separate conditions. Currently a portion of the literature adopts 
simplistic qualitative classification systems and often the cleft type is not reported. This is 
problematic as that data obtained may not relatable to patients with different cleft types.  
6.2 Limitations of the study 
Although the patient selection criteria excluded individuals with syndromic forms of CLP, only 
patients which displayed overt symptoms of known syndromes were excluded from the study. 
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Further, following sample collection, all samples were anonymised thus any individual patients 
that were diagnosed with syndromic CLP following their cleft repair, would have been included 
in this study due the patient’s post-operative diagnosis being unknown. This is problematic as 
it leads to the possibility that a number of samples may not have been comparable to the 
remainder of the patient cohort due to potentially having distinct aetiological origins. Future 
analysis of cleft samples should include genetic testing for known syndromic forms of CLP 
with post-operative reviews to definitively determine sample homogeneity. In addition, 
although multiple samples were isolated from each cleft phenotype, the precise anatomical 
origin of each individual sample was not controlled, this was due to tissue availability being 
limited to that which was not required for the repair. As clefts of the same type can differ in 
terms of their dimensions, there is often differing tissue requirements for each repair as they 
may involve implementation of differing surgical protocols for different patients. As the 
clinician must prioritise the surgical repair the precise tissue isolation site could not be 
controlled. This may have led to a degree of heterogeneity within samples derived from the 
same cleft types as different regions of the lip and palate were donated for analysis, this must 
be taken into account as it is possible that the variations in cell behaviour observed between 
samples may have been due to the differing anatomical origins of the samples. In addition, 
despite efforts to obtain as many samples a possible for each cleft phenotype, the number of 
samples was limited between a minimum of five, for isolated CP, and a maximum of 9, for both 
lip and palate derived CLP samples. Due to this, the number of replicates for each cleft type 
was too low to make and definitive conclusions; rather, potential associations and differences 
could only be outlined.  
There was significant difficulty in obtaining a true age-matched and anatomical-matched 
control with which cleft fibroblast behaviour could be compared. This was due to the ethical 
issues in obtaining healthy donor tissue from the lip or palate of non-cleft patients. Due to this, 
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human gingival fibroblasts (HGF) were selected as control cells for PCR applications due to 
being readily available human oral fibroblasts. Many of the genetic markers assessed in the 
present study were shown to be significantly upregulated across the sample cohort when 
compared with the non-cleft HGF control. This could potentially suggest that disrupted gene 
expression may be due to the pathological nature of the fibroblasts and that aberrant gene 
expression of ECM associated genes is a hallmark of cleft derived fibroblasts. However, the 
control used here was derived from adult gingival tissue therefore it did not share the same 
anatomical origin of cleft fibroblasts which were isolated from either the lip or palate. The 
anatomical origin of fibroblasts can have a significant influence on their behaviour, it has been 
shown that gingival fibroblast cell lines express significantly increased expression of 
inflammatory and ECM markers whilst significantly decreased expression of TGF signalling 
markers when compared with dermal fibroblasts (Mah et al, 2014). Further, there can be 
significant variation in the expression between different fibroblast population within the oral 
cavity as it has been shown that periodontal ligament fibroblasts produced significantly greater 
amounts of ECM proteins relative to their gingival fibroblast counterparts (Hou et al, 1995) 
furthermore differences between populations of oral fibroblast populations are also significant 
when derived from the same donor (Palioto et al, 2002). This suggests that anatomical 
differences between the HGF control used here and the cleft fibroblasts may account for many 
of the significant differences observed between the control and cleft samples. Equally the HGF 
control was derived from adults whereas cleft fibroblasts were isolated from infants typically 
aged between three and nine months. As with anatomical origin the age of the patient from 
which the fibroblasts are derived can also have a significant effect. It has been shown that that 
neonatal fibroblasts differed from adult fibroblasts in terms of expression of genes associated 
with ECM deposition, morphogenesis and cell adhesion (Mateu et al, 2016). This suggests that 
the disparity in gene expression observed between the HGF control and cleft fibroblasts may 
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be due the age of the patient from which they were isolated. A minority of studies pertaining to 
cleft fibroblast behaviour have managed to obtain neonatal fibroblasts from non-cleft oral 
tissues. When assessing the effect of diphenylhydantoin (PHT), a drug that induces CP, control 
fibroblasts were obtained from infants undergoing surgery for palatal trauma (Bosi, et al, 1998). 
Similarly, when assessing the effects of nicotine on cleft fibroblasts, control fibroblasts 
obtained from infants with palatal trauma were used (Baroni et al, 2009). However, obtaining 
this type of control tissue was not possible in the present study as infants with oral trauma are 
uncommon and any cases would be treated as a matter of urgency before parental consent could 
be obtained. Others have also compromised on control fibroblasts, when assessing cleft 
fibroblast behaviour neonatal human dermal foreskin fibroblasts have been used (Beyeler et al, 
2014) as well as adult dermal fibroblasts (Zivicova et al, 2017). Due to the absence of a true 
age matched and anatomical matched control, the data generated here, which compared gene 
expression and cell behaviour with controls, may not be valid as the behaviour of the controls 
utilised here may not be indicative of how non-pathological age and anatomical matched 
fibroblasts would behave, thus definitive conclusions cannot be made. Future studies that 
comparatively assess cleft fibroblast behaviour should incorporate the use of multiple controls 
such as those isolated from neonates with oral trauma.  
6.3 Conclusion and recommendations for future work 
The data presented in this thesis suggest that individual cleft patients can vary significantly both 
in cell behaviour, such as motility and ECM deposition, and in their gene expression profiles. 
These disparities in fibroblast behaviour and gene expression may be potential contributing 
factors in the pathological wound healing seen in some patients following cleft repair, this could 
potentially account for why different patients with the same cleft type and surgical treatment 
protocol present significantly different clinical outcomes. Despite the differences in cleft 
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fibroblast behaviour observed here, there was limited correlation with cleft phenotype thus 
fibroblast behaviour could not be reliably correlated with the type of cleft that manifested. 
However, fibroblasts derived from cleft lip in isolation presented cell behaviours consistent 
with the hallmarks of HTS, including elevated motility and collagen deposition, thus these 
patients may be at increased risk of pathological wound healing relative to the other cleft types 
assessed here. The results obtained in this thesis highlight a number of areas that should be 
explored further. Therefore, recommendations for future cell based cleft research include:  
 Cleft tissues, from which fibroblasts were isolated, comprise of organised ECM with 
three dimensional distribution and multiple cell types. As cleft fibroblasts derived from 
these tissues revealed significant patient-to-patient differences is the ECM production, 
it would be interesting to assess ECM distribution within tissue samples, through use of 
histological staining immunostaining methodologies, followed by quantification. This 
could potentially reveal the physical ECM distribution within pathological cleft tissue 
between patients and can subsequently be compared between cleft types. Tissue that is 
both age-matched and anatomically-matched, potentially derived from infants with oral 
trauma, should be used as controls. 
  Cleft fibroblasts samples were shown to split into two statistically distinct groups in 
terms of wound closure, fast and slow. Cleft patients with fast migrating fibroblast could 
potentially be at increased risk of pathological wound healing due to premature 
myofibroblast differentiation leading to elevated ECM deposition. Future studies should 
characterise fibroblasts based on motility, as conducted here, but also carry out long 
term follow up patient examinations in order to assess clinical outcome (i.e. 
development of ONF or HTS) which can subsequently be correlated with the migratory 
behaviour of their fibroblast in vitro. This would provide evidence as to whether 
increased motility is related to pathological wound healing in surgical cleft repair. 
 243 
 
Further, fibroblasts could be isolated from tissue samples taken from patients 
undergoing revision surgery due to development of ONF. The behaviour of ONF 
fibroblasts could then be compared to previously established fibroblast behaviour across 
the sample cohort in order to establish which markers are associated with increased risk 
of ONF development. 
 Following exposure to folic acid, cleft fibroblasts significantly upregulated MTHFR and 
FOLH1, both of which are markers involved in the folate metabolism pathway and are 
linked to the methionine pathway. As the fundamental process of the methionine 
pathway is to convert homocysteine into methionine, and homocysteine has been 
associated with cleft development, the effect of folic acid on other genetic markers 
associated with both folic acid and methionine pathways should be studied further to 
uncover how exposure can influence cell behaviour and potentially cleft development.  
 Epithelial cells have a significant role in normal craniofacial development. For example, 
in normal palate formation the opposing palatal shelves, which are covered in 
epithelium, merge due to the superficial interaction of epithelial cells to form the midline 
epithelial seam. As cleft tissues derived from patients comprise of heterogeneous cell 
populations future studies should isolate epithelial cells from these tissues and conduct 
further analysis, particularly of cell-adhesion molecules. It would be interesting to 
assess if adhesion molecule expression is different between patients with cleft palate 
only, which had failed palatal shelf fusion, and those with cleft lip, which had successful 
shelf fusion.  
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